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TRANSCRIPTIONAL, EPIGENETIC, AND SIGNAL EVENTS IN ANTIFOLATE
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A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
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Virginia Commonwealth University, 2009
Major Advisor: Dr. Richard G. Moran, PhD
Professor, Department of Pharmacology and Toxicology

A targeted approach to the development of antifolate therapies has been sought for
many years.

Central to the success of such development is an understanding of the

molecular mechanisms dictating the sensitivity of cells to antifolates and the fundamental
differences of these processes between normal and neoplastic phenotypes.

This

dissertation addressed transcriptional mechanisms and cell-signaling events responsible for
the efficacy of antifolate therapies. Transcriptional processes and cell signaling pathways
are often aberrant in neoplastic tissues, providing a potential point of distinction between a
normal and neoplastic cellular state.
xxii

Folylpolyglutamate synthetase (FPGS) catalyzes the formation of poly-γ-glutamate
derivatives of folates and antifolates, which permits intracellular retention and
accumulation of these compounds. The mouse fpgs gene uses two distant promoters to
produce functionally distinct isozymes in a tissue-specific pattern. We questioned how the
two promoters were differentially controlled. An analysis of DNA methylation and histone
post-translational modifications across the length of the mouse fpgs gene showed that
epigenetic mechanisms contributed to the tissue-specific control of the upstream (P1), but
not the downstream (P2) fpgs promoter. RNAPII complexes and general transcription
factors were present over P1 only when P1 was transcribed, but these components were
present over P2 in most tissues, and promoter-proximal pausing was evident in brain.
Clear promoter occlusion was found over P2 in liver. These studies concluded that tissuespecific coordination of dual promoters required multiple interacting controls.
The mammalian target of rapamycin (mTOR) controls protein translation
initiation, and is central to a cell-signaling pathway rich in tumor suppressor and oncogenic
proteins. mTOR dysregulation is a common feature of several human cancers and inhibition
of this protein has been sought as an ideal cancer drug target. We have determined that
antifolates inhibiting the two folate-dependent steps of purine synthesis (GART or AICART)
activate AMP-dependent protein kinase (AMPK) and inhibit mTOR. The mechanism of
AMPK stimulation appears to be mediated by either nucleotide depletion (GART inhibitors),
or ZMP accumulation (AICART inhibitors). These studies discovered a new mechanism for
antifolates

that

surprisingly

defines

them

xxiii

as

molecularly

targeted

therapeutics.

Chapter 1: Introduction and Overview

Folates are forms of the essential water-soluble B vitamin, folic acid. Humans
deficient in folates can suffer from a number of serious pathologies including birth
defects, such as neural tube defects and cleft palate, cardiovascular disease, and
megaloblastic anemia (229). The folic acid molecule consists of a pteridine moiety
linked at carbon 6 by a methylene bridge to p-aminobenzoylglutamic acid. Within the
cell, folic acid is reduced to 5,6,7,8-tetrahydrofolate (THF), and THF and N5 and N10substituted reduced folates are the metabolically active forms of this vitamin (Figure 1-1)
(9, 167, 199). Folate metabolism is compartmentalized in mammals between the cytosol
and the
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Figure 1-1. Structure of 5,6,7,8-Tetrahydrofolate (THF).

1

mitochondria, and early evidence showed that folic acid distributes equally between these
two compartments in rat liver (47).

Cellular folates represent a family of structurally

related cofactors that play critical roles in one-carbon transfer reactions required for
purine nucleotide and thymidylate synthesis, as well as the synthesis of methionine from
homocysteine (9). Methionine is converted to S-adenosylmethionine, which serves as a
methyl donor for several methylation reactions within the cell, including DNA and
histone methylation (229).

Folates are transported into the mitochondria via the

mitochondrial folate carrier (158, 183, 241) and serve as cofactors for the mitochondrial
serine hydroxymethyltransferase, for formation of formyl groups by the glycine cleavage
system, and for the synthesis of the formylmethionine tRNA involved in the initiation of
mitochondrial protein synthesis. Regulation of cellular folate levels is a key component
of maintaining the fidelity of DNA and RNA synthesis, amino acid metabolism, and
epigenetic processes within tissues (229).

Several key folate-dependent steps in

metabolism are illustrated in Fig. 1-2.
In mammals, circulating folates are monoglutamate forms, which are best viewed
as the transport forms of this vitamin (24, 175). Dietary folates are absorbed primarily in
the duodenum and upper jejunum of the small intestine through a high affinity protoncoupled folate transporter (PCFT) that functions optimally at low pH (190, 269). In
humans, a loss-of-function mutation in the gene encoding the PCFT results in hereditary
folate malabsorption disease (190). There are two folate transporters involved in moving
folates across membranes at neutral pH: the reduced folate carrier (RFC) and the folate
receptors (FR) (30, 79). The RFC moves folates in a facilitative manner using an anion
exchange mechanism and the FRs transport folates intracellularly via endocytosis (269).

2

RFC null mice can survive embryonic development only if pregnant females are injected
with folic acid, but pups die post-natally at 12 days due to hematological pathology;
transport using this protein is critical throughout the life of the animal (269). On the
other hand, mice where all FRs have been deleted die during development unless the
pregnant females are given 5-formyl-THF; these mice survive gestation and develop into
adulthood normally, highlighting the necessity of these receptors to maturing embryos
(269).
Once inside the cell, folates serve as substrates for the enzyme folylpoly-γglutamate synthetase (FPGS), which catalyzes the conversion of monoglutamate folates
to poly-γ-glutamate derivatives using ATP and glutamic acid (16, 167, 199) (Fig. 1-2).
Mitochondrial and cytosolic forms of FPGS are encoded by the fpgs gene in dividing
cells in mouse and humans using alternative start sites, which are distinguishable by the
presence of a mitochondrial leader sequence at the N-terminus of the mitochondrial
protein. The two isoforms allow the accumulation of folylpolyglutamates in the cytosol
and mitochondria, the two cellular compartments involved in folate-dependent onecarbon metabolism (72). Folypolyglutamates are more efficient substrates for many
folate-dependent enzymes and the cellular retention and accumulation of cofactors to
high levels is necessary to meet the metabolic demands of rapidly dividing cells (167,
239).

Mammalian cells that harbor inactivating FPGS mutations die from lack of end

products of folate-dependent steps of metabolism in normal media (157, 239).
In the early 1940’s, Dr. Sydney Farber at the Jimmy Fund in Boston made an
observation that the administration of folic acid to children with acute lymphocytic
leukemia (ALL) increased the progression and severity of the disease (65). Because of
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this remarkable observation, he generated and tested the hypothesis that a folic acid
antagonist might inhibit or arrest the proliferation of tumor cells and improve the
mortality and morbidity of pediatric ALL, which at the time was an incurable disease. In
1948, he published the results of his study in the New England Journal of Medicine:
administration of the folate antagonist 4-aminopteroyl-glutamic acid (aminopterin, AMT)
to children with ALL frequently led to complete remissions of this disease, the first time
such a remission was every observed (66).

Farber’s approach to target highly

proliferative tumor cells by inhibiting steps critical to cellular division has been the basis
for the development of chemotherapeutic agents and strategies for the past 60 years
(162). This fundamental study marked the beginning of the use of folate antagonists, i.e.
antifolates, as chemotherapeutic agents.
The use of AMT was replaced shortly after the original studies with a slightly less
toxic compound, methotrexate (MTX) (64). Both MTX and AMT primarily inhibit
dihydrofolate reductase (DHFR); the enzyme responsible for the reduction of folate and
dihydrofolate to tetrahydrofolate. Because reduced folates are the active folate cofactors
required for one carbon transfer metabolism, treatment with AMT or MTX leads to the
inhibition of purine and thymidylate biosynthesis, with severe consequences on DNA and
RNA production. MTX remains the first line therapy for ALL and is now even more
frequently used in the treatment of several autoimmune diseases including psoriasis,
rheumatoid arthritis, and sarcoidosis (189, 196, 197).
The basis for antifolate drug design efforts shifted toward the production of
analogs that could be highly metabolized following the observation that MTX, like the
naturally occurring folates, was metabolized to polyglutamate derivatives (17). MTX
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polyglutamates accumulate to high intracellular levels with sufficient exposure of
leukemic cells, and are retained for substantial periods of time following removal of
extracellular drug (17, 73, 199). Long-term inhibition of DHFR is mediated by the polyγ-glutamyl derivatives of MTX (199, 212) and the targets of this form of the drug are
expanded to two other folate-dependent enzymes: thymidylate synthase (TS) (3) and 5aminoimidazole carboxamide ribotide transformylase (AICART) (5).

The intracellular

formation of polyglutamate forms of MTX greatly enhance the cytotoxicity of this drug,
and extend the length of time that intracellular metabolism is disrupted due to
intracellular retention of the drug (41, 199). The importance of FPGS activity on the
efficacy of MTX suggested that the rationale for selection of antifolate agents should
target compounds that are efficient substrates of this protein.
In the late 1970’s, the main target for the design of novel antifolate metabolites
shifted from DHFR to the folate-dependent enzymes involved in thymidine and de novo
purine synthesis. The first drug to emerge from these efforts was N10-propargyl-5,8dideazafolate (CB3717), a potent TS inhibitor (125). CB3717 was a moderately efficient
substrate of FPGS; polyglutamated derivatives of CB3717 were 100-fold more potent as
inhibitors of thymidylate synthase than the parent compound and were no longer efficient
substrates for cellular efflux (117). Phase I clinical trials determined that the compound
was active against breast, ovarian, and liver cancer, but CB3717 had remarkable liver and
kidney toxicity due to the insolubility of the drug in acidic pH (35, 117). In spite of the
fact that CB3717 proved to be too toxic for use in humans, the potent effect of this
compound under clinical conditions was the first evidence suggesting that designing
antifolates targeting thymidylate synthase or other folate-dependent biosynthetic enzymes
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had great chemotherapeutic potential (35, 117). This led to the synthesis of a number of
additional molecules that were more water-soluble and a second generation analogue of
CB3717, N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-methyl)-N-methylamino]-2thienoyl)-L-glutamic acid (DI694, ralitrexed, RTX), which was found to be more potent
and had less toxic side-effects than the parent compound (118). Like CB3717, RTX is a
substrate for FPGS, in fact, a far superior substrate, and polyglutamate deriatives are
more potent TS inhibitors than the than unmodified form of this compound (117, 118).
RTX is currently used in the treatment of advanced colorectal carcinoma disease in
Europe and Asia, but was never approved for use in the United States (50).
A second line of drug development efforts for tetrahydrofolate antimetabolites
resulted in the identification of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol,
DDATHF), a potent inhibitor of GART, an enzyme in de novo purine synthesis(18, 165,
237) (Figures 1-3 and 1-4). Cell culture experiments determined that DDATHF was a
potent inhibitor of cell growth and a very efficient substrate for FPGS, allowing
conversion of drug to polyglutamate forms at low µmolar concentrations in cells (18,
165). Further studies showed that the polyglutamated forms of this molecule were more
potent inhibitors of GART than the parent drug (205). DDATHF was a promising
antifolate; however, in phase I clinical trials DDATHF was found to induce severe
unmanageable thrombocytopenia which prevented repetitive administration of the
treatment (191).

After nearly a decade of attempts to circumvent this toxicity,

combination of DDATHF and folic acid tremendously improved the toxicity profile of
lometrexol(195), but the use of this compound in the clinic was never successfully
pursued.
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The efficiency of both 6-R and 6-S diastereomers of DDATHF as a substrate for
FPGS and the tight binding affinity of these compounds for GART initiated the synthesis
of second-generation de novo purine synthesis inhibitors. Eliminating the C5 methylene
position in DDATHF produced a potent cytotoxic agent, LY231514 (pemetrexed, PTX),
which was originally tested in human CCRF-CEM cells(238)(Figure 1-4). Surprisingly,
cell growth reversal studies determined that this agent was no longer an inhibitor of
GART, but rather a potent inhibitor of TS (238)(Fig. 1-2). PTX is a very efficient
substrate for FPGS, perhaps the most efficient FPGS substrate ever made, creating
anabolites that are retained intracellularly after drug exposure to submicromolar
concentrations of parent drug (224, 238). Very importantly, cell culture experiments
determined that, unlike other traditional TS inhibitors, administration of exogenous
thymidine, which prevents thymidylate synthase inhibition, does not completely reverse
the cytotoxic effects observed from the drug; this suggested that PTX had at least one
other target (224). A study of the activity of PTX against several recombinant rodent and
human enzymes in vitro led to the conclusion that both GART and DHFR were potential
secondary targets for the polyglutamate forms of PTX (224). PTX is currently used as
first line therapy for the treatment of non-small cell lung cancer and mesothelioma and is
being tested in phase II clinical trials for the treatment of renal cell cancer in combination
with gemcitabine (42). In chapter 4 of this dissertation, we questioned the conclusion
that GART and DHFR were the secondary targets of PTX, and found that in fact, the
additional site of PTX-mediated inhibition was AICART, a site of action that had
substantial impact for understanding the activity of this drug.
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The rationale for the design of antifolates as chemotherapeutic agents has been
based largely on the understanding that tumor cells are highly sensitive to alterations in
the pathways involved in nucleotide biosynthesis and amino acid metabolism. This has
proven very useful for the treatment of numerous types of cancers including ALL and
colorectal carcinoma with MTX and Ralitrexed, respectively. However, as is the case for
many classes of chemotherapeutic agents, the clinical use for many of these
antimetabolites is limited by toxicity in normal dividing tissues, such as those found in
the gastrointestinal tract. As such, a large effort has been made over the past two decades
to design drugs against molecular targets that are unique to tumor cells.

The

development and use of gleevec for the treatment of chronic myelogenous leukemia is the
prototypical paradigm for rational drug design (55). Gleevec specifically inhibits the
kinase activity of the Bcr-Abl fusion protein made from the gene modified by the
Philadelphia chromosome translocation, a protein that does not occur in humans without
this translocation (55), making treatment based on Bcr-Abl similar to antimicrobial
chemotherapy wherein drugs can be designed against proteins peculiar to prokaryotes.
Our laboratory has focused intensely on understanding the molecular basis for the
effectiveness of antifolate agents in an effort to identify a potential mechanism that could
be exploited to specifically target tumor cells with this class of antimetabolites. As
discussed above, central to the therapeutic utility of a large number of antifolates is their
ability to serve as an efficient substrate for polyglutamation, catalyzed by the enzyme
FPGS. A few laboratories, including ours, have focused on understanding the control of
this protein at the molecular level in normal tissues and tumor cells. FPGS protein levels
in mammals are regulated in both a division-specific and tissue-specific fashion and both
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of these controls occur at the transcriptional level (12, 71, 244). Abundant FPGS levels
are detected in all normal and neoplastic dividing cells and are only found in a few select
differentiated mammalian tissues (12, 166). In mouse, there are two isoforms of FPGS
produced from two promoters, which include different first exons in the mRNA: one
protein is found exclusively in dividing cells and the second is found only in
differentiated tissue (244). The isoforms of FPGS identified have different substrate
specificity attributed to the differences in the sequences of the N-terminal peptides (244).
These studies suggested that the design of antifolates specific for polyglutamation by
individual FPGS isoforms could be a potential mechanism of tissue-selective targeting of
antifolate therapy for cancer.

To date, appreciable levels of expression of only one

isoform of FPGS has been detected in human tissues, even though the second fpgs
promoter used in mice has been identified in humans (245). These observations initiated
the studies presented in chapters 2 and 3 of this dissertation. We sought an understanding
of the regulatory mechanisms involved in the synthesis of one FPGS isoform over a
second in mouse tissues. We identified and explored the epigenetic and transcriptional
interference mechanisms regulating the two promoters of the mouse fpgs gene, in an
effort to understand how tandem promoters are coordinately controlled in mammals and,
perhaps, to define the conditions where both promoters may be used in humans.
As discussed above, PTX inhibits TS primarily, but cell culture experiments
suggest that this drug also has activity against additional folate-dependent enzymes (224).
With the success of PTX in the clinical setting, understanding the additional targets of
PTX became highly relevant to both current treatment regimens and to identifying
additional cancer types that may be sensitive to PTX.
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We have recently performed a

series of cell culture experiments that have developed evidence that the target for PTX
secondary to TS is the second folate-dependent enzyme in de novo purine synthesis
AICART. These studies are discussed in chapter 4 of this dissertation. The significance
of this is substantial, since the substrate for AICART is ZMP, a known activator of the
AMP-activated protein kinase, AMPK (49), a key controlling element in the mTOR
pathway (48). The mTOR pathway, responsible for balance of energy metabolism,
protein and lipid synthesis, and growth, involves a series of upstream controlling proteins
recognized as tumor suppressor proteins, including LKB1, PTEN, TSC1 and 2, and
others recognized as cellular oncogenes, such as AKT and PI3 kinase (48).

Aberrant

mTOR regulation is a common phenotype to a variety of cancers due to loss of tumor
suppressors or over expression of oncogenes within the pathway. Inhibition of this
pathway by a clinically successful antifolate, PTX, suggests that its efficacy may involve
mTOR inhibition and the development of additional antifolates specifically blocking
AICART may be a promising molecular targeted approach towards neoplastic cells
dependent on overactive mTOR.
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Figure 1-2. Pathways involved in folate metabolism. GART (glycinamide
ribonucleotide formyltransferase), AICART (aminoimidazole carboxamide
ribonucleotide formyltransferase), DHFR (Dihydrofolate reductase), TS
(thymidylate synthase) THF (tetrahydrofolate), 10 CHO-THF (10-formyl
tetrahydrofolate), 5, 10 CH2 -THF (5, 10-methylene tetrahydrofolate). Adapted
from Dr. Julie Bronder’s dissertation (31).
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Figure 1-3. Steps in de novo purine synthesis. The two folate-dependent
enzymes in this pathway are glycinamide ribonucleotide formyltransferase
(GART) and aminoimidazole carboxamide formyltransferase (AICARFT).
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Figure 1-4. Chemical structures of the antifolate compounds (6R)DDATHF and 231514.
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Chapter 2: Multiple control mechanisms at the dual promoter mouse fpgs gene
responsible for coordination of tissue-specific expression in vivo.

INTRODUCTION
I. Folylpoly-γ-glutamate synthetase (FPGS) and the tissue-specific expression pattern
of the mouse fpgs gene.
In mammals, circulating folates are monoglutamate forms, which are best viewed
as the transport forms of this vitamin (24, 175). Folates serve as cofactors in metabolic
pathways that require one-carbon transfer; i.e., de novo purine synthesis and thymidylate
synthesis (9). Dietary folates are transported into the cell by the folate receptor, the
reduced folate carrier, and the proton-coupled folate transporter (30, 79, 190). After
passage into peripheral cells, folates are converted to poly-g-glutamate derivatives by the
enzyme folylpoly-g-glutamate synthetase (FPGS) (16, 167, 199). The addition of multiple
glutamate residues to these molecules traps them within the intracellular compartment.
Without this metabolic trapping mechanism, mammalian cells die for lack of the end
products of folate metabolism (157).
FPGS is also necessary for the action of most antifolates, and point mutations in
FPGS are a common mechanism for tumor cell resistance to these drugs (10). As is the
case for endogenous folates, polyglutamated antifolate molecules are not substrates for
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efflux and become concentrated within the intracellular compartment, maintaining the
inhibitory effects of these molecules throughout the lifespan of the cell, a major therapeutic
advantage for drugs that are efficient FPGS substrates. Since the cytotoxic effects of
antifolate therapies depend upon the presence of FPGS, determining the levels of this
protein in tumors and normal tissue was important to identify candidate tumor-types and
normal tissues that would be highly sensitive to these therapies.
Early studies carried out by Moran and Colman used an in vitro enzyme assay to
determine the FPGS activity in normal and neoplastic tissues of the mouse (166). The
distribution of FPGS activity found in these mammalian tissues suggested that the
expression of this protein was under strict regulation (12). High levels of enzyme activity
were detected in all normal and neoplastic dividing cells, as well as certain tissues with a
known dividing cell compartment, i.e. intestinal epithelium (12). In contrast, analysis of
differentiated mouse tissues determined that only in mouse liver and kidney are
measurable levels of FPGS expressed (12). Further analysis in developing rodent fetal
tissues supported the idea that rapidly dividing cells require FPGS (12). In contrast,
maturation of adult tissues and the induction of cellular growth arrest precipitated a rapid
decline in FPGS expression (12, 59). From these studies, it was concluded that FPGS
expression is controlled by mechanisms linked to both cellular proliferation and tissue
specificity (12, 59).
The concept that transcriptional regulation is involved in establishing the FPGS
activity patterns was first suggested through Northern blot analysis performed by Sarah
Freemantle, a previous post-doctoral fellow in this laboratory, examining the levels of fpgs
15

mRNA in several tissues of the mouse (71) (Fig 2-1). The results of this experiment
showed striking patterns of tissue-specific fpgs mRNA expression. Abundant levels of
fpgs transcript were detected in mouse leukemic cells, L1210, and in two differentiated
tissues: mouse liver and kidney (Fig 2-1). These expression profiles of fpgs mRNA
determined for each tissue paralleled the FPGS pattern of activity found in previous studies
(71). The Northern blot studies supported the original idea that the control of FPGS
expression is based on mechanisms that are both division-specific and tissue-specific and
suggested that regulation was occurring at the level of transcription.
The mouse fpgs gene has two promoters spaced 9.5 kilobases apart within a
genomic locus spanning 20 kilobases (Fig. 2-2) (200, 201, 244).

The downstream

promoter (P2) is located in a CpG island and is activated when three Sp1 proteins bind to
the consensus sites located immediately upstream of the transcriptional start site (43). The
upstream promoter (P1) is classified as CpG-sparse, and while attempts have been made to
understand the cis elements and trans-acting factors controlling P1, they remain poorly
defined (43). This is most likely the case because studies performed to identify regulatory
regions using reporter promoter constructs are based on transient transfections of dividing
cells, but the P1 promoter is expressed only in differentiated tissue and the required factors
may not be present in the transfected cell line. Transcripts generated at P1 include two
upstream exons (A1a and A1b) linked to exons 2-15 (Figure 2-2) (202, 244). In contrast,
when P2 is used, mature transcripts contain exons 1-15 (Figure 2-2). The alternate fpgs
mRNAs produce two isozymes with regulatory consequences: the protein generated from
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P2 transcript is subject to feedback inhibition by folate polyglutamates, and the enzyme
encoded by P1 mRNA is less sensitive to this control (7).
Fiona Turner, a former student in this laboratory, used ribonuclease protection
assays (RPAs) to define the conditions for the use of the two mouse fpgs promoters (244).
These studies uncovered an additional layer of complexity at the mouse fpgs gene that
greatly helped to explain earlier data. Dr. Turner’s studies established the premise for the
experiments discussed in this chapter: she established that the use of the P2 promoter is
reserved for all neoplastic and normal dividing cells (244). This conclusion was stated on
the basis of definitive RPAs demonstrating that fpgs mRNA from dividing cells, i.e.
L1210, when hybridized to a probe from the P1-specific exon generated a protected
fragment size supporting that the fpgs mRNA contained exons 1/4, but not exons A1a or
A1b (Figure 2-3, left panel). However, when L1210 mRNA was hybridized to the P2
probe, the protected fragment size indicated the presence of exons 1-4 in the fpgs transcript
(Figure 2-B, right panel). In contrast, P1 was found to be the promoter almost exclusively
used in mouse liver and kidney, as evident by the fragment size detected when the P1
probe was hybridized to the fpgs mRNA (Figure 2-3, left panel) (243, 244). Hence, from
these studies it appeared that transcriptional initiation at the mouse fpgs gene is tightly
regulated to ensure that tissues expressing this gene are restricted to the use of only one
promoter.
We were very interested in these observations and saw the mouse fpgs gene as an
excellent model of a complex genetic locus employing the use of multiple mechanisms to
achieve tissue-specific patterns of expression from two promoters. We designed a series of
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studies aimed at understanding the transcriptional mechanisms dictating promoter choice at
the mouse fpgs gene permitting the synthesis of one FPGS isoform over the other in a
tissue-specific fashion. Our studies focused on mechanisms of epigenetic regulation and
transcriptional interference at the mouse fpgs locus.

II. Basic mechanisms of transcription
A. Overview
The process of transcription can be divided into three general stages: initiation,
elongation, and termination.

Throughout the transcription cycle the transcriptional

machinery is faced with substantial obstacles that must be managed in order to maintain
high fidelity transcription.

These challenges include but are not limited to: 1. steric

hinderance by nucleosome placement along the DNA, 2. pre-mRNA processing involving
splicing factors and machinery to ensure correct mature mRNA synthesis, and 3. 5’
capping and 3’ end polyadenylation. As a result, every phase of the transcription cycle
requires a highly coordinated interplay between RNAPII, transcription factors, histone
modifying enzymes, chromatin remodelers, and mRNA processing factors. We discuss the
stages of transcription and some mechanisms involved in regulating transcription below as
separate sections for the sake of clarity, keeping in mind that it is the interplay of all these
events that coordinate the complex patterns of eukaryotic gene expression (Figure 2-4).

B. General features of transcriptional initiation:
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The formation of a pre-initiation complex (PIC) occurs when the general
transcription factors IID, IIB, IIE, IIF, IIH, TBP and RNAPII assemble at the promoter
region of a gene (90). Activators bind cis elements located upstream of the core promoter
and recruit coactivator complexes, such as SAGA and/or mediator, that mediate regional
acetylation of histones and chromatin remodeling to allow PIC formation (90, 132). An
open complex is formed when the helicase activity of TFIIH melts the DNA surrounding
the transcriptional start site and the template is positioned in the active site of RNAPII (90,
132). Transcription initiation begins when the first phosphodiester bond of RNA is formed.
Upon successful initiation, the complex undergoes a process referred to as promoter
clearance, often involving a series of abortive initiation events (Fig 2-4). In cases where a
gene is actively transcribed, RNAPII escapes from the factors bound to the promoter and
proceeds down the template strand in the 3’ to 5’ direction.

C. General features of transcriptional elongation
During elongation, a set of regulatory proteins traverse the coding region through
direct interactions with RNAPII, unlike the DNA binding proteins associated with
initiation. The C-terminal domain (CTD) of the Rbp1 subunit of RNAPII provides the
scaffold for secondary proteins to bind to the elongation complex (2, 90, 104, 133). This
region is composed of 25-52 repeats of the heptad sequence YSPTSPS. The differential
phosphorylation of the serines at positions 5 and 2 determine the proteins recruited to the
enzyme along the length of the gene (90, 133) (Fig 2-4). At the 5’ end of a gene, CDK7, a
kinase in the TFIIH complex, phosphorylates serines at the 5 position of the heptad repeat
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potentially generating a highly modified CTD (Figure 2-4). This modification recruits and
activates the 5’ mRNA capping machinery through binding guanyltransferase, a member
of the capping complex (104). Additionally, phosphorylation of serine 5 of the CTD
recruits the Polymerase Associated Factor (PAF), which facilitates the binding of histone
H3 lysine 4 methyltransferase (HMTs), and FACT, a histone chaperone needed to mobilize
nucleosomes off the DNA 3’ to the elongation machinery and replace the nucleosomes
behind the transit of the elongation complex (92, 141, 262). Towards the 3’ end of a gene,
phosphorylation of Serine 2 accumulates as a consequence of CDK9 kinase activity, a
protein member of the P-TEFb elongation complex (2) (Figure 2-4). This modification
recruits polyadenylation factors and histone H3 lysine 36 methyltransferase, proteins
specific for the terminal phase of the transcription cycle (2, 130) (Figure 2-4). The
distinguishing features of the proteins bound to RNAPII and the CTD PTMs during the
transcription cycle provide methods for distinction between the different phases of
transcription. We employed the use of these tools in our studies examining transcriptional
processes occurring at the mouse fpgs gene.

D. Promoter-proximal pausing
Promoter-proximal pausing, also known as stalling or poising, was first described
at c-myc, human-immunodeficiency virus (HIV), and heat shock response genes in
Drosophilia (184). In the original studies at the c-myc gene, full-length mRNA levels of
c-myc declined upon cellular differentiation, but nuclear run-on assays detected persistent
RNA synthesis between exon 1 and intron 1 (19).
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The results from these experiments

suggested that the 5’ end of the gene was engaged in the production of mRNA transcript,
even when full-length c-myc mRNA was not being produced. As such, it appeared that a
block at elongation, rather than initiation was controlling expression of c-myc mRNA (19).
The components controlling promoter-proximal pausing have been identified largely
through

studies

using

transcription

inhibitor

5,6-dichloro-1-b-

Dribofuranosylbenzimidazole (DRB) (154). Increasing doses of DRB have been shown to
greatly reduce the synthesis of 100 nt transcript in vitro, but short-length transcripts of 2530 nt were able to accumulate even at high concentrations of drug, suggesting that drugmediated inhibition of transcription occurred at a point in elongation (253). Two negative
elongation factors, DRB sensitivity-inducing factor (DSIF) (252) and Negative Elongation
Factor (Nelf) (264) were identified in studies examining the components responsible for
DRB sensitivity (Figure 2-4).

These proteins associate with RNAPII and have been

shown to control promoter proximal pausing in both Drosophila and human cells (259).
PTEFb is DRB-sensitive and responsible for the release of RNAPII complexes from a
stalled mode to a productive elongation state (153, 154) through the phosphorylation of
serine 2 of the CTD of RNAPII and DSIF and NELF (184) (Figure 2-4) (266). Current
thought proposes that the phosphorylation of DSIF and NELF results in the release of
NELF from the stalled complex, and the entrance of TFIIF, a factor that enhances
productive elongation (46). While many of the major players involved in promoterproximal pausing have been identified, the sequence of events leading to the establishment
of a poised state and the release from pausing into a productive elongation mode are
largely unknown.
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E. Tissue-specific expression
Over two hundred different cell types comprise mammalian organisms and are
created from varying transcription of an identical genomic sequence. A population of
mRNA transcripts is common to all cells, and are generated from genes commonly referred
to as housekeeping genes, however expression of unique subsets of genes are reserved for
specific cell-types and the resulting expression patterns establish cellular identify. A major
determinant of tissue-specific expression is the production of lineage-specific transcription
factors in developing and differentiated tissues. Tissue-specific transcription factors bind
cis-acting DNA elements and through direct interactions with basal transcriptional
machinery and coactivators or corepressors impact gene expression. For example, there are
six families of liver-specific factors characterized to date: HNF1, HNF3, HNF4, HNF6,
C/EBP and D-binding protein (215), and their presence support the expression of liverspecific genes in developing and differentiated hepatocytes (266). The expression of liverspecific genes is hugely important in maintaining a differentiated state, and loss of HNF1
and HNF4 is a common feature of mammalian hepatoma cell lines. Re-expression of these
proteins has been correlated with the reestablishment of liver-specific cellular processes
found in mature hepatocytes (228).
The accessibility of consensus sequences in tissue-specific promoters to the DNA
binding proteins is considered to play a major role in regulating patterns of tissue-specific
gene expression (215).

As such, patterns of chromatin histone post-translational

modifications (PTMs) and DNA methylation should be considered regulators of tissuespecific expression. For instance, precedent literature argues that certain histone PTMs are
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a prerequisite for the sequence-specific binding of the transcription factor Myc (86). The
role of epigenetics in tissue-specific expression remains incompletely studied. Hence, we
have considered the mouse fpgs gene as a model of tissue-specific expression and set out to
examine the patterns of DNA methylation and histone PTMs across this locus in different
tissues to address the potential roles of these epigenetic mechanisms in establishing the
tissue-specific expression patterns observed.

III. Epigenetics mechanisms and transcription
A. General comments
Epigenetics is the “study of heritable changes in gene function that occur without
changing the underlying DNA sequence”. The field of epigenetics is extremely broad and
covers topics of chromatin biology, DNA methylation, and non-coding RNAs.

The

importance of these processes in gene regulation is tremendous and genome-wide studies
using advanced ChIP-Chip and ChIP-Seq technologies have drastically enhanced our
awareness of the complexities involved in epigenetic regulation. However, we are far from
understanding the entire story. In fact, a current challenge of the field is understanding the
interplay between the different epigenetic mechanisms and defining the sequence of events
leading to observable changes in gene regulation. In our studies, we have used the mouse
fpgs gene as a model to consider the potential cooperation between chromatin structure and
modifications and DNA methylation in the determination of tissue-specific patterns of
expression in the adult animal.
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B. Histone biology
A major step forward in understanding the chromatin structure was taken in 1974
by Robert Kornberg, when he proposed that the structure was based on a repeating unit of
two molecules of the histones H2A, H2B, H3, and H4, and approximately 200 base pairs
of DNA (Figure 2-5) (134). Interestingly, the concept that histones were not simply
structural obstacles interfering with RNA synthesis was described ten years prior to
Kornberg’s chromatin structure theory, when a series of experiments revealed that nuclear
histones were both acetylated and methylated (6). In this study, Allfrey proposed that such
modifications, particularly acetylation, “may affect the capacity of histones to inhibit
ribonucleic acid synthesis in vivo” (6).
The fields defining the roles of chromatin structure, modifications, and function in
DNA replication and RNA transcription have greatly expanded the observations made in
these initial studies. The positioning of nucleosomes within the genome appears to be
highly regulated, supported by the fact that nucleosome free-regions exist at a large
proportion of promoter regions across the genome (141). Assembly of Kornberg’s histoneDNA units, now called the nucleosome, positions the amino-terminal tail of each histone
such that it protrudes from the core structure and is available to serve as a substrate for
modifying enzymes (135).

Histone post-translational modifications (PTMs) include

acetylation, methylation, phosphorylation, ubiquitination, and sumoylation (135) (Figure
2-5). The enzymes responsible for modifying histones are recruited to specific positions in
chromatin often through protein-protein interactions with molecules involved in
transcriptional elongation, DNA methylation, and variety of other cellular processes.
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These interactions result in the deposition of histone PTMs across chromatin in a highly
ordered fashion to create a pattern of histone PTMs, originally referred to as the histone
code (119), which are now thought to be critically involved in the regulation of
transcription.
The truly sweeping functions of histone PTMs are currently an area of intense
investigation. Current thought proposes that the roles of histone PTMs in transcription can
be classified into at least one of three general mechanisms: 1. Histone PTMs, such as
histone acetylation, affect chromatin stability and structure leading to changes in DNA
availability to factors in the cellular milieu, 2. Histone PTMs can alter the genomic
processes occurring at a specific DNA location by either preventing or recruiting the
binding of factors to modified areas of chromatin, and 3. Histone PTMs are dynamic and
reversible and reflect the changing activities over a stretch of DNA sequence. Several
histone PTMs known to be involved in transcription have been profiled across the locus of
a highly active gene with a single promoter (247). In the studies discussed in this chapter,
we extended these observations through the examination of several histone PTM profiles
over the two promoters of the mouse fpgs gene in several tissues.
i. Chromatin modifications involved in transcriptional regulation
We elected to profile histone PTMs across the mouse fpgs gene that are known to
play a role in the transcriptional activation or repression of genes in yeast and other
systems (141). We studied histone H3 and H4 acetylation, as well as, histone methylation

25

at lysines 4, 9, 27, and 36.

Composite profiles of these modifications generated from

genome-wide studies in yeast are shown in Figure 2-6.

ii. General terms and concepts
Bromodomain:

Proteins that contain this domain bind to acetyl-lysine residues in

histones N-terminal peptide tails.

Structural analysis of the p300/CBP coactivator

identified three amino acid residues, Tyr 760, Tyr 802, and Asn 803, involved in
recognition of the acetyl-lysine and these residues are conserved across family members
(168).

The aromatic residues form a hydrophobic binding pocket in which neutral

acetylated lysines are bound preferentially to unmodified lysine residues (27). Additional
proteins containing bromodomains have a range of functions and include HATs (i.e.
GCN5), transcription factors (i.e. TAFII250), and chromatin remodelers (i.e. Brg1 in
Swi/Snf complex) (168).
Chromodomain: This domain consists of 50 amino acids and is composed of α-helices
and a three stranded anti-parallel β-strand sheets. Chromodomains are found in a variety
of proteins and facilitate protein-protein and protein-DNA interactions (27).

One

important recognition site for chromodomains is methylated lysines within histones, which
allows the docking of proteins involved in chromatin regulation directly to the nucleosome.
Heterochromatin Protein 1 (HP1) was the first protein identified to bind histones through
its chromodomain at methylated lysine 9 of histone H3 (172). Structural analysis of HP1
with a methylated histone H3 peptide revealed that three aromatic side chains Tyr 21, Trp
42, and Phe 45 form a hydrophobic binding pocket for the N-methyl groups on lysine 9
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(172). Chromodomain containing proteins include chromatin remodeling complexes (e.g.
CHD1 and Mi2) and Polycomb proteins (135).
SET domain containing methylases: This class of enzymes are responsible for the
methylation of lysines at residues 4, 9, 27 and 36 of histone H3 (225). Structural studies
have shown that the N-terminal and C-terminal regions of the domain orient to form a
hydrophobic pore, referred to as the lysine-access channel, which positions lysines in close
proximity to the methyl donor S-adenylhomocysteine (27).
Polycomb complexes: Polycomb group proteins (Pcg) mediate the stable repression of
key developmental genes in embryonic stem cells to maintain a state of pluripotency (29).
The PcG proteins form two complexes, Polycomb repressive complex (PRC) 1 and 2.
PRC2 is composed of EE2, EZH2, and SUZ12 in mammals and is directed to target genes
through recognition of the DNA cis element the Polycomb Response Element (Pre) (225).
EZH2 catalyzes the addition of methyl groups to lysine 27 of histone H3(225). PRC1
directly binds to H3K27me3 and stabilizes compaction of chromatin and transcriptional
repression. Genome-wide studies using mouse and human embryonic stem cells have
located PRC2 and PRC1 components at genes predominately involved in development and
differentiation (29, 139).

iii. Histone acetylation and deacetylation
Histone acetylation is the most comprehensively studied histone PTM to date and is
a proven component of several aspects of histone biology, including nucleosome assembly,
chromatin folding, and transcriptional control (218). The addition of an acetyl group to the
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ε-amino of specific lysines within the histone tail neutralizes the positive charge of this
region, which, in the context of the nucleosome, disrupts the charge-charge interaction
between the positively charged histone tail and the negatively charged DNA (218). As a
result, nucleosome stability is compromised and the availability of DNA sequence to the
binding of cellular trans factors necessary for transcription is greatly enhanced (249).
Additionally, acetylated histones are docking sites for proteins with bromodomains (135).
All four of the core histones serve as substrates for the family of histone
acetyltransferases (HATs), which carry out the enzymatic acetylation of histone tails (218).
Interestingly,

several

transcription

regulatory

proteins,

i.e.

TAFII250,

possess

acetyltransferase activity (230). In contrast, histone deacetylases (HDACs) are a class of
proteins that remove acetyl groups from lysines. HDACs mediate the silencing of genes
and are often associated in multi-subunit repressor complexes (218). HDACs detected at
the coding regions of active genes have been shown to facilitate transcriptional elongation
through preventing initiation at cryptic promoters located within the body of genes.
Recent studies have described that histone acetylation at active genes is restricted to
the 5’end of the locus (Figure 2-6) (247). Genome-wide studies in yeast and higher
eukaryotes have mapped the acetylation of lysines 9 and 14 of histone H3 and lysine 16 of
histone H4 to the 5’ end of active genes (186, 198, 216).

Interestingly, abundant

acetylation at these lysines has also been detected across promoter regions poised for
transcriptional activation, such as the p21 promoter (81). Commonly detected profiles of
histone H3 and H4 acetylation across an active genetic locus are illustrated in Fig 2-6.
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iv. Histone lysine methylation
Genome-wide studies have shown that different histone methylation profiles can be
used to distinguish genomic regions as transcriptionally active or silent. Both lysines and
arginines within the histone tails are acceptor sites for methylation (225). The ε-amino
group of histone lysine residues can accept up to three methyl groups and therefore can
exist in either a mono-, di-, or tri-methylated form, adding an additional layer of
complexity to this class of histone PTMs compared to histone acetylation (225). The
family of enzymes responsible for methylating histone lysines is referred to as histone
methyltransferases (HMTs), and the residues discussed below are substrates for the SET
domain-containing class of HMTs (225). Originally, chromatin marks of histone
methylation were thought to be permanent, but the first histone demethylase, LSD1, was
identified a few years ago and several other classes of demethylases have since been
identified (222). Because lysine residues 4, 9, 27, and 36 within histone H3 have a
recognized involvement in the regulation of transcription in other systems, we questioned
their role in the regulation of the tissue-specific expression patterns of the two mouse fpgs
promoters.

a. Histone H3 lysine 4 methylation
Histone H3 lysine 4 methylation (H3K4me) is considered a mark of euchromatin,
as such it is detected across genomic regions that either are currently generating transcript
or are poised for activation (87, 207). The patterns of H3K4me1, 2, and 3 described in
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yeast are shown in Fig 2-6. In yeast, H3K4me1 peaks at the 3’end, H3K4me2 is detected
over the coding region, whereas H3K4me3 is restricted to the 5’ ends of active genes (186)
(Fig 2-6). Genome-wide maps of histone methylation patterns in mouse and human cells
showed that all three methylation states correlate with transcriptional levels, but at highly
active genes H3K4me3 was greatly increased and mono- and di- forms of this modification
were substantially less abundant (15, 20). The link between H3K4me3 and the 5’ end of
genes has been greatly expanded upon over the past year (see discussion).
As discussed above, the phosphorylation of RNAPII within the CTD recruits the
Paf1 complex, which binds directly to at the 5’-end of genes to the histone H3 lysine 4
methyltransferases, such as Set 1. This results in the deposition of methyl groups on lysine
4 of regionally positioned histone H3 (136). Interestingly, the recruitment of PAF is also
thought to facilitate ubiquitination of histone H2B lysine 120 (261), a modification that has
been shown to be important in the addition of the second and third methyl groups at lysine
4 of histone H3 (54).
The functions of H3K4me3 are still being uncovered but its importance in
facilitating transcription is highlighted by the fact that the chromatin-remodeling complex,
NURF, has been shown to bind to this PTM through a PHD finger domain (143).
Interestingly, evidence suggests that the presence of methylation of histone H3 at lysine 4
may be integral in preventing transcriptional repression of marked promoters from de novo
DNA methylation. Recently, LSD1, a demethylase specific for lysine 4 and 9 of histone
H3, has been shown to be required for the maintenance of global DNA methylation in
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mouse development (255).
b. Histone H3 lysine 36 methylation
In yeast and mammals, histone H3 lysine 36 methylation is also abundant across
actively transcribed genes. While all three methylation states exist to some degree at
active genes, most of the current work has focused on the tri-methylated state at lysine 36
of histone H3 and its role in transcriptional regulation.

Genome-wide studies in yeast

have determined that this histone PTM is most abundant towards the 3’ end of active
genes, in striking contrast to the pattern determined for H3K4me3 (Fig 2-6). Studies at
highly active mammalian genes have also found H3K36me3 enrichment at the 3’ end of
these loci (11, 247). The contrast between the distribution of H3K4me3 and H3K36me3
across active genes is extremely interesting. Like the family of histone H3 lysine 4
methyltransferase, the localization of HMTs specific for lysine 36 (i.e. Set 2) are
dependent upon the phosphorylation status of the CTD of RNAPII, but unlike H3K4me3,
H3K36me3 is coincident with the phosphorylation of serine 2 residues within the CTD of
RNAPII (130).
The function of H3K36me3 appears to mediate transcriptional repression in the
coding region of active genes. The mechanism of H3K36me3-mediated transcriptional
repression was uncovered in two studies that determined that H3K36me3 was bound by a
Rpd3, a histone deacetylase complex, via the chromodomain of Eaf3, a subunit of the
Rpd3 complex (38, 128). Thus, H3K36me3 appears to establish compact chromatin in the
wake of elongating RNAPII, preventing initiation at cryptic promoters that have been
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released from bound nucleosomes by the passage traveling RNAPII through the genomic
region.
c. Histone H3 K27 methylation
The different methylation states of histone H3 lysine 27 are associated with both
euchromatic and heterochromatic states of chromatin. H3K27me1 has been detected in
human cells most abundantly at active promoters, whereas H3K27me2 and me3 levels
were higher at silent promoters (15).

H3K27me3 serves a docking site for the

chromodomain of PRC1 (225), which results in polycomb-mediated heterochromatin
formation (see above).

The role of H3K27me1 at active promoters remains poorly

understood.
d. Histone H3 K9 methylation
Histone H3 lysine 9 methylation is a histone PTM that has been detected at both
euchromatic and heterochromatic regions of chromatin in higher eukaryotes. Lysine 9
methylation of histone H3 creates a binding site for the heterochromatin protein 1 (HP1)
family of molecules.

In euchromatin, both H3K9me2 and me3 are often found at

promoters that are transcriptional silent and the coding regions of active genes (Fig 2-6).
In contrast, H3K9me3 is the mark that is predominately found throughout the entire region
of heterochromatin. Su(var)3 was the first HMT identified and it is responsible for the
methylation of lysine 9 of histone H3 in Drosophilia (192). Several homologues of
Su(var)3 have been shown to methylate lysine 9 in mammals including Suv39h, G9a and
Eu-HMTase I. Interestingly, studies in knockout ES cells determined that G9a and Eu32

HMTaseI are critical for establishing the patterns of H3K9me2 in euchromatin, whereas
disruption of Suv39h results in the loss of H3K9me3 in heterochromatin (53).
A very interesting aspect of H3K9 methylation is the potential connection between
this histone PTM and DNA methylation in mammals. Previous work has shown that
H3K9 methylation directs DNA methylation in Neurospora crassa and Arabidopsis
thaliana, but the causal relationship between these two epigenetic marks in mammals
remains largely unknown (74).

Evidence exists to supports each of these epigenetic

modifications, i.e. DNA methylation and H3K9 methylation, as the primary mediator of
transcriptional silencing (140, 210). For example, the methyl-binding protein -1 (MBD1)
is known to interact with the lysine 9 specific HMT, SETDB1, suggesting that DNA
methylation may be a prerequisite for H3K9 methylation (210). In contrast, studies in
Suv39h -/- embryonic stem cells showed a substantial reduction in H3K9me3 and DNA
methylation across silenced genomic regions, supporting the counter argument that H3K9
methylation mediates DNA methylation (140).
C. DNA methylation as an epigenetic mark and regulator of transcription:
DNA methylation occurs at CpG dinucleotides and is an epigenetic modification
required by mammals to ensure proper embryonic development and survival (142). The
DNA methyl transferases (Dnmts) are the enzymes responsible for establishing and
maintaining genomic methylation patterns (131). The de novo Dnmts, Dnmt3a and
Dnmt3b, modify unmethylated DNA, whereas Dnmt1 acts on a hemi-methylated substrate
during replication. DNA methylation is thought to mediate transcriptional repression by
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masking DNA binding regions from sequence specific transcription factors or by the
recruitment of methyl binding proteins (MBPs) (Figure 2-7) (131). MBPs have been
shown to complex with HDACS, chromatin remodeling complexes, and histone H3 lysine
9 methyltransferase to establish a repressive chromatin state (Figure 2-7) (123, 131, 210).
Although the interplay of histone PTMs and DNA methylation has been shown to exist, the
sequence of events leading to a transcriptionally inactive state remain open and
unanswered.
Two types of promoters exist in the mammalian genome when classified by CpG
dinucleotide content: regions with densely packed CpGs, called CpG islands, compose
60% of mammalian promoters and are usually found unmethylated (23). The second
category includes promoters with a sparse number of CpGs that are often methylated (23).
This profile of methylation is established during embryogenesis and is stable in normal
somatic cells (193); however, certain tissue-specific genes undergo demethylation in their
tissue of expression (32, 75, 227). Whether demethylation at these genes is a primary
event or a consequence of transcriptional activation by other mechanisms is unknown.
While a requirement for DNA methylation has been well established in genomic
imprinting, X-chromosome inactivation, and in the progression of certain cancers, its
participation in the regulation of TSE in normal tissues remains unclear (121). Recently,
genome-wide studies have provided evidence supporting a role for DNA methylation in
TSE (58, 227). In those studies, a proportion of mammalian promoters were methylated in
a tissue-specific manner, and this methylation was correlated with transcriptional silencing
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(58, 227). In the experiments discussed in this chapter, we explored the role of DNA
methylation in the regulation of the tissue-specific expression of the P1 promoter.

IV. Concepts of Transcriptional Interference
Transcriptional interference (TI) in broad terms describes a situation where
transcriptional processes at one genomic region influence the potential for transcriptional
activity at a second genomic region, which is usually located immediately upstream or
downstream.

TI mechanisms thought to be involved in gene regulation include: 1)

competition for cis elements or trans factors required for transcriptional activation, which
has been proposed to regulate the β-globin locus during mouse development (70); 2)
histone PTMs positioned across a genomic region as a consequence of transcriptional
activity at one locus preventing initiation at a second gene, i.e. H3K36me3 deposition in
the body of a gene prevents initiation at intragenic promoters (128); and 3) promoter
occlusion, where transcription complexes generated at one gene blocks initiation at a distal
gene by preventing transcription initiation factors and machinery from properly interacting
with the promoter region (28, 62, 83, 107, 155).
With the increasing number of genes found to have multiple promoters, it has
become increasingly important to understand if and how TI may influence the conditions
under which certain promoters within a genetic locus are used. The two promoters of the
mouse fpgs gene are arranged in tandem and are regulated such that use of each promoter
is controlled in a tissue-specific fashion. We questioned if and how processes of TI
dictated promoter choice at the locus in different tissues of the mouse.
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V. Objectives of this study
Previous studies in our laboratory and others determined that the mouse fpgs gene
is expressed in a tissue-specific fashion and possess two promoters that are used under
discrete conditions: the upstream P1 promoter is active exclusively in mouse liver and
kidney, while the downstream P2 promoter is utilized by all dividing tissues and cells
(244). In this study, we investigated how the two mouse fpgs promoters are controlled to
accomplish this tissue-specific pattern of expression. We identified several mechanisms
regulating expression from this locus including epigenetics, transcriptional interference,
and factors pausing early stages of elongation. There were three critical pieces of data that
lead us to explore the relevance of epigenetics and transcriptional interference in the
control of the mouse fpgs gene: 1. P1 was determined to be within a tissue-specific
differentially methylated region (TDMR), where methylation of P1 inversely correlates
with promoter activity (Fig 2-9). 2. DNAse hypersensitivity analysis determined that the
chromatin structure surrounding P2 is open and sensitive to DNAse I digestion in all
tissues, but P1 is only digested in liver and kidney, when this promoter is active. It
appeared that DNA methylation and chromatin state may determine the tissue-specific
expression from P1. 3. Real-time analysis of fpgs mRNA levels generated from P2 in
mouse liver determined that expression from P2 in this tissue is measurable, in contrast to
the situation in mouse brain where fpgs mRNA levels are undetectable, but transcription is
severely restricted when compared to the levels detected in L1210 cells (Table 2-2). These
data suggested that the P2 promoter in mouse liver was capable of firing, but was being
repressed, perhaps because of happenings at P1 in this tissue. Based on these studies, we
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aimed to gain insight into the profiles of histone PTMs and transcriptional complexes
across the entire fpgs locus in L1210 cells, mouse brain, and liver.

MATERIALS AND METHODS
Materials
C57BL/6 mice were used in all the mouse studies and were originally obtained from
Charles River. Chemicals and reagents were purchased from Sigma (St. Louis, MO) and
Fischer (Pittsburgh, PA).

Antibodies were obtained from Upstate Biotechnology

(Billerica, MA), Santa Cruz (Santa Cruz, CA), and Abcam (Cambridge, MA) and will be
discussed individually in the sections to follow. Protein G Sepharose (cat #17-0618-01)
beads were purchased from Amersham Biosciences (Uppsla, Sweden).

25 nmoles of

DNA oligo primers were purchased for these studies from Intergrated DNA Technologies
(IDT). Quanti-tect Sybr Green PCR Master Mix (product # 204143) was purchased from
Qiagen (Valencia, CA) and used for all of the Real-time PCR analysis. A bath sonicator
(Diagenode) was used to shear genomic DNA into 100-300 bp size fragments. The Realtime PCR machines used in these studies were BioRad DNA Engine Peltier Thermal
Cyclers with a Chromo 4 Real-Time Detector attachment. Opticon Monitor Software was
used to analyze the Real-Time data.
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Cell culture
L1210 mouse leukemic suspension cells were maintained at a density between 105106 cells/ml in RPMI-1640 medium (Gibco/Invitrogen) supplemented with 10% Fetal
Bovine Serum (FBS) and stock cultures were fed every 2 days. Cells were grown at 370C
in 5% CO2.

Chromatin Immunopreciptation (ChIP)-histone modifications.
Harvesting and cross-linking mouse brain and liver
C57BL/6 were anesthetized using isoflurane and sacrificed by cervical dislocation.
Blood was removed from the liver in situ by flushing cold phosphate buffered saline (PBS)
into the hepatic vein using a 21-gauge needle and syringe. The organs were harvested and
diced using a sterile razor blade and the tissue was weighed. Diced mouse liver or brain
(300-500 mg) was placed in 30-40 mls of RPMI-1640 supplemented with 10% FBS and
1% formaldehyde (HCHO). The samples were rocked at 250C for 10 minutes (brain) or 15
minutes (liver). Fixation was stopped by the addition of glycine to the media to achieve a
final concentration of 0.125M. The samples were rocked at 250C for an additional 5 min.
Tissue samples were pelleted by centrifugation at 450 x g at 4oC for 10 minutes. Pellets
were resuspended in 5 mls of PBS with 1mM phenylmethanesulphonylfluoride (PMSF),
swirled, and poured into a Dounce homogenizer.

Samples were dounced 20-24x to

achieve single cell suspension. PBS with 1mM PMSF (12 mls) was used to rinse out the
dounce homogenizer and samples were passed through sterile gauze to remove tissue
clumps. The suspensions were spun down at 1500 RPM at 4oC for 10 minutes.
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Cross-linking L1210 cells
L1210 cells were suspended at a density of 5 x 105/ml with 1% HCHO in RPMI1640 medium in a T175 flask. The cell suspension was gently stirred with a small stir bar
at 250C for 8 minutes, to ensure that the cells did not settle to the bottom of the flask
during cross-linking.

Glycine was then added to the media to achieve a final

concentration of 0.125 M and the cells were mixed for an additional 5 minutes. Ten million
cells were pelleted by centrifugation at 1500 RPM at 4oC for 10 minutes, resuspended in 5
mls of PBS + 1mM PMSF, and again pelleted.
Cross-linked cells and mouse tissues were washed in buffer I (0.25% Triton X-100,
10mM EDTA pH 8.0, 0.5mM EGTA pH 7.5, 10mM Hepes, pH = 7.5), and then in buffer
II (0.2M NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA pH 7.5, 10mM Hepes, pH 7.5) All
ChIP buffers contained 1 µg/ml pepstatin, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 mM
fresh PMSF. Stock concentrations of 0.5M Tris, pH 7.5 and 8.0 were prepared by adding
the recommended amounts of Trizma-HCL and Trizma-base using the Trizma chart to
achieve the appropriate pH at 250C. The pH of the solution was then measured using at
250C using a Mettler Toledo pH meter. Hepes, buffer pH 7.5 (1M) was prepared and pH
was adjusted using 8 N NaOH. Cells were pelleted and frozen at -800C or processed as
described below.
Protein G Sepharose Bead preparation and Immunoprecipitation
The 300 mg of liver, 100 mg of brain, or 2.5 x106 L1210 cells were resuspended in
300 µL samples of lysis buffer 25 mM Tris buffer, pH 7.5 (containing 150 mM NaCl, 5
mM EDTA, 1%Triton X-100, 0.1 % SDS, and 0.5 % sodium deoxycholate), and sonication
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was carried out in a bath sonicator (Diagenode) to achieve 100-300 bp DNA
Fragmentation of the DNA was followed by reverse cross-linking and purifying DNA (for
details see below) from 20 µl aliquots of sample followed by visualization of fragment
sizes on a 1% agarose gel stained with Ethidium Bromide (Fig 2-8) . Sonication was
performed with repeated cycles of 30 sec pulse and 30 sec off, followed by the addition of
fresh cold ice water to the bath. The total sonication time for each sample was 25 minutes
(liver and brain) and 20 minutes (L1210 cells). Following sonication, the samples were
spun down at 21,000 x g, at 4o C for 10 minutes. The supernatant was removed and all the
samples were pooled for each tissue. The samples were then diluted to achieve the final
tissue ratios used in the immunoprecipitation: 50 mg (liver), 30-40 mg (brain), and 12.0x10 6 L1210 cells in 300 µl of lysis buffer. Three hundred microliters of sample lysates
were aliquoted into 1.5 ml centrifuge tube. Thirty microliters of Protein G-Sepharose
beads/sample were placed in a 1.5 ml centrifuge tube. The beads were aliquoted using a
20-200 µl range pipet tip with the end cut off. This assisted in pipetting the beads. One
hundred microliters of beads were washed with 500 µl of freshly made lysis buffer and
spun down at 240 x g at 40C for 1 min. This was repeated three times. One hundred
microliters of lysis buffer was then added to the beads to obtain a 50% lysis buffer/Protein
G Sepharose bead mix (final volume = 200 µl). Thirty µl of 50% slurry will be used for
each reaction. Prior to use, the beads are blocked to help minimize non-specific IgG
binding. To block 200 µl of a 50% slurry mix, 0.33 mg/ml of BSA and sonicated lambda
are added to the 50% slurry (0.05 mg/ml per 30 µl or per reaction). Three hundred
microliters of lambda were sonicated for 5 min set to 30 sec pulse and 30 sec off. The
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50% slurry with BSA and sonicated lambda were rotated for 2-3 hours end-over-end at
40C. The beads were spun down at 240 x g at 40C for 1 min. The supernatant was
removed and the beads were washed with 500 µl of lysis buffer and spun down at 240 x g
at 40C for 1 min. This was repeated three times. The beads were then resuspended in 100
µl of lysis buffer to achieve a 50% slurry mix. The samples were incubated with 30 µl of
50% slurry for 1 hr at 4°C. This step is referred to as preclearing. Note: It is important to
gently mix the 50% slurry with a pipet tip before pipetting.

Following incubation, the

beads were spun down at 240 x g at 40C for 1 min. The clarified lysates were placed in a
fresh tube and the beads discarded. The lysates were rotated at 4°C overnight with 5 µg of
antibodies against the following: Total Histone H3 (Abcam, ab1791), mono-methylH3K27 (Upstate, 07448), di-methyl-H3K27 (Upstate, 07452), tri-methyl-H3K27 (Upstate,
07449) tri-methyl-H3K9 (Upstate, 07442), tri-methyl H3K4 (Upstate, 07473), acetyl-H3
(Upsate, 06599), acetyl-H4 (Upstate, 06598), acetyl-H3K9 (Upstate, 07352), and IgG
(Upstate Biotech, 12-371). Ten µg of antibody against tri-methyl H3K36 (Abcam, ab9050)
was also used. Thirty microliters of 50% slurry of lysis buffer/Protein G-Sepharose beads
were added to the antibody-lysate mix and rotated at 4°C for 1 hour. The beads were spun
down (as above), the supernatant was removed and discarded. The supernatant for the
sample with IgG antibody was placed in a fresh 1.5 ml centrifuge tube so that it could be
used later as input DNA. The beads were washed two times with RIPA buffer (150mM
NaCl, 50 MM Tris, pH 8, 0.1% SDS, 0.5% NaDoc, 1.0% NP-40), and once with high salt
buffer (500 mM NaCl, 50 mM Tris, pH 8, 0.1% SDS, 1.0% NP-40), then LiCl buffer (250
mM LiCl, 50 mM Tris pH 8.0, 0.5% Na deoxycholate, 1.0% NP-40), and two times with
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Tris EDTA, pH 8.0 (10mM Tris, 1mM EDTA, pH 8.0) (TE). For these washes, 500 µl of
buffer was added to the beads and the suspension was rotated end-over-end for 10 minutes
at 4°C in 1.5mL centrifuge tubes. Following these washes, 200 µl of elution buffer (2%
SDS, 10 mM DTT, 0.1M NaHCO3) was added to the beads and the samples were rotated
for 15 minutes at 250C.

This step caused the release of proteins and protein/DNA

complexes bound to the antibodies by denaturing the antibodies and breaking the
disulphide linkages between the large and small IgG subunits. The elution was performed
twice. Concentrated (4M) NaCl was added to the eluted materials to a final concentration
of 0.2M and they were placed at 65 ºC overnight to reverse the formaldehyde induced
cross-links. The saved input material was also placed at 65 ºC.
DNA purification
Following these incubations, 1 ml of 100% ethanol was added to the 400 µl of
eluted material and the mixtures were held at -800C for 30 minutes to precipitate DNA.
Samples were spun down, washed with 70% ethanol, and resuspended in 180 µl of TE.
The samples were incubated with 1 µl of 10 mg/ml of RNAse A, and incubated at 370C for
30 min. Twenty microliters of 5x Proteinase K digestion buffer (50 mM Tris, 25 mM
EDTA, pH 8.0, 1.25% SDS) and 1 µl of 20 mg/ml Proteinase K to the samples and they
were incubated at 420C for 1 hour.

Incubation was followed by phenol chloroform

extraction by adding equal volume of phenol:chloroform (1:1), pH 6.8. The samples were
vortexed and spun at 16,000 x g for 5 min at 250C. The aqueous phase was recovered and
precipitated in 2.5 x the volume of ice-cold 100% ethanol and 1/10th the volume of 3M Na
acetate, pH 5.2, and 1 µl of glycogen (20 µg) as a DNA carrier. The samples were held at 42

800C for 30 min or overnight. The precipitated DNA was pelleted by centrifugation at
20,000 x g for 10 minutes at 40C. The samples were then washed with 1 ml of ice-cold
70% ethanol and again pelleted. The ethanol was decanted and the pellet was allowed to
air dry for 5 min on the bench top. Samples were then resuspended in a final volume of
100 µl of TE.
The input material not precipitated before treatment was treatment with RNase A
and Proteinase K. The steps following Proteinase K digestion were the same for the input
material as were described for the samples. Real-time PCR was used to quantitate the
content of DNA fragments using a 1 µl aliquot of each sample (see below for details).
Real-time PCR reactions PCR primer pairs amplified regions of genomic DNA every 1.52.0 kb across the length of the fpgs gene (Fig 2-11).

Prior to amplification of the

immunoprecipitated material with primers specific for the mouse fpgs gene, real-time PCR
was prepared using sample DNA and primers specific for regions in the gapdh and globin
promoters and coding regions. These data served as controls for each immunoprecipitation
with a given antibody. The GAPDH and Globin data is not presented in this chapter.
Chromatin immunoprecipitation-RNAPII and transcription factor studies.
The ChIP protocol described above was applied to study the distribution of
RNAPII bound over smaller overlapping segments of the fpgs promoters and the
distribution of transcription factors near P2. Cross-linked DNA fragments were sonicated
down to 100-300 bp, as above. Lysates were rotated at 4ºC overnight with 8 µg of antiRNAPII (Upstate Biotech, 05-623), 4 µg anti-IgG (Upstate Biotech, 12-371), or 5 µg of
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antibodies against phosphoserine 5 peptide from RNAPII (Abcam, ab5131), phosphoserine
2 peptide from RNAPII (Abcam, ab5095), TBP (Santa Cruz, sc-273), TAFIIp250 (Santa
Cruz, sc-17134), TFIIB (Santa Cruz, sc-225), NELF-A (Santa Cruz, sc-23599), or SP1
(Santa Cruz, sc-59). Real-time PCR was performed with 1 µl of final sample dissolved in
100 µl of TE.

The primer sets used covered the entire upstream and downstream

promoters of the fpgs gene. The P1 fpgs promoter region was divided into five segments,
using primers that amplified nucleotides -379 to -119, -126 to 30, 7 to 153, 121 to 288, and
287 to 449 relative to the upstream transcriptional start site. The P2 fpgs promoter was
divided into six fragments amplifying nucleotides -698 to -469, -475 to -333, -340 to -167,
-194 to -52, -83 to relative to the transcriptional start site (Fig 2-, Appendix). In the studies
using antibodies against general transcription factors the primers sets used were specific to
P2; P1 was not amplified in these studies. The primer sets used across P2 for the general
transcription factor studies amplified fragments -340 to -167, -194 to -52, -83 to relative to
the transcriptional start site (Fig 2-18). The GAPDH and Globin primer sets discussed
above were also used in these experiments as controls (data not shown).

Peptide competition study using total RNAPII, phospho-Serine 5, and phospho-Serine
2 RNAPII specific antibodies.
The specificities of the antibodies against RNAPII phosphorylated serine-5 CTD
peptide and phosphorylated serine-2 CTD peptide were determined by incubating L1210
cell lysates and each antibody with increasing amounts of the serine 2 phosphopeptide
(Abcam, ab 12793), serine 5 phosphopeptide (Abcam, 18488) and unphosphorylated CTD
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peptide (Abcam, 12795) (See Table 2-1). Five µg of each antibody was rotated with either
0.1, or 1, or 10 µg of peptide in 100 µl of lysis buffer for three to four hours at 40C. In
these studies, sonication of 2-3 million L1210 cells was carried out in 200 µl. The beads
were prepared as discussed in the previous section. The lysates were prepared as discussed
in the previous section. Following the pre-clearing step discussed above, the 100 µl
antibody-peptide mix was added directly to the 200 µl of L1210 samples. The rest of the
ChIP protocol was carried out as described above.

Peptide inhibition for α-phospho-

Serine 5 was determined using primers amplifying a region of the P2 fpgs promoter, and
specificity for α-phospho-Serine 2 was tested across a fragment of the gapdh coding
sequence.

Primer Design
Primers were designed with the assistance of the oligos deoxynucleotides analyzing
tools on the IDT website (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/).
The primers selected had a melting temperature ranging from 56oC - 60oC, a length
between 18-24 bp, and a GC content between 50-60%. Primers that generated hairpins,
homo-dimers, or hetero-dimers between sense and antisense primers with a delta G value
larger than -6.0 kcal/mol were not selected. The delta G value was determined using the
oligo analyzer (see above) on the IDT website. The mouse genome was searched for each
primer sequence in order to identify primers that included sequences with high similarity to
other genomic regions using the University of California Santa Cruz Genome Browser. If
a high degree of similarity was detected primers were redesigned. Twenty-five nmoles of
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each primer purified by standard desalting were ordered through the IDT website. The
lyphollized primers were resuspended in High Performance Liquid Chromatography
(HPLC) grade water (Fischer) to achieve a stock concentration of 150 µM. Primers were
further diluted to 15 µM in HPLC grade water before they were added to any Polymerase
Chain Reaction (PCR) mix. Primers designed following the parameters discussed above,
usually allowed correct product formation in end-point or semi-quantitative PCR.
However, even with the most stringent design it was sometimes the case that primer sets
were not adaptable to Real-time PCR. In these cases, low-levels of non-specific products
were formed in the PCR that were not detectable by visualization on agarose gel, but were
detected as fluorescence in the Real-Time PCR machine. When multiple products are
detected in a Real-Time PCR assay, the data is not interpretable. As a result, it proved
useful to run test Real-Time PCR reactions prior to using a primer set in large-scale. For
these preliminary experiments, 0.8 ng and 200 ng of genomic DNA and water served as the
templates, and the reactions were performed using the real-time protocol described below.
In this experiment, a single peak in the melting curve would indicate that the primer pair
was suitable for real-time applications. Ten microliters of each reaction was also visualized
on an agarose gel in order to identify primer dimers or non-specific products. The 0.8 ng
and 200 ng of genomic DNA and water were used, because occasionally, they gave
different results. There were several times when primer pairs would work well at 200 ng,
but result in multiple products, or primer dimers, at low concentrations of template DNA
or in the reactions where only water was added.
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Semi-quantitative PCR
Semi-quantitative PCR was used in the initial studies examining RNAPII residence
across P1 and P2 in L1210 cells and mouse liver. The HotStar Taq Plus Master Mix
(Qiagen, Product # 203643) was used for all Semi-Quantitative experiments. A master
mix was prepared using the HotStar Taq Mix, HPLC water, and 0.3 µM of sense and
antisense primers. Twenty four µl of master mix was distributed into PCR strip tubes
(Biorad). One µl of sample DNA or HPLC water or a fraction of input DNA (0.1%) was
added to triplicate tubes. The strips were placed in the 96-well plate of the BioRad PCR
machine and PCR was performed with the amplification conditions 95oC, 45 sec; 57oC, 45
sec; 72 oC, 45 sec, with a final extension at 72 oC for 5 minutes. All samples were first
incubated at 95 oC for 15 minutes to activate the complex Taq polymerase. The number of
PCR cycles used varied from 26 to 36. Initially, samples were removed at the cycles 26,
28, 30, and 32, following incubation at 72oC, and transferred to a second 96-well format
hot block set at 72oC, to allow for the final extension incubation of 5 minutes for each
sample. Ten microliters of each reaction mix were applied to a 1% agarose gel and
separated DNA fragments were visualized following staining with ethidium bromide. The
cycles selected varied and were chosen to capture the amplification reaction in the
exponential range.
Real –time PCR
Real-time PCR was performed using Quantitect Sybr Green PCR Master Mix
(Qiagen) and BioRad DNA Engine Peltier Thermal Cyclers with Chromo 4 Real-Time
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Detector attachments. A master mix was prepared using the Sybr green mix, HPLC water,
and 0.3 µM of each sense and antisense primers. Seventy-two microliters of the master
mix was aliquoted into 0.6 ml PCR tubes. Three microliters of standard, sample, or input
DNA or HPLC water were added to the appropriate PCR tubes (sub-master mix). As
above, a fraction of the input DNA (0.1%) was used. The sub-master mix was vortexed
and collected by brief centrifugation, and 25 µl of the mix was transferred to the Biorad
Low-White Tube PCR strips in triplicate. Four standard reactions were prepared using 5fold serial dilution of sonicated mouse genomic DNA (100 ng/µl, 20 ng/µl, 4 ng/µl, 0.8
ng/µl) (details on standard curve below). The reactions were pre-incubated at 95oC for 15
min and the amplification condition for each primer pair were 95oC for 45s; 58 oC for 45s,
72 oC for 45s followed by a final extension time at 72 oC for 5 min. Forty PCR cycles were
performed for the real-time studies and a plate read step was programmed at the end of
each cycle to capture the fluorescence in each tube. Melt curve analysis was programmed
at the end of the run to measure fluorescence of each reaction in one degree increments
between the temperatures of 50 oC- 100 oC. The melt curve analysis is an essential step in
clarifying whether one specific product was amplified in the reaction (see below).

Analysis of Real-time PCR data
The standard curve is an essential component to analyzing real-time PCR data
when using multiple primer sets. The standard curve is generated by plotting the log of the
dilution factor against the Ct value (see below) obtained during amplification of each
reaction. The equation of the linear regression line and the coefficient of determination
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(R2) were determined using the Opticon software and a R2 value greater than 0.99
indicated that primer pairs were amplifying optimally. The data obtained from the samples
will be assigned a value based on the Ct (see below) values determined for the standard
reactions.
The threshold cycle number (CT), or the cycle number at which amplified product
accumulates to a level where fluorescent signal is detected, was used to quantify the
amount of DNA in each reaction. Measured fluorescence for sample and input reactions
were converted into values relative to mouse genomic DNA by comparing the CT of the
samples to the CT values determined for the standard reactions.

The values for the

triplicate samples were averaged and divided by the averaged input values.
Melt curve analysis was used to identify if multiple products were formed during
the different reactions.

In this analysis, fluorescence in a tube is measured after the

temperature is raised in 10C increments.

As the temperature increased, double-stranded

DNA products melt and fluorescence detected decreases. The negative first derivative was
plotted as a function of temperature using the Opticon Monitor Software provided with the
BioRad machines. Different products will melt at different temperatures and in this case
the melt curve profile will have multiple peaks. A single peak indicated a specific product
and data with multiple peaks was discarded as representing multiple products. Standard
deviations were calculated using the formula: sample/input X (sqrt ((delta input/input)2 +
(delta sample/sample)2)).
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RESULTS
DNA cytosine methylation near the P1 and P2 promoters.
A previous student in this laboratory, Dr. Fiona Turner, initialized the studies on
the epigenetic control mechanisms operative at control of the two mouse fpgs promoters by
by performing bisulfite sequencing (Fig. 2-9) and DNAse hypersensitivity (Fig. 2-10)
assays using genomic DNA surrounding the two fpgs promoters. The distribution of CpG
dinucleotides in the regions of the two fpgs promoters differed significantly. The P1
promoter is in a region in which CpG dinucleotides are sparsely represented (19
dinucleotides distributed over the region from -650 to +900 nt, relative to the first
transcriptional start site), whereas the P2 promoter is embedded in a CpG island
(%GC=58.9, ObsCpG/ExpCpG= .71, CpGs distributed over the 1000 nt centered on the
first transcriptional start site), as defined in (232).
We were very surprised by the results of the bisulfite sequencing. The methylation
patterns defined over the two fpgs promoters were strikingly different (Figure 2-9). DNA
from mouse liver showed an undermethylated state over P1, whereas L1210, bone marrow,
and brain DNA had virtually quantitative methylation at each CpG over this same region.
In striking contrast, the CpGs surrounding P2 were completely unmethylated in all tissues
studied, including normal and neoplastic tissues in which the P2 promoter was
transcriptionally active (L1210 and marrow). Liver, in which transcripts initiating at P2
were barely detectable, and brain, in which the entire fpgs gene was transcriptionally
inactive (Figure 2-9) (Table 2-2).

These data suggested that the two fpgs promoters

represented two interesting cases, one where hypomethylation of a CpG-sparse promoter
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predicted transcriptional activity, and the second a tissue-specific CpG-island promoter
that was not methylated in any tissue, even those in which it was not expressed (Figure 29).

Mapping of chromatin structure near the two fpgs promoters.
The chromatin state of a region surrounding a promoter influences the availability
of DNA cis elements to cellular trans factors, and when nucleosomes are tightly packed
these interactions are restricted and transcriptional activation prevented. Dr. Turner asked
if the chromatin state of P1 and/or P2 of the fpgs gene determined the tissue-specific
activity of the two promoters. DNase I hypersensitivity assays were used to determine the
accessibility of these regions to proteins by determining the cleavage patterns in genomic
DNA after exposure of intact nuclei to DNase I (Figure 2-10). At low levels of DNase I
digestion, a full-length 8.5 kb HinDIII fragment hybridized to the probe for the P1 region
but, with increasing amounts of DNase I, a smaller fragment (4.4 kb) was detected in DNA
extracted from renal and hepatic nuclei (Fig. 2-10, left panels). This band was not seen in
DNA extracted from mouse L1210 leukemia cells and mouse bone marrow, two dividing
cell types that do not utilize the P1 promoter, nor was it observed in DNA from brain
nuclei, which do not transcribe the fpgs gene from either promoter. When the P2 region
was examined using a probe from the downstream HinDIII fragment, a DNase
hypersensitivity site was detected in DNA extracted from nuclei from all the tissues
examined, i.e., L1210 cells, bone marrow, liver, kidney, and brain (Fig. 2-10, right panels).
The DNase hypersensitivity sites found for each promoter mapped to positions about 13051

150 bp upstream of the transcriptional start sites defined as diagrammed in Fig. 2-10. This
implied that the chromatin configuration centering on 130-150 bp upstream of P1 allowed
access to this region only in those tissues that utilize this promoter (liver and kidney), but
that the chromatin encompassing the P2 promoter was accessible in all tissues studied,
whether or not this promoter was transcriptionally active.
Taken together, the DNA methylation and DNAse hypsersensitivity data indicated
that epigenetic mechanisms working upstream of P1 may be causally involved in
determining the activity of this promoter, but neither DNA methylation nor gross
chromatin structure predicted the activity of P2 in the different tissues. We sought a more
complete understanding of the epigenetic controls working at the fpgs gene suggested in
these original experiments. We focused our efforts on profiling several histone PTMs
across the entire 20 kb fpgs locus in tissues using P1 (mouse liver), using P2 (L1210 cells),
and in a tissue where the gene is completely silenced (mouse brain). The questions we
aimed to address in these studies included: 1. Are the patterns of histone PTMs across P1
different between tissues and is the repressive nature of DNA methylation reinforced by
changes in these modifications? 2. Do the histone PTMs of nucleosomes spanning P2 in
mouse liver explain why P2 expression is restricted in this tissue? 3. In brain, is the fpgs
locus marked with histone PTMs commonly associated with a silenced/heterochromatic
state? and 4. Are the patterns of histone PTMs across the dual promoter fpgs locus similar
to those previously described for a highly expressed single promoter gene by Vakoc et. al
(247)?
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The histone marks studied were selected based on evidence that defined role(s) for
these PTMS in transcriptional activation or silencing in yeast or mammalian cells or on a
relationship with DNA methylation or proteins mediating DNA methylation. We chose to
probe for antibodies against histone H3 acetylation (H3Ac), histone H4 acetylation
(H4Ac), histone H3 lysine 36 tri-methylation (H3K36me3), histone H3 lysine 27 mono-,
di-, and tri-methylation (H3K27me1, me2, and me3), histone H3 lysine 9 di- and tri
methylation (H3K9me2 and me3), histone H3 lysine 4 di- and tri- methylation (H3K4me2
and me3), and total histone H3. Composite profiles of these histone PTMs obtained from
work performed at single genes in yeast are reflected in Fig 2-6. We used these antibodies
in our ChIP protocol for the individual tissues followed by Q-PCR to generate tissuespecific histone PTM profiles across the 20 kb fpgs gene. Prior to performing Q-PCR
using the fpgs gene specific primers the enrichment of these antibodies in all three tissues
where tested using primers in the GAPDH promoter and coding region and the globin
promoter and coding region. Samples immunoprecipitated with an antibody raised against
IgG were also analyzed as a non-specific background control in all of our experiments.
Previous to our studies, Vakoc et. al mapped several histone PTMs (H3K4me3, H3K9me3,
H3K27me1, 2, and 3, and H3K36me3) across the very highly expressed PABPC1 gene and
these studies demonstrated the power of following histone marks along the body of a gene
(247). We used this literature precedent as a guide to select regions of genomic DNA of
the fpgs gene for amplification by Q-PCR. Primer pairs were designed to amplify regions
every 1.5-2.0 kb down the entire length of the gene. The placement of these primer pairs is
depicted in Figure 2-11.
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ChIP walking across the fpgs gene describes the level of histone H3 in multiple mouse
tissues.
In our initial studies we examined the density of nucleosomes over the length of the
20 kb fpgs locus in L1210 cells, mouse brain, and mouse liver using an antibody to total
histone H3 levels (Figure 2-10). The data obtained from these experiments were critical to
the interpretation of the histone PTM maps generated in the studies to follow (Figure 210). In order to understand the meaning of changes in levels of histone PTMs, we needed
to ensure that observed shifts were not simply the result of changes in total nucleosome
density. In theory, ChIP data for modified histone residues should be expressed as a ratio
with total histone H3 to allow an estimation of the degree of modification per molecule of
histone H3. For the most part, the data obtained in the histone PTM experiments were
expressed as primary ChIP signals, to allow the reader to come closer to seeing the data,
rather than heavily manipulated ratios.

In a few cases, we used a ratio of histone PTM

ChIP signal to total histone H3 signal to account for histone density changes (Fig 2-17).
In our studies, the density of histone H3 reached a local minimum over the P2
promoter in L1210 cells, mouse liver, and brain and co-localized with the DNase
hypersensitivity site mapped to this P2 region in these tissues (Figure 2-10). Somewhat
surprisingly, a similar histone H3 local minimum was not seen in liver over the P1 region,
in spite of the DNase hypersensitivity site over that region (Figure 2-10). There was an
observable increase in total H3 ChIP signal detected in L1210 cells and brain of the
genomic regions starting 5 kb upstream to 12 kb downstream of the P2 promoter. (Figure
2-10) This pattern was not present in mouse liver. These data indicate that the position of
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nucleosomes were altered by high levels of transcriptional elongation across the genomic
regions surrounding the P2 promoter in mouse liver.

Histone acetylation concurs with transcriptional initiation over P1, but not P2.
Previous studies in yeast and human cells indicate that active promoters have
substantial acetylation of lysines in the N-terminal peptides of histones H3 and H4 (144,
186). We probed the histones decorating the entire length of the fpgs gene, including
segments containing P1 and P2 promoters, by ChIP using antibodies against acetylated
histone H3 at lysines 9 and 14 and histone H4 at lysine 16 (Figure 2-12). As expected,
abundant acetylation of both histone H3 and histone H4 was detected in mouse liver over
P1 (Figure 2-12), high levels of acetylation started 1 kb upstream of the promoter and
extended 3 kb into the fpgs gene. In L1210 cells, the nucleosomes over P1 were not
enriched in acetylated histone H3 or histone H4 (Figure 2-12), but the levels increased
substantially starting 2 kb upstream of P2 and spanned 2 to 3 kb for either histone H3 or
histone H4 acetylation, respectively (Figure 2-12). The large regions of DNA over which
histone H3 and histone H4 were acetylated were very surprising and were only captured
because we followed the histone PTMs across several DNA segments that sampled the
length of the entire gene. Interestingly, histone H3 and histone H4 acetylation was also
found over P2 in mouse liver (Figure 2-12), although the span of genomic DNA over
which histone acetylation was found over P2 in liver was much narrower than seen in
L1210 cells (> 1.5 kb) (Figure 2-12). This difference was repeatable and was seen with an
antibody to H3K9Ac.

In mouse brain, a tissue in which both P1 and P2 are
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transcriptionally inactive, the pattern of H3 acetylation was almost identical to that
detected in L1210 cells (Figure 2-12), with a substantial level of histone H3 detected 2 kb
upstream to 1 kb downstream of P2 (Figure 2-12). Interestingly, histone H4 acetylation
detected in mouse brain was at undetectable levels upstream of P2 (Figure 2-12), unlike the
levels detected in both liver and L1210 cells, and the span of nucleosomes acetylated at the
region surrounding P2 was narrower than the signal measured over P2 in L1210 cells
(Figure 2-12). These data suggest that deposition of histone H4 acetylation may be more
closely linked to the transcriptional activity of a particular locus than histone H3
acetylation. Since histone acetylation is thought to mark an open promoter, finding H3 and
H4 acetylation over P2 in mouse liver and brain raises the question of why P2 is not
actively firing in these tissues.
The similarities detected between L1210 cells and mouse brain in the data on
histone acetylation profiles in Figure 2-12 and the data to follow were, at the time, very
surprising to us. We thought that the brain experiments would be an excellent control for
our studies, which were originally meant to compare liver in which P1 is active and L1210
in which P2 is active. Our observations were put into perspective by studies in a hallmark
genome-wide paper from the laboratory of Dr. Richard Young (87), which was published
as we were preparing this study for resubmission to Molecular and Cellular Biology.
Young’s work concluded that, contrary to common belief, the promoter regions of most of
the protein-coding genes in human embryonic stem cells were bound by proteins indicative
of the process of transcriptional initiation (87). They also extended these observations to a
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subset of differentiated cells. Since then other genome-wide studies have confirmed and
extended these conclusions as will be presented in the discussion.

Histone H3 lysine 4 methylation over P1 and P2.
In an effort to understand the differential control of P1 and P2 in different tissues,
we compared the patterns of histone H3 methylation over the length of the fpgs gene in
liver and leukemic cells. These results were particularly meaningful when related to the
pattern previously seen at a very highly expressed single promoter gene (247). Di- and trimethylation of histone H3 at lysine 4 have been found to be marks of euchromatin and
active transcription in yeast (186) and human cells (144). The distrubution of di- and trimethylation on nucleosomes covering an active gene have been shown to be quite
different, as shown in Figure 2-6.

Studies performed in yeast at single genes have

determined that di-methyl lysine 4 of histone H3 is present throughout euchromatic regions
of chromatin, whereas tri-methylation of this residue is restricted to the 5’ end of genes
initiating transcription (186, 207). We examined the patterns of both di- and tri-methyl
lysine 4 of histone H3 across the fpgs locus under different circumstances. In L1210 cells,
the peak of di-methylation of histone H3 at lysine 4 encompassed the P2 promoter and
spanned ca 4 kb of chromatin region (Figure 2-13). H3K4me2 was detected throughout
the entire fpgs locus in mouse liver, with a peak spanning the 2 to 3 kb of chromatin
downstream of P1, and a second narrower peak 1 kb downstream of P2 (Figure 2-13).
Interestingly, these results paralleled almost exactly the patterns established using
antibodies against acetylated histone H3 (Figure 2-13) in L1210 cells and mouse liver. In
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striking contrast, trimethylation of histone H3 at lysine 4 formed a distinct peak over P1 in
liver and P2 in L1210 cells; these peaks continued for 3-4 kb after the transcriptional
initiation site (Figure 2-14). Surprisingly, a second smaller peak of H3K4me3 was found
over P2 in mouse liver (Figure 2-14). We wondered if this low-level of signal reflected the
processes producing the minimal amount of transcript generated from P2 in mouse liver
(Table 2-2). Rather surprisingly, the pattern detected in brain was exactly the same as that
seen in L1210 cells, in spite of the fact that transcription at P2 was high in L1210 and
undetectable in mouse brain (Table 2-2). Clearly, the reasons for this histone PTM across
P2 in either mouse liver or brain were more complicated than we originally thought. We
concluded from this set of studies that the H3K4me3 mark over the P1 promoter exactly
concurred with transcriptional activity, but there was no such relationship found over the
CpG-island embedded P2.
One major limitation of the ChIP data obtained using mouse liver, brain, and L1210
cells was that the enrichment signals between tissues were not quantitatively comparable.
The variations in tissue-type, treatment of starting material, and the efficiency of crosslinking procedures in different tissues prevented quantitative analysis across tissues. This
limited the conclusions we were able to make from these data in a few cases and made
interpretation challenging across samples. For example, the small peak of H3K4me3
detected over P2 in liver was similar in breadth to the peaks detected in L1210 cells and
mouse brain (Figure 2-14).

However, based on our experience with the antibodies

generated against histone PTMs, the signal detected over P2 in mouse liver was unusually
low and most likely substantially less than the levels detected in brain.
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Histone H3 lysine 9 and lysine 27 methylation over P1 and P2.
Methylation of H3K9 and H3K27 has been linked to the formation of
heterochromatic regions resulting in the repression of transcription in yeast and
mammalian cells (225). More recently, H3K27me1 and H3K9me3 have been found in the
coding regions of active mammalian genes (247). We examined the modifications of these
lysines within histone H3 at the fpgs gene in order to determine if they were involved in
the silencing of P2 in mouse liver and/or either promoter in mouse brain. We were
particularly interested in the methylation status at histone H3K9 because of the wellstudied relationship between DNA CpG methyl-binding proteins (i.e. MeCp2) and histone
methyltransferases responsible for the histone H3K9me PTM (i.e. SETB1) (Figure 2-15).
We expected to detect H3K9me2 and/or me3 across regions surrounding P1 in tissues
where the surrounding DNA was found methylated, but not in mouse liver where lysine 9
of histone H3 was acetylated (Figure 2-15). In mouse liver, H3K9me3 was not detected
anywhere along the fpgs gene (Figure 2-15). Surprisingly, H3K9me3 was also low across
fpgs in L1210 cells. Dr. Turner had previously probed the P1 and P2 promoters in L1210
cells and mouse liver using an antibody against H3K9me2 in a ChIP assay. In those
studies, H3K9me2 was not present at either promoter in liver or L1210 cells, but was
found over the silenced globin promoter that was used as a positive control. We are still
puzzled by the fact that H3K9 methylation was not detected over P1 in L1210 cells. It is
interesting to note that few, if any, studies have examined the coexistence of H3K9me and
DNA methylation at promoters that are as CpG sparse as P1, and it may be the case that
this relationship only exists across regions of DNA that are CpG dense.
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Mono-methylation of H3 at K27 was present across the fpgs gene in both liver and
L1210 cells (Figure 2-16), in agreement with recent studies that indicate H3K27me1 as a
marker of actively expressing genes in euchromatin (247). However, this mark was also
abundant over the fpgs locus in brain (Figure 2-16).

Within the accuracy of the DNAse

hypersensitivity mapping estimates, the minimum of H3K27me1 found at P2 in all three
tissues (L1210, liver, and brain) co-located with the DNase I hypersensitivity site in this
region (Figure 2-16). Similar profiles of H3K27me3 were detected throughout the fpgs
gene in all three tissues studied (Figure 2-16) and the levels measured were relatively
constant across the body of the gene, particularly when the changes between fragments
were compared to the major shifts observed in profiles of H3K4me3 (Figure 2-14) and
H3K27me1 (Figure 2-16). We took this to suggest that trimethylation of lysine 27 of
histone H3 was not causing the silencing of P2 in mouse liver or the complete silencing of
the fpgs gene in mouse brain, in spite of the fact that several examples have been described
where H3K27me3 causally silences mammalian genes through the recruitment of
Polycomb complexes which results in the formation of heterochromatin (225).
Interestingly, H3K27me2 reached a discernible peak between the two promoters in L1210
cells (Figure 2-16), with a maximum at 7 kb. The loss of this ChIP signal in L1210 after
P2 may indicate either the absence of H3K27me2 at nucleosomes decorating the active
downstream region in leukemic cells or it might indicate the presence of a second PTM
across this region that masks the epitope recognized by the H3K27me2 antibody, e.g.,
phosphorylated H3 S28.
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Histone H3 K36 methylation across the mouse fpgs gene
Methylation of histone H3 at K36 in yeast has been linked to regions of
transcriptional elongation and was shown to participate in the recruitment of the histone
deacetylase (HDAC), Rpd3, downstream of an active promoter in several cases (38, 128,
130).

The recruitment of HDACs to H3K36me3 limited histone acetylation within

transcribed regions, and yeast strains mutant in either Set2, the histone methyltransferase
responsible for methylation of lysine 36, or in subunits of Rpd3, exhibited increased
acetylation in open reading frames and an increase in aberrant transcripts generated from
cryptic promoters within these regions (38, 128, 130). Hence, we thought H3K36me3
would be a probable candidate for the suppression of activation of P2 in mouse liver. We
mapped the abundance of H3K36me3 across the fpgs gene to determine whether the spatial
distribution of this PTM down the fpgs locus would suggest such a causal role (Figure 217). This did not seem to be the case, since H3K36me3 was present throughout the body
of the fpgs gene, except for a distinct minimum at P2 in both liver and L1210 cells (Figure
2-17).

The level of H3K36me3 near P2 was lower than could be explained by the

decreased level of total H3 over this region, as best evidenced by the ratio of ChIP signal
for H3K36me3 to total H3 (Figure 2-17). The density of H3K36me3 then built up towards
the 3'-end of the fpgs gene in both tissues, similar to the higher distribution of this mark
towards the 3'-end of other yeast and mammalian genes (186, 247). Interestingly, in both
mouse liver and L1210 cells, the regions where H3K36me3 was found to be maximal were
the regions in L1210 cells and mouse liver that histone acetylation reached a minimum.
H3K36me3 was quite low across the body of the fpgs gene in brain from +3 to +15 kb,
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consistent with the transcriptional inactivity of fpgs in this tissue (Figure 2-17). However,
a marked increase in this modification occurred at the very 3’ end of the fpgs locus in brain
(Figure 2-17).

We considered two possible explanations for this observation: 1.

H3K36me3 detected in brain at the fpgs locus reflects the level of this PTM that
accumulated during development of mouse brain. 2. The 3’end of the fpgs gene abuts the
3’end of the eng gene, and the distal H3K36me3 observed is “spill over” from the
neighboring gene. Nevertheless, we could conclude that H3K36me3 was not directly
involved in tissue-specific suppression of transcriptional initiation at P2, because it was
low across this region in mouse liver.

Integration of information on histone PTMs and DNA methylation
The results from the experiments discussed above shed light on several aspects of
the tissue-specific regulation of the two promoters of the fpgs gene. We determined that
epigenetic mechanisms were critically involved in the control of the P1 promoter. Our
studies implicated a link between DNA methylation and the tissue-specific silencing of a
CpG-sparse promoter, a role for DNA methylation that had not yet been extensively
studied. As we progressed through these studies, it became very clear that the two
promoters were regulated by different mechanisms. Likewise, the possibility that several
mechanisms were either independently or in combination regulating the P2 promoter was
suggested by comparing the data obtained from mouse liver and brain. The histone PTM
profiles described across the fpgs locus in mouse brain were almost identical to those
found in L1210 cells, hence neither chromatin compaction nor histone modifications nor
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DNA methylation were preventing this promoter from firing in mouse brain. In contrast,
the histone acetylation and methylation of lysine 4 of histone H3 were present but
interestingly, lower over P2 in mouse liver.

We considered the possibility that the

restricted histone PTM patterns detected over P2 in mouse liver reflected the small amount
of transcription initiating at P2 in mouse liver (Table 2-2).
We hypothesized that the high level of transcriptional activity occurring at P1 in
mouse liver may prevent successful transcriptional initiation at P2 in this tissue. We
proposed that elongation complexes generated at P1 were limiting assembly of preinitiation complexes at P2.

Previous studies using in vitro model systems supported the

notion that when two promoters were arranged in tandem the activity at the upstream
promoter greatly influenced the activity measured from the downstream promoter, a
process referred to as transcriptional interference.

RNAPII is detected across P1 and P2 in mouse liver.
In order to test this hypothesis, we designed a series of experiments to examine the
presence of transcriptional complexes across P2 in mouse liver. In the initial studies, we
fine-mapped the residence of RNAPII over the two promoters using six overlapping PCR
fragments covering approximately 1 kilobase of P1 and P2. The location of the primers
across both promoters is illustrated in Figure 2-18. ChIP was performed on L1210 cells
and mouse liver using a commercial antibody generated against total RNAPII. In the initial
studies, immunoprecipitated DNA was amplified using semi-quantitative PCR.

Ten

microliters of each reaction were visualized on a 1% agarose gel. As expected, RNAPII
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was minimally detected over P1 in L1210 cells, when compared to the non-specific IgG
control signal, but was found across most of the P2 promoter region (Fig 2-19). We
detected RNAPII over P1 in mouse liver, but very interestingly, a substantial level of this
protein was also found spread across most of the P2 promoter region (Figure 2-19).
The sensitivity of the semi-quantitative PCR was not sufficient to observe small
changes between primer sets nor to visualize the differences quantitative aspects of the
overall patterns of RNAPII residency between L1210 cells and mouse liver at P2. Hence,
Q-PCR was used in the next set of studies. The profiles of RNAPII residency generated
from these second generation studies were far more straightforward to interpret then the
gel pictures from the semi-quantitative experiments. For these experiments, we adapted the
primers described in Fig 2-18 to our Q-PCR protocol, with the exception of primer set #1
within the P1 region. We were not able to design primers for this particular fragment that
did not give multiple products (identified by the melt curve, see methods) in the PCR
reactions.

Fine-mapping of RNAPII across P1 and P2 in L1210 cells and mouse liver using QPCR.
The use of Q-PCR confirmed our original observations and greatly extended our
understanding of the difference between the pattern of RNAPII over P2 in L1210 cells and
mouse liver. RNAPII detected at P1 was very low in L1210 cells, but was still present at
levels significantly higher than the IgG controls across this region (Figure 2-20 B, left
data).

In contrast, RNAPII occupancy was much greater in mouse liver near P1
64

fragments, peaking immediately 3' of the transcriptional start site and decreasing
substantially between 200 and 400 bp downstream of the transcriptional start site (Figure
2-20 B). A similar pattern of RNAPII detection was seen for L1210 cells near the P2
promoter as seen in liver near P1: polymerase occupancy peaked at or slightly after the
transcriptional initiation site (Fig. 2-20 B, right data) and rapidly fell off downstream (see
below). However, in mouse liver, RNAPII was resident over the entire P2 region,
increasing before the DNase I hypersensitivity site defined in Figure 2-10 and remaining
high over the P2 transcriptional start site and substantially downstream (Figure 2-20 B).
The pattern of RNAPII observed at P1, in mouse liver, and at P2, in L1210 cells, reflected
the profile of RNAPII previously described at the active p21 gene in a human colorectal
carcinoma cell line. Based on that study in Hct116 cells, we took the peaks of RNAPII
around the TSS at P1 in mouse liver and P2 in L1210 cells to represent stalled molecules
engaged in the assembly of initiation complexes (81). Likewise, the measurable decrease in
RNAPII observed ca 400 bp into the fpgs gene at P1 in mouse liver (Figure 2-20 B), was
evidence that elongating RNAPII complexes were moving rapidly through the coding
region of the fpgs gene, and were much less likely to be captured then paused initiation
molecules using ChIP technology. The profile of RNAPII detected at P2 in mouse liver
was unique because substantial levels of protein were found across the entire promoter
region covering the linear DNA fragments previously mapped as requisite transcription
factor binding sites (43)(Figure 2-20 B). We wanted to determine if the accumulation of
RNAPII detected at P2 in mouse liver was specific to this genomic region or was
representative of processes occurring across the entire body of the fpgs gene in liver.
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RNAPII has a bimodal distribution pattern along the fpgs gene in mouse liver.
We employed the primer sets used in the studies examining the histone PTMs to
map the occupancy of RNAPII at intervals along the 20 kb fpgs gene. We found striking
differences between the patterns seen in mouse liver and leukemic cells (Fig. 2-20 A). In
L1210 cells, there was a single segment of DNA that co-precipitated with RNAPII,
namely, which centered on the transcriptional start site at P2 (Figure 2-20 A). In liver,
there were two peaks, one centered on P1 and a second higher peak beginning at P2. Given
that transcripts in mouse liver that initiate from P2 were barely detectable (Table 2-2), it
was most likely that the RNAPII over the P2 promoter represented enzyme incorporated
into elongation complexes that had originated at P1. We designed several experiments to
test this hypothesis.

The C-terminal domain (CTD) of RNAPII over P2 is phosphorylated at Serine 2 in
liver.
It has been shown that phosphorylation of serine 5 residues in the repeated
YSPTSPS peptide heptad in the CTD of RNAPII is present throughout transit of a gene,
but is maximal on RNAPII found over the region of a gene associated with assembly of an
initiation complex (81, 133).

In contrast, phosphorylation of serine 2 in this motif

accumulates only as the elongation complex travels through a transcribed sequence and is
highest over the cleavage/polyadenylation signal (81, 133). We hypothesized that if the
RNAPII complexes detected over P2 in mouse liver were predominately engaged in
transcriptional elongation, a measurable increase in the level of protein using the phospho66

Serine 2 antibody would be located over P2, when directly compared to the amount
measured over P1 in mouse liver. Because these studies were critically dependent on the
specificity of the antibodies for the phospho-serine 2, phospho-serine 5, and unmodified
peptides, we tested the specificities of these antibodies under our ChIP conditions.

Specificity of phospho-Serine 5 and phospho-Serine 2 antibodies
Phosphopeptides used to raise the Serine 5 and Serine 2 phosphospecific antibodies
and an unphosphorylated peptide were purchased to test the specificity of the antibodies.
Increasing concentrations of the peptides (0.1 µg, 1 µg, and 10 µg) were pre-incubated
with the antibodies raised against phospho-Serine 5 and phospho-Serine 2 to determine
how well these peptides would block the antibody-epitope recognition reaction (Figure 221). Following incubation, the antibody-peptide mix was added to sonicated L1210 cell
lysates and the samples were incubated overnight at 4C and processed using our ChIP
protocol (Figure 2-21). Q-PCR was performed on immunprecipitated DNA using primers
against the P2 fpgs promoter and a fragment within the GAPDH coding region, locations
were RNAPII complexes phosphorylated at Serine 5 or Serine 2 were predicted to be
enriched, respectively. We chose the P2 fpgs promoter to assess the phospho-Serine 5
antibody because it represents the 5’ end of a highly active gene, where serine 5
phosphorylation of the CTD should be maximal (Figure 2-21 A). Primers amplifying a
portion of the coding region of the GAPDH gene, a region where serine 2 phosphorylation
of the CTD of RNAPII should be substantial, were used to test the phospho-serine 2
antibodies (Figure 2-21 B). The enrichment of the P2 promoter in the immunoprecipitated
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DNA using phospho-Serine 5 antibody was severely blocked when the antibody was preincubated with 1 or 10 µg of phospho-Serine 5 peptide (Figure 2-21), whereas incubation
with either the unphosphorylated or phospho-Serine 2 peptide had no effect on the level of
signal detected (Figure 2-21). The phospho-Serine 2 antibody was more sensitive to
inhibition and detection of the GAPDH coding region within the samples was almost
completely blocked by the addition of 0.1 µg of phospho-Serine 2 peptide (Figure 2-21),
but neither the phospho-Serine 5 nor the unphosphorylated peptide affected the level of
signal measured (Figure 2-21).

RNAPII CTD post-translational modifications over P1 and P2 of the mouse fpgs gene.
We followed phosphorylation of the C-terminal domain of RNAPII at serine 5 and
serine 2 over the two fpgs promoters as an index of whether the RNAPII detected at P2 in
mouse liver was binding in a futile initiation complex or was engaged in elongating a
transcript initiated upstream. We used the signal measuring total RNAPII across the two
promoters to normalize the levels obtained using the phospho-specific antibodies. As
expected, minimal levels of RNAPII were detected over P1 in L1210 cells (Figure 2-22)).
In contrast, a substantial amount of RNAPII was detected over P2 in L1210 cells, peaking
near the +1 position corresponding to the TSS of P2 (Figure 2-22). Two experiments are
presented for the RNAPII profiles over the two fpgs promoters in mouse liver. In the first
experiment, serine 5 phosphorylated RNAPII over P1 was the most abundant signal, and
total and phospho-serine 2 RNAPII signal were similar (Figure 2-23). In the second
experiment, phospho-serine 5 and total RNAPII levels were similar and phospho-serine 2
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levels were much lower (Figure 2-23). The patterns of enrichment signals detected for the
three antibodies across either promoter in mouse liver or L1210 cells were not highly
consistent between experiments. In fact, we found that changing the lot of antibody used
could change the value of signal measured for a given antibody.

These data highlight the

importance of analyzing changes in levels within one antibody and comparing between
experiments using levels detected at a control gene.

In this case, we used the levels

detected at P1 as the control to analyze the data collected for P2 in mouse liver. The levels
of phospho-Serine 5 and phospho-Serine 2 RNAPII were normalized to the amount of total
RNAPII in order to identify when changes in phospho-specific RNAPII levels were the
result of an increase in overall RNAPII levels or due to the hyperphosphorylation of the
RNAPII molecules present at a given position (Figure 2-23). Interestingly, in mouse liver,
substantial levels of both phospho-Serine 5 and phospho-Serine 2 RNAPII molecules were
detected over P1 (Figure 2-23). Ratios of the phospho-specific signals relative to the total
level of RNAPII were generated using data collected on a fragment centered on the
position 50 bp from the P2 promoter TSS position and the fragment centered on 75 bp
downstream of the P1 promoter TSS (Figure 2-23). These data are shown in the bar graph
in Figure 2-23. At P2 in L1210 cells, where this promoter is active, the ratios of phosphoSerine 5 and Serine 2 to total RNAPII were 2.0 and .66, respectively. Similarly, in mouse
liver, when P1 is active, a ratio of 1.6 and 1.0 were determined for phospho-Serine 5 levels
and .83 and .5 were calculated for the level of phospho-Serine 2 (Figure 2-23). The data
collected at P2 in L1210 cells and P1 in mouse liver were taken as representative of the
pattern in an initiation complex: serine 5 phosphorylation per molecule of RNAPII was
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highest near nt +1, the transcriptional start site, while serine 2 phosphorylation was lower
and proportional to the level of RNAPII throughout this region.
The profiles of RNAPII obtained at the P2 fpgs promoter in mouse liver were very
interesting. The level of RNAPII phosphorylated at Serine 2 detected at P2 increased
substantially compared to the amounts observed at P1 in mouse liver in both experiments.
Accumulation of RNAPII complexes over P2 peaked at the position centered on 50 nt
downstream of the P2 TSS (Figure 2-23). Phosphorylated Serine 2 RNAPII relative to the
total RNAPII increased approximately 3-fold between the P1 promoter and the P2
promoter regions in liver (Figure 2-23). In contrast, changes in the level of phospho-Serine
5 between the two promoters were reflected by the changes in total RNAPII levels,
indicating that the levels of serine 5 phosphorylation were not detectably different between
P1 and P2 in mouse liver (Figure 2-23). We interpreted these data as direct evidence that
the RNAPII detected over P2 in liver was a component of an actively transcribing
elongation complex.
In what was initially a very surprising observation, the distribution of RNAPII
across P2 was also easily detectable in mouse brain (Figure 2-24).

However, this

observation was in agreement with a human whole-genome tiling study that appeared just
as we had done these studies that indicated that even inactive promoters are usually
attempting to load initiation complexes (87)(see Discussion). Interestingly, the RNAPII
was detected broadly across the P2 promoter in brain, similar to the data presented for the
P2 promoter in mouse liver (Figure 2-23). We initially took this to suggest that the pattern
of RNAPII occupancy observed at P2 in L1210 cells may be characteristic of promoters
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engaged in high levels of active transcription. However, the phosphorylation pattern of
RNAPII across P2 in mouse brain was, however, remarkably similar to that profile
observered in L1210 cells: RNAPII present across the brain P2 was phosphorylated at
serine 5 to a higher degree and serine 2 phosphorylation was minimal, indicating that these
complexes were indeed futile initiation complexes.

Evidence that elongating RNAPII over P2 blocks assembly of transcriptional
initiation complexes in liver.
Transcription from the mouse fpgs P2 promoter has been shown to depend on
several Sp1 sites (43). A typical Sp1-driven promoter involves binding of TBP to Sp1
with subsequent recruitment of other components of the pre-initiation complex (PIC). We
assessed the binding of components of the PIC to fpgs P2 in mouse liver, brain, and L1210
cells. The general transcription factors selected were Sp1, TBP, TFIIB, and TAFIIp250;
the residence of these proteins at active promoters have previously been used as a mark of
pre-initiation complex assembly at the p21 promoter (81). Since it appeared that the P2
promoter of the fpgs gene, at least in brain, may be controlled at the level of elongation, we
also tested for the presence of NELF-A, a subunit of the Nelf complex, that has been
suggested to play a critical role in RNAPII pausing at the early stages of transcriptional
elongation in both Drosophilia and human experimental systems (169, 267). As shown in
Figure 2-25, in L1210 cells and mouse brain, Sp1 and TBP were loaded onto the region of
DNA immediately upstream of the transcriptional initiation site, as well as did TFIIB,
TAFIIp250, and the NELF-A protein (Figure 2-25). These proteins persisted on the P2
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locus past the point of initiation (+200 nt) (Figure 2-25). In striking contrast, Sp1 was very
low at -200 nt in liver, and TBP was not detectable. TAF250 and NELF-A were also very
low. At +200 nt in liver, Sp1, TFIIB, TAFIIp250, and Nelf A, were detected at low levels
and the TBP was undetectable (Figure 2-25). Interestingly, high levels of Nelf-A, relative
to the abundance of the general transcription factors detected at P2, were measured in
mouse brain (Figure 2-25). This may suggest a role for Nelf in the silencing of P2 in
mouse brain (see discussion). We concluded that the binding of several proteins needed
for assembly of a successful PIC was being actively restricted at P2 in liver. This is
consistent with a promoter interference mechanism whereby the elongating RNAPII
complexes initiating at P1 were physically occluding the DNA over the P2 region in liver.

DISCUSSION
Genome-wide analysis of transcription start sites, in humans and mice, have
revealed that over 50% of genes contain multiple promoters (37). Alternate promoter
usage permits a single genetic locus to generate distinct protein products in response to
different cellular backgrounds. How exactly is promoter choice dictated? Describing the
mechanisms driving promoter selection is of great importance to our understanding of
basic processes of transcription, but also has the potential to uncover the basis for new
therapeutic strategies that could selectively target gene activity in one particular tissuetype. In our studies, we have used the mouse fpgs gene as a model to address the controls
coordinating the use of two promoters in a tissue-specific fashion.
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The mouse fpgs gene is transcribed from two alternative promoters, one of which
(P2) drives transcription in normal dividing cells types and in tumors, the other (P1)
controls transcription predominantly in two differentiated tissues, liver and kidney. We
sought to explain how these two promoters are regulated in a virtually black and white
manner; that is, tissues using P2 never initiate at P1, and tissues that initiate at P1 have a
very limited, although detectable, usage of P2. Our analysis leads to the conclusion that
activity at P1 correlates with the presence or absence of CpG methylation, making fpgs one
of the few known cases in which methylation inversely correlates with expression in nonneoplastic tissues at a CpG-sparse promoter. In contrast, CpG methylation did not play a
role in tissue-specific initiation from P2. An analysis of some of the most studied histone
PTMs showed patterns across the span of this 20 kb gene only partly predictable from
previous studies. Over the P2 promoter in mouse brain we detected RNAPII and general
transcription factors, as well as, histone acetylation and lysine 4 of histone H3 methylation,
suggesting that in mouse brain, RNAPII complexes were poised for transcriptional
activation at P2. However, the real surprise in our results is that RNAPII does not seem to
have access to P2 for transcriptional initiation in liver when P1 is active, despite open
chromatin context and lack of CpG methylation in the P2 region. Hence, mouse fpgs is a
clear case of transcriptional interference in an endogenous mammalian gene.

The

studies presented in this chapter have described several different mechanisms of
transcription at the mouse fpgs gene, their implications and relevance to current literature is
discussed below.
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Tissue-specific chromatin state of the mouse fpgs gene
By profiling several histone PTMs across the mouse fpgs gene we gained an
understanding for the chromatin context surrounding the fpgs gene in L1210 cells, mouse
liver, and mouse brain. The marks of histone H3 and H4 acetlyation and tri-methylation of
lysine 27 of histone H3 are distinguishing features of euchromatin and hetermochromatin,
respectively (135). We were surprised to find detectable levels of histone acetylation
(Figure 2-12) upstream of the P2 promoter in L1210 cells and mouse brain, since this
region of the gene, in these tissues, was transcriptionally silent. Likewise, we expected to
detect H3K27 tri-methylation across the genomic regions between P1 and P2 in L1210
cells, and likely across the entire locus in mouse brain.

The levels of H3K27 tri-

methylation detected followed similar patterns across the fpgs gene in all three tissues
studied; thus, it was unlikely that this region was silenced by heterochromatic formation
(Figure 2-16). Taken together, these data indicated that the fpgs locus was positioned in
genomic regions of euchromatin in L1210 cells, mouse liver, and mouse brain independent
of the transcriptional activity occurring at this locus.
Why is the mouse fpgs gene in brain not in a heterochromatic state? Genome-wide
maps of histone PTMs in human embryonic stem cells and a few differentiated tissues
have classified genes based on their “chromatin state” in pluripotent cells (161). They
propose that the pattern of several histone PTMs, namely histone H3 lysine 4 and 27 trimethylation, found at genes in embryonic stem cells is closely linked to cellular state and
gene function. They found that almost all CpG-rich promoters in embryonic stem cells are
associated with H3K4me3 (161). Additionally, upon differentiation, most of the CpG-rich
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promoters retain this histone mark. On the other hand, CpG-poor promoters were typically
not modified in embryonic stem cells and marks of activation or repression were only
detected in differentiated states.
Interestingly, the two promoters of the mouse fpgs gene represent examples of the
two classes of promoters identified based on chromatin state; the CpG poor P1 promoter
was marked with H3K4me3 only in mouse liver, and the P2 CpG island promoter was
marked with H3K4me3 in all tissues. Since such a large number of genes have been found
to have multiple promoters, it will be important to investigate how different chromatin
states at a single genetic locus will impact the overall chromatin context surrounding the
entire transcriptional unit.

With this in mind, we wondered if the persistent H3K4me3

mark at P2 in all tissues was sufficient to prevent heterochromatin formation across the
fpgs gene in mouse brain.

Profiling of mono-methyl lysine 27 of histone H3 across the mouse fpgs gene in L1210
cells, mouse liver, and mouse brain reveals unexpected patterns from prior literature.
A very interesting observation was the presence of H3K27me1 throughout the
entire coding region of the fpgs gene in all three tissues. At the time these studies were
performed, little to no information was known about the presence of H3K27me1 at active
genes. Since then, high-resolution genome-wide histone methylation analysis has shown
H2K27me1, along with H3K9me1, in the coding regions of most active human genes (15).
It has been proposed based on this global analysis that all mono-methylated forms of
histone H3 lysines are associated with active transcription (15).
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However, we detected

abundant levels of mono-methylated H3K27 over fpgs in mouse brain, a tissue where this
locus is completely silenced (Figure 2-16). Perhaps mono-methylation of H3K27 is not a
mark of transcriptional activity, but rather a mark of euchromatin. The distinct patterns of
observed of the mono-, di-, and tri- methylated forms of histone H3 at lysine 27 highlight
the complexity of the mechanisms leading to a particular histone methylation pattern.
How the distinct patterns are generated most likely depends on the nature of the
surrounding histone PTMs, especially since most HMTs are able to methylate the ε-amino
lysine at all three positions (225). The number of possible modified states is enormous and
assessing each mark in the context of the surrounding histone PTMs, DNA methylation
status, and transcriptional activity appears to be a necessary step in further understanding
the biological consequences of a given histone PTM, or combinations of histone PTMs. It
is highly likely that multiple PTMs in sum constitute a signal for molecular phenomena.
Initial studies investigating this concept used mass spectrometry to map the combination of
PTMs on histone H3 in T. thermophila and identified permutations of PTMs associated
with transcriptional activation and repression (236). An example illustrating the interplay
between histone PTMs has been described at active eukaryotic genes; histone H2B
ubiquitination has been shown to enhance the conversion of di-methyl lysine 4 on focal
histone H3 to the tri-methylated state (261). The postulate that specific combinations of
histone PTMs on surrounding nucleosomes may dictate the methylation state of lysine 27
of histone H3 has yet to be tested.
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Is tissue-specific methylation regulating the P1 CpG-sparse promoter?
The hypothesis that DNA methylation is involved in controlling tissue-specific
expression has been tested in both genome-wide studies (227, 256) and in studies focusing
on a few single genetic loci (75). However, these studies have largely addressed the
methylation status of CpG islands across different tissues, in spite of the fact that most
tissue-specific promoters are thought to be CpG-sparse. Similarly, the processes leading to
transcriptional silencing at promoter regions via DNA methylation are understood largely
in the context of aberrantly hypermethylated CpG islands in neoplastic cell lines (121) and
the ability of these mechanisms to silence CpG-sparse promoters in normal tissues has only
been tested in a few circumstances (75, 203, 254). Thus, the potential for epigenetic
mechanisms to regulate tissue-specific expression in normal tissue remains unclear. In
spite of this fact, current thought proposes that CpG-sparse promoters are methylated
independent of activity state and less frequently rely on epigenetic mechanisms for
transcriptional activation or repression (164). Our analysis of the DNA methylation across
the P1 promoter of the mouse fpgs gene in tissues where this promoter is either
transcriptionally active or silent argues a role for DNA methylation in the tissue-specific
control of CpG-sparse promoters (Figure 2-9). Support for this concept has recently been
provided. Bisulfite sequencing of the CpG dinucleotides in human chromosomes 6, 20, and
22 in several mouse tissues identified a population of differentially methylated CpG-sparse
promoters (58). This population of promoters had not previously been detected because
the limitiations of methods commonly used for genome-wide methylation anaylsis, e.g.
MeDIP and RLGS, prevent the assessment of methylation at single CpG resolution (227,
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256).

Our analysis of epigenetic marks over the P1 promoter identified correlations

between DNA methylation and histone PTMs previously predicted through studies at CpGisland promoters; i.e., three histone PTMs associated with active genes, H3Ac, H4Ac, and
H3K4me3, were coincident with hypomethylation of regional CpG dinucleotides across P1
in mouse liver. However, we were surprised to find that in tissues where the CpGs of the
P1 promoter were methylated, regional nucleosomes were not methylated at H3K9, a PTM
commonly associated with DNA methylation at silenced promoters (Figure 2-15) (74).
Lysine 9 methylation of H3 is tightly linked to DNA methylation and transcriptional
repression in some systems, particularly Arabidopsis thaliana and Neurospora (74, 234),
which has led to the proposal that DNA methylation is targeted to genes that have been
silenced by other mechanisms. We took the absence of H3K9 methylation at P1 in the
presence of DNA methylation to suggest that epigenetic control of the tissue-specific CpGsparse P1 promoter may involve unique combinations of epigenetic marks to ensure proper
patterns of expression.
While it is difficult to separate out cause and effect in vivo, studies using
genetically modified mouse models with altered expression of proteins involved in
establishing either DNA methylation or histone PTM patterns have tried to address the
sequence of events controlling the patterns of epigenetic modifications leading to gene
regulation (137). Recent studies have shown that the depletion of Dnmt1 in mouse
embryonic fibroblasts resulted in a marked increase of H3K4 methylation and H3
acetylation (137). On the other hand, loss of either the histone demethylase, LSD1 (255)
or the histone H3 lysine 9 methylase, G9a (53), in embryonic stem cells resulted in global
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changes in DNA methylation patterns. These data suggest that the sequence of events
leading to certain combinations of epigenetic marks is not universal. Further insight into
the role of DNA methylation and histone PTMs in the regulation of gene expression may
be gained from classifying promoters based on the primary epigenetic process that initiates
mark the regulation of each individual promoter. In the absence of the expected repressive
histone H3K9 modification at the chromatin surrounding the P1 fpgs promoter in tissues
where this promoter is silent, our results suggest that DNA methylation is the prime
determinant of tissue-specific chromatin condensation and repression of the P1 promoter.
We concluded that, in adult dividing tissues of the mouse, the P1 fpgs promoter was locked
in a transcriptionally inactive configuration by DNA methylation and that transcriptional
activity at P1 in liver was reinforced by a series of histone PTMs commonly associated
with transcriptional activity.

Potential mechanisms of regulation of P1 via DNA methylation.
We considered the mechanism of the proposed DNA methylation-induced
transcriptional repression of the P1 promoter. DNA methyl-CpGs are binding sites for
MBPs which serve as scaffolds for the recruitment of histone deacetylases (123, 170) and
for chromatin remodeling complexes associated with transcriptional silencing. MBPs have
been shown to preferentially bind promoter regions with more densely packed CpG
dinucleotides, and the potential for this class of proteins to mediate transcriptional
silencing at CpG sparse promoters needs to be further explored. Interestingly, in L1210
cells, where P1 is silent and methylated, low levels of RNAPII were reproducibly detected
79

across the promoter region, supporting the idea that the entire fpgs locus is in a dynamic
state of euchromatin, where trans factors occasionally have access to DNA binding
elements. In this context, the DNA methylation of the P1 promoter may be functioning to
prevent the transcription factor and RNAPII binding events required to successfully
assemble pre-initiation complexes at the P1 promoter.

Support for this concept was

recently furnished in a very important genome-wide study that correlated methylation
status of promoters with histone PTMs in mouse embryonic stem cells and certain
differentiated tissues (159). That study found that the DNA of CpG-sparse promoters were
unmethylated in embryonic stem cells and regional nucleosomes were marked with H3K4
methylation but, in more differentiated cells, the methylation status of CpGs in these
promoters distinguished a transcriptionally active gene from a silenced gene (159). In
contrast, CpG island promoters were unmethylated across the different developmental
stages. If methyl-CpGs block cis elements from transcription factor binding at P1 of the
fpgs gene, high levels of tissue-specific transcription factors in the nucleus may relieve this
occlusion, providing a discrete method of transcriptional activation for certain tissuespecific promoters. As was suggested by the case of fpgs P1, nucleosomes surrounding
tissue-specific promoters controlled by DNA methylation may not be methylated at H3K9.
This may have functional implications for these promoters by preventing highly stable
repression and maintaining the ability for transcriptional activation to occur when the
cellular context changes. Thus, the fpgs P1 promoter may represent a class of tissuespecific promoters identified by differential DNA methylation patterns and CpG sparsity,
where histone PTMs associated with transcriptional activation are present because of the
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presence of RNAPII initiation complexes, rather than being causative of transcriptional
initiation and histone repressive marks are not used.

Are epigenetic mechanisms silencing P2 in mouse liver and brain?
The P2 region was devoid of DNA methylation in all tissues studied whether or not
this promoter was used to initiate transcription (Figure 2-10). The histone PTMs near P2
show distinct patterns in different tissues: In either a tissue in which P2 was exclusively
used (L1210 cells) or one in which the entire fpgs locus was silent (brain), there was a
broad peak of H3Ac and H4Ac centered on the hypersensitivity site at this promoter, but
there was a much more compact peak of these acetylated nucleosomes over P2 in liver
(Figure 2-12). Likewise, a substantial peak of H3K4me3 centers on P2 in L1210 and
brain, but a distinctly smaller peak was found over this same region in liver. It appeared
from these data that the processes involved in regulating the silencing of P2 in mouse liver
and brain were different (Figure 2-14).

Poised RNAPII at P2 in mouse brain: the role of negative elongation factors
In a very important recent paper, genome-wide analysis of human embryonic stem
cells found that the promoters of most protein-encoding genes were associated with
nucleosomes containing H3K4me3 and H3Ac and were also bound to RNAPII, while only
a fraction of these transcriptionally-primed promoters produced mature full-length
transcripts (87). Additional work in Drosophilia has confirmed this work and begun to
address the functional significance of and mechanisms establishing the poised RNAPII
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complexes at these promoters (169). Prior to these studies, promoters with assembled
transcriptional complexes poised for activation were thought to be few (19), however it is
now clear that there is a large number of genes regulated at the early stages of elongation.
The active histone PTM (H3Ac, H4Ac, and H3K4me3) and the substantial level of
RNAPII detected over P2 in mouse brain (Figure 2-24) placed this promoter in the class of
promoters identified by Guenther et. al that are poised for transcriptional activation. This
is very surprising in the case of fpgs P2, which will never again be activated in normal
brain.
Current models of transcriptional poising propose that the phosphorylation of
NELF by P-TEFb displaces NELF bound to the poised RNAPII, allowing TFIIF access to
RNAPII; this release of NELF facilitates the transition from a stalled state to productive
elongation (184). The role of NELF in establishing the poised state of RNAPII genomewide has been supported through the use of siRNA strategies in fly systems (169). Twothirds of the poised RNAPII complexes in Drosophilia were relieved when levels of NELF
were reduced. In our studies, we probed for NELF at the P2 promoter of the mouse fpgs
gene in L1210 cells, mouse liver, and brain (Figure 2-25). Since P2 in mouse brain
appeared to be bound by stalled RNAPII elongation complexes we thought NELF would
be detected at P2 in mouse brain, but not in L1210 cells. Surprisingly, NELF was detected
at P2 in both L1210 cells and mouse brain. A similar observation was made at the p21
promoter in human colorectal carcinoma cells: NELF was detected at the p21 promoter
when the promoter was bound by RNAPII in a stalled state and remained at the promoter
upon transactivation of the p21 gene by p53 (81). While the presence of NELF may be an
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essential component to poised RNAPII complexes, our data suggests that the recruitment
of NELF to P2 is not a determinant of RNAPII poising at P2 in mouse brain. We took this
to suggest that additional components, such as post-translational modifications or binding
partners of NELF, are involved in the stalling of RNAPII at P2 in mouse brain. Recent
genome-wide studies have detected NELF residence at promoters with poised RNAPII
complexes and at promoters of highly active genes (138), suggesting that the observations
we made at P2 in L1210 cells and mouse brain are universal. Interestingly, in Drosophila
S2 cells NELF depletion up-regulated a number of rapidly responding genes, such as
Hsp70, but a large proportion of genes previously shown to bind NELF showed a
decreased level of expression (77).

Both our studies and genome-wide studies suggest

that the hypothesis that NELF recruitment and displacement coordinates promoterproximal pausing is an oversimplification. It will be important to understand the different
states of NELF at both active and stalled genes to understand the role of this protein in
each condition.

Profiles of RNAPII at poised and active genes: insights into mechanisms of stalling
The profiles of RNAPII across the P2 promoter in L1210 cells and mouse brain
were remarkably different. Molecules of RNAPII were reproducibly detected across the
entire P2 region in mouse brain, whereas in L1210 cells a sharp peak of RNAPII was
detected near the P2 TSS (Figure 2-22 and 2-24). One explanation for this observation is
that differences in sonication between mouse brain and L1210 cells influenced the pattern
of RNAPII detected across P2. However, data from a recent genome-wide study suggests
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that our observations are not likely due to technical issues (214).

RNAPII occupancy

mapped across promoters bound by stalled and active molecules throughout the genome in
CD4+ T cells revealed similar profiles to those determined in our studies: sharp peaks of
RNAPII occupancy at the TSS defined promoters actively engaged in transcription, and
inactive promoters were bound by RNAPII across most of the promoter region (214).
Overall these data suggest that on average the positioning of RNAPII at the promoter of
active genes appears to be highly regulated, resulting in the observed narrow peak of
occupancy near the TSS detected at the P2 promoter of the mouse fpgs gene, in L1210
cells (Fig 2-22), and at active promoters genome-wide. In contrast, the broad profile of
RNAPII molecules bound to P2 in mouse brain (Figure 2-24) suggests that recruitment of
enzymes to the P2 promoter region of the fpgs gene involves fundamentally different
processes over the stalled vs. the productive chromosomal context. While it is difficult to
separate out cause and effect, we expect that if the P2 promoter in mouse brain was
activated, the pattern of RNAPII residency at P2 would reflect the profile observed in
L1210 cells.

The mechanisms causing the establishment of the two distinct patterns of

RNAPII residency at active and stalled genes remains an open question. Interestingly, a
high-resolution

nucleosome-mapping

study

determined

that

the

positioning

of

nucleosomes across stalled and active promoters were very similar, suggesting that
nucleosome placement does not dictate the difference in RNAPII binding patterns at
promoters of stalled and active genes (214). While the position of nucleosomes may be
similar, the composition of individual nucleosomes may be drastically different between a
stalled and active promoter regions. Conventional histones can be replaced within a
84

nucleosome with histone variants that differ in their primary sequence from canonical
histones that have functional consequences for gene regulation (135).

Two histone

variants in particular, H2A.Z and H3.3, have been linked with transcriptional regulation.
Genome-wide studies in yeast and humans have identified H2A.Z enrichment at promoter
regions upstream and downstream of TSS (15). Likewise, a role for the histone variant
H3.3 has been implicated through global analysis in Drosophila, where this variant was
found localized to the promoter regions of active genes (163). It will be important to
determine if nucleosomes surrounding promoter regions of stalled genes have a unique
composition of histone variants.
We conclude that the silencing of P2 in mouse brain and mouse liver represents
different phenomena. In brain, P2 and P1 are completely silenced whereas, in liver,
initiations are blocked by elongation complexes. Accordingly, low levels of initiation can
be detected from P2. The fact that transcriptional poised complexes assemble at P2 in
brain makes it more likely that the absence of such complexes at P2 in liver is due to an
active exclusion process.

Transcriptional interference at P2 in mouse liver: mechanism and consequences
In mouse liver, there were abundant transcripts from the fpgs gene, almost all
initiating at the P1 promoter (Table 2-2).

The profiles of histone PTMs commonly

associated with the 5’ end of active or poised genes (H3Ac, H4Ac, and H3K4me3) were
detected over P2 in mouse liver, however the levels detected were substantially restricted
compared to the amount observed at P2 in mouse brain or L1210 cells or at P1 in mouse
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liver. We took this to suggest that something was limiting the assembly of RNAPII and
initiation factors at the P2 promoter, in spite of active traverse of transcriptional elongation
complexes through this region of genomic DNA.

How was this happening?

Literature

precedent suggested a promoter interference mechanism whereby activity at the P1
promoter prevents transcriptional initiation at the P2 promoter (83, 155, 188). In higher
eukaryotes, this method of transcriptional repression has been described in the tandemly
arranged unr and N-Ras genes, where transcription of the unr gene interferes with
initiation at the N-Ras promoter, which is spaced only 150 nt downstream of the unr
termination signal (28). Similarly, deletion of an embryonic ß-like globin gene, Ey, caused
the activation of a second ß-like globin gene, ßho, which is located immediately
downstream of the deleted gene (107). However, the mouse fpgs gene represents an
interesting case in which transcriptional interference is used to coordinate use of two
potentially active promoters, spaced a fairly large distance (10 kb) apart. Our analysis of
the P2 promoter in liver indicates that RNAPII elongation complexes are residing over an
extended length of the fpgs genomic locus, covering the nucleosome-deficient DNase
hypersensitive region before P2 and continuing downstream, physically limiting initiation
at P2 (Figure 2-23). In support of this concept, we observed that the residence of several
key general transcription factors at the P2 promoter in mouse liver was severely limited
(Figure 2-25).

Such a physical occlusion mechanism has been proposed to involve the

decreased binding of transcription factors, such as Sp1, or through steric obstruction of
DNA binding regions required for transcription factor interactions (83, 107, 155). We
concluded that the mouse fpgs gene represents an example of this mechanism, one of the
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few documented for an endogenous gene, and the only example in the literature to date
demonstrating TI as a means of organizing transcription from a multi promoter gene.

What causes elongating RNAPII to stall at P2 in mouse liver?
Substantial levels of RNAPII molecules were detected at both the P1 and P2
promoters of the mouse fpgs gene in mouse liver. The accumulating complexes over P2 in
mouse liver appeared to be hyperphosphorylated at serine 2 residues within the CTD of
RNAPII (Figure 2-25), suggesting that these molecules of enzyme over P2 in mouse liver
were engaged in elongation.
We considered several mechanisms as explanations for the accumulation of
RNAPII observed at P2 in mouse liver. The presence of specific epigenetic marks and
chromatin structure may play a role in establishing the profile of RNAPII at P2 in mouse
liver and my analysis to date has focused on these factors. This analysis has not given us a
concrete explanation of the RNAPII stalling. CpG methylation declines to almost
undetectable levels 500 nt upstream of the P2 TSS, coincident with an increase in histone
H3 and H4 acetylation and H3K4 tri-methylation in all tissues studied (Figure 2-9). The
correlation of RNAPII accumulation with the hypomethylated CpG island in the coding
region of the fpgs gene in mouse liver suggests that the observed change in DNA
methylation and histone PTMs may impair the transit of elongating RNAPII across the P2
promoter region.

Previous work using transgenic mice addressed the influence of

intragenic DNA methylation on transcriptional elongation efficiency and determined that
CpG methylation, coincident with loss of histone acetylation and H3K4 methylation,
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impeded RNAPII processing across the methylated stretch of genomic DNA (146). Based
on this evidence it seemed unlikely that loss DNA methylation or histone PTMs associated
with the P2 promoter region in mouse liver were directly causing the accumulation
observed.

One potential epigenetic mechanism causing the increased RNAPII levels

observed is the positioning of nucleosomes across the P2 promoter region in mouse liver.
The DNAse Hypersensitivity site and Total histone H3 maps presented (Fig 2-10) assess
gross chromatin structure, but recent high-resolution mapping studies highlight the
functional significance of fine differences in nucleosome positioning not previously
appreciated (214). It will be very interesting to determine the position of nucleosomes
across the P2 region in L1210 cells, mouse liver, and mouse brain. These studies may find
that the passage of RNAPII complexes across the P2 region in mouse liver is determined
by chromatin structure.
Currently, we propose that elongating RNAPII complexes accumulate over P2 in
mouse liver as a result of collisions with transiently bound initiation factors. The residence
of general transcription factors and the accumulation of H3K4me3 at P2 in mouse liver,
albeit at minimal levels, indicate that PICs are occasionally able to assemble at the P2
promoter in this tissue. We hypothesize that passage of RNAPII molecules across P2 is
transiently blocked by the presence of initiation factors and the displacement of these
factors is required for elongating RNAPII molecules to proceed down the rest of the gene
(Figure 2-26). If this were the case, blocking PIC assembly at P2 in mouse liver should
prevent the accumulation of RNAPII complexes over this region. It is interesting to note
that mouse kidney also uses the P1 promoter to generate fpgs mRNA, but in this tissue the
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P2 promoter also generates a substantial level of transcripts initiating at P2. The level of
fpgs mRNA generated from P1 is higher in liver than in kidney, and we consider that the
lower amount of initiation occurring at P1 in kidney may account for the higher level of P2
expression detected in mouse kidney. It will be interesting to explore the residence of
RNAPII and histone PTMs across P2 in kidney and may provide further insight in to the
mechanism of TI at the fpgs locus.

Are there consequences to the stalling of RNAPII at P2 in mouse liver?
The mouse fpgs gene generates two splice variants in a tissue-specific pattern from
two different promoters (244). In dividing cells, such as L1210, transcription initiates at
the P2 promoter and the mature mRNA includes exons 1-15 (Fig 2-3). In contrast, in
mouse liver, a tissue where the P1 promoter is active, the 5’ exons A1a and A1b are
directly linked to exons 2-15, splicing out exon 1 (Fig 2-2). The distance between exons
A1b and 2 is remarkably long and how the splicing machinery handles 10 kb of pre-mRNA
in order to achieve the correct splicing pattern of exon A1b to exon 2 remains unclear.
The generation of alternative splice variants is dependent upon the availability of splicing
factors, splicing machinery, and regulatory sequences within the immature mRNA.
However, work over the past ten years has shown that the rate of transcriptional elongation
also directly impacts alternative splicing patterns (187). This concept was first addressed
in experiments designed to test the hypothesis that mRNA processing occurred
simultaneously with transcription. Proudfoot et al. altered the splicing pattern of the αtropomyosin gene by artificially positioning RNAPII pause sites within the gene, thus
89

delaying the transcription of a splicing inhibitory element and causing the inclusion of an
alternative exon in the mature mRNA (187). Additional studies used a mutant form of
RNAPII, with a slower elongation rate, to show that the inclusion of alternate exons is
enhanced when transcription is accomplished with the mutant form of RNAPII (51). We
are very interested to address the postulate that the accumulation of RNAPII at the P2
promoter in mouse liver represents a stalled complex, which dictates the splicing pattern of
fpgs mRNA detected in this tissue. The potential of alterations in the rate of RNAPII
transit across the body of a gene to generate multiple splice variants from a single gene is a
tremendously interesting concept, and the mouse fpgs gene may be an excellent model
system to determine the sequence of events involved in this affect.

Two classes of promoters distinguished by methylation genome-wide?
Recent studies have examined RNAPII occupancy, H3Ac, and H3K4me3 at
promoter regions in several differentiated mouse tissues. That study expanded on the
previous observations made in genome-wide studies by classifying promoters based on
their CpG status and describing patterns across several mouse tissues. In doing so, it
became clear that CpG islands are most often bound by RNAPII and regional histones are
acetylated and methylated at lysine 4 of histone H3 in a tissue-independent fashion (13). In
contrast, CpG-sparse promoters were bound by RNAPII in a tissue-specific pattern and
presumably in tissues only when they are expressed. The fpgs gene has one of each type of
promoter identified in the abovementioned study (13). The difference between these two is
that P1 appears to be controlled by DNA methylation, and P2 is not. It will be of
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tremendously interesting to determine if DNA methylation is a distinguishing
characteristic between the poised promoters and the tissue-specific promoters identified in
the differentiated tissues of the mouse.
Overall, we conclude that the mouse fpgs gene uses at least two mechanisms,
epigenetic marking of the P1 promoter and transcriptional interference at the P2 promoter,
to ensure that each of two isoforms of FPGS are expressed as needed in dividing and select
differentiated tissues.
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Peptide name Peptide
sequence
RNAPII CTD
repeat peptide

YSPTSPS

RNAPII CTD
repeat peptide phospho S2

YSPTSPS

RNAPII CTD
repeat peptide phospho S5

YSPTSPS

PO4

PO4

Table 2-1. Sequences of the C-terminal domain heptad repeat of RNAPII peptides
used to test the specificity of the serines 2 and serines 5 phospho-specific
antibodies. The position of the phosphate group in each synthetic peptide is illustrated.
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L1210
Liver
Brain

P1
(pg FPGS mRNA + SD)
<0.0001
0.21 + 0.0054
<0.0001

P2
(pg FPGS mRNA + SD)
0.15 + 0.014
0.001 + 0.0001
<0.0001

Table 2-2. Quantitative RT-PCR determination of FPGS expression from P1 and
P2 in mouse L1210, liver and brain. Total RNA (5µg) was reverse transcribed using
Superscript III in a total volume of 20µl, and 1µl was used in real time pCR assays using
primers specific for exons A1a/A1b to exon 3 (P1) or exon 1 to exon 3 (P2). Standard
curves for quantitation were constructed using plasmids carrying cDNAs corresponding
to the products of transcription from P1 (exons A1a through 3) and P2 (exons 1 through
3) , respectively.
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Figure 2-1. Northern analysis of FPGS gene expression in normal human
and murine tissues. Total RNA (10 µg) from murine normal tissues from
female DBA/2 mice was probed with a 1.7-kb downstream murine FPGS cDNA.
Freemantle, S. J. et al. J. Biol. Chem. 1997;272:25373-25379.
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Figure 2-2. Schematic diagram of the tissue-specific expression patterns of the
two promoters of the mouse fpgs gene. The two promoters of the fpgs gene are
splaced 9.5 kb apart and are differentially activated; the P1 promoter is used
exclusively in mouse liver and kidney and generates transcripts with exons A1a and
A1b linked directly to exons 2-15, splicing out exon 1; the P2 promoter is used in all
normal and neoplastic dividing cells and mature fpgs mRNA generated from P2
includes exon 1-15. The ovals at P2 mark the location of the three Sp1 sites
regulating the P2 promoter.
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A.

P1 probe

P2 probe

B.

Figure 2-3. Tissue-specific use of P1 and P2 of the mouse fpgs
gene. A. Schematic diagram of riboprobes, the PCR-generated RNA
standards, and the expected protected fragment size. B. RPA using
both probes on neoplastic and normal mouse tissues. Blue and red
circles identify the fragments generated using mouse liver and L1210
cells, respectively. Adapted from Turner et. al, Cancer Research,
59. 6074-6079, 1999.
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Figure 2-4. Stages of RNAPII-mediated transcription and promoter proximal
pausing. (a) The phases of transcription: initiation, elongation, and termination. A
pre-initiation complex is assembled with general transcription factors (GTFs) and
RNAPII at the promoter region. Transcriptional elongation is marked by an the
phosphorylation of the CTD of RNAPII. At the 3’ end a termination signal is reaced
and the mRNA molecule and RNAPII are released. (b) Steps of promoter-proximal
pausing. In recent years, it has become apparent that a larger proportion of mammalian
genes have a phase of promoter-proximal pausing during their transcription cycle.
Adapted from Koch and Jourquin, Cell press, 2008.
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Figure 2-5. DNA wrapped around nucleosomes, histone tails, and
histone tail post-translational modifications (PTMs). A. Nucleosomes
(yellow cylinders) and DNA (red strands) interact to assemble chromatin.
B. Two histone subunits of H2AB, H2B, H3, and H4 assemble into an
octamer to form the basic unit of chromatin, the nucleosome. The Nterminal tail of each histone protrudes from the core of the nucleosome and
key residues (black circles) serves as a substrate for histone modifying
enzymes. C. A portion of the histone H3 tail with some of the potential
PTMs. The potential modifications include: acetylation (Ac, green flag),
mono-, di-, or tri- methylation (Me, octagon), phosphorylation (P, yellow
circle)
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Figure 2-6. Composite profiles of the histone post-translational modifications
(PTMs) studied across the mouse fpgs locus in L1210 cells, mouse liver, and
mouse brain. The patterns are presented across a model gene and the correlation
with active or repressed transcription rates is denoted by the + and – symbols. The
presented profiles were obtained from genome-wide studies mainly in yeast, but
H3K9 and H3K27 patterns were described in higher eukaryotes Adapted from Li
and Workman, 2007 Cell.
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Figure 2-7. Mechanisms of DNA methylation-mediated repression. A. DNA
methylation occludes cis elements from transcription factor binding. B. Methyl-binding
proteins (MBPs) recognize methylated DNA and recruit histone deacetylases (HDACs)
and histone H3 K9 methyltransferases. Adapted from Klose, Genomic Marks and
Mediators 2006.

100

300 bp

Figure 2-8. 1% agarose gel with sonicated material obtained for the
ChIP studies presented in this chapter using L1210 cells, mouse liver,
and mouse brain. Three hundered microliters of lysates were sonicated
for 25 min (mouse liver and brain) and 20 min (L1210 cells). A 20 µl
aliquot of sonicated material was incubated at 650C overnight followed
by DNA purification and visualized on a 1% agarose gel stained with
ethidium bromide. DNA fragments ranged from 100-300 bp on average.
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Figure 2-9. CpG methylation in the regions of the mouse fpgs promoters
in various tissues. CpG methylation in the P1 promoter region correlates with
transcriptional activity; the P2 promoter region is unmethylated regardless of
activation. Genomic DNA was treated with 5M sodium bisulfite, amplified by
PCR, cloned, and the sequences of 10 clones were determined for each region.
At the position of each CpG dinucleotide in the genomic sequence, the
percentage of clones containing a methylated cytosine is represented in the
graph, plotted relative to the positions of exons A1a, A1b and 1 (filled boxes).
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Figure 2-10. Chromatin density over the mouse fpgs locus. A. A
prominent DNase I hypersensitivity site is present in the P1 region only in
tissues in which the promoter is active; the P2 region is accessible to
DNase I in expressing and non-expressing tissues. Nuclei were incubated
with increasing concentrations of DNase I for 5 minutes at 25°C. Genomic
DNA was extracted, digested with HinDIII, and run on an agarose gel. Blots
were probed with PCR-generated sequence at the 5’ ends of the HinDIII
fragments (asterisks in lower diagram). The bands in the control lanes indicate
the gel-mobility of the full-length HinDIII fragments. The location of the
DNase I hypersensitive sites (HSs) and the tissues containing such sites are
indicated in the lower diagram. B. ChIP determination of the level of
histone H3 over the fpgs gene. Chromatin from mouse liver (triangles), brain
(squares), or L1210 leukemia cells (circles) was cross-linked, sonicated, and
immunoprecipitated with either a pan-H3 antibody (filled symbols) or a nonspecific IgG (open symbols). The content of DNA for various segments of the
fpgs locus was determined by real-time PCR using primers spaced 250-300 nt
apart; symbols are placed at the middle of each PCR fragment. Input represents
amplified product from 0.1% of the starting material. The positions of the two
transcriptional start sites are shown as the cross-hatched bars. The experiments
in this and all subsequent ChIP figures were performed at least twice, and the
data are from a representative experiment.
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Figure 2-11. Schematic representation of amplified regions across the
20 kb of the mouse fpgs gene. The fpgs gene was divided into twelve
fragments separated 1.5-2.0 kb apart. Each amplicon ranged between 150300 bp in size.
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Figure 2-12. Distribution of acetylated histone H3 and H4 along
the fpgs locus in mouse tissues expressing transcript from P1 or P2.
Chromatin from L1210 leukemia cells (A), mouse liver (B) and mouse
brain (C) was cross-linked, sonicated, and immunoprecipitated with
either an antibody against acetyl-H3 (circles), acetyl-H4 (squares), or a
non-specific IgG (open symbols). The content of DNA for various
segments of the fpgs locus was determined by real-time PCR as in
Figure 2B. The positions of the two transcriptional start sites are shown
as the cross-hatched bars.

106

107

Figure 2-13. Analysis of the di-methyl histone H3 lysine
modifications decorating the two fpgs promoter regions in
mouse liver (B) and L1210 cells (A). ChIP analysis was
performed using antibody raised against H3K4me2. Quantitation
was performed using real-time PCR. Immunoprecipitation was
also performed with an IgG antibody (X), as a non-specific control.
The cross-hatched vertical bars represent the location of the P1 and
P2 transcriptional start sites.
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Figure 2-14. Distribution of histone H3 methylated at lysines 4 along
the fpgs locus in mouse tissues expressing transcript from P1 (liver), P2
(L1210) or from neither promoter (brain). Chromatin from L1210 cells
(A), mouse liver (B) and mouse brain (C) was cross-linked, sonicated, and
immunoprecipitated with either an antibody against H3K4me3. For each
immunoprecipitation, a separate non-specific IgG control was used (open
symbols). The positions of the two transcriptional start sites are shown as
the cross-hatched bars.
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Figure 2-15. Analysis of the histone H3 K9 modifications decorating the two fpgs
promoter regions in mouse liver (filled triangles) and L1210 cells (filled circles).
The acetylation or tri-methylation of histone H3 K9 reflects the chromatin
configuration and transcriptional activity of the P1 promoter. ChIP analysis was
performed using antibody raised against H3K9me3. Quantitation was performed
using real-time PCR. Immunoprecipitation was also performed with an IgG antibody
(X), as a non-specific control. The cross-hatched vertical bars represent the location
of the P1 and P2 transcriptional start sites.
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Figure 2-16. Distribution of histone H3 methylated at lysine 27 along the fpgs
locus in mouse tissues expressing transcript from P1 (liver), P2 (L1210) or from
neither promoter (brain). Chromatin from L1210 cells (A), mouse liver (B) and
mouse brain (C) was cross-linked, sonicated, and immunoprecipitated with either an
antibody H3K27me1, H3K27me2, or H3K27me3. For each immunoprecipitation, a
separate non-specific IgG control was used (open symbols). The content of DNA
for various segments of the fpgs locus was determined by real-time PCR. The
positions of the two transcriptional start sites are shown as the cross-hatched bars.
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Figure 2-17. Distribution of histone H3 methylated at lysine 36 along
the fpgs locus in mouse tissues. A. Chromatin from mouse liver
(triangles), mouse brain (squares), and mouse L1210 leukemia cells
(circles) was cross-linked, sonicated, and immunoprecipitated with either
an antibody against H3K36me3 or IgG (open symbols). The content of
DNA for various segments of the fpgs locus was determined by real-time
PCR as in Figure 2B. The positions of the two transcriptional start sites
are shown as the cross-hatched bars. B. The ratio of ChIP signal for
H3K36me3 to that for total histone H3. The amount of H3K36me3 is
expressed as a ratio of the ChIP signal for total histone H3 to determine
whether the minimum in the H3K36me3 signal seen in A reflects total
H3 density or a lack of methylation at H3K36 on the regional
nucleosomes.
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Figure 2-18. Schematic representation of overlapping primer sets used to
amplify the P1 and P2 promoter in high-resolution ChIP experiments. The P1
promoter was divided in to six fragments covering the region between -630 and
+315 nt, relative to the P1 promoter transcriptional start site. The P2 promoter was
probed using six amplicons against the region between -701 and +240 nt, relative to
the P2 promoter transcriptional start site. Adjacent products overlapped by ca 50 nt.
The location of the DNase HS determined previously are labeled HS.
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Figure 2-19. Semi-quantitative PCR identifies RNAPII across the P1 and
P2 promoter regions in mouse liver and only at the P2 promoter in L1210
cells. High-resolution ChIP walking studies were performed using an antibody
against RNAPII and IgG as a non-specific control. Six regions of genomic DNA,
labeled 1-6, were amplified for both the P1 and P2 promoters. The location of
each amplicon is illustrated in Fig. 2-18. 0.1% of total input DNA was added to
PCR reactions using each primer pair. A portion of the β-globin promoter was
amplified as a negative control for RNAPII binding. The reactions were run for
28 PCR cycles and 10 µl of product were run on a 1% agarose gel stained with
ethidium bromide.
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Figure 2-20. Residency of RNAPII over fragments of the two mouse fpgs
promoters in mouse liver and L1210 cells. A. The amount DNA from regions
spaced along the fpgs gene immunoprecipitated by an antibody to RNAPII was
quantitated by real-time PCR as in Figure 2B. The position of P1 is plotted at 0 kb
and P2 is at 10 kb on the abscissa. Data for L1210 cells is shown as black bars, for
liver as grey bars. In B, the DNA regions immediately surrounding P1 (left panel) and
P2 (right panel) were fine-mapped by ChIP using the same antibody. Non-specific
binding was determined by immunoprecipitation with IgG, as shown by open triangles
(liver) and circles (L1210). The primer set plotted at 0 in A is also plotted at 0 for the
P1 blow-up in B. The primer set plotted at 10 kb in A is plotted at 0 for the P2 blow
up in B. Data are plotted in B at the midpoint of each amplified region.
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Figure 2-21. Phosphopeptides used to raise phosphospecific antibodies
against the CTD of RNAPIII specifically block the ChIP signal under our
conditions. Increasing concentrations of the phosphopeptides used to raise
antibodies against RNAPII CTD phosphorylated serine 2 and RNAPII CTD
phosphorylated serine 5 or the equivalent unphosphorylated peptide were
incubated for 2 hours with antibodies prior to their use in ChIPs as described in
the Materials and Methods. Subsequently, the antibodies were added to lysates
of L1210 cells, and the DNA in precipitates was quantitated by real-time PCR
using a set of primers directed against a region of the GAPDH promoter and
against a region of the P2 promoter of L1210 cells, regions chosen for moderate
signals against the phosphoserine 5 and phosphoserine 2 antibodies, respectively.
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Figure 2-22. Phosphorylation of RNAPII at serine 2 and 5 detected over
fragments of the P1 and P2 fpgs promoters L1210 cells. ChIP walking studies
were performed using an antibody against RNAPII (filled circles), antibodies raised
against the C-terminal domain heptad (YSPTSPS) repeat of RNAPII phosphorylated
at serine 2 (inverted triangles) and serine 5 (open circles), as well as an antibody
raised against IgG (open triangles) as a nonspecific control. Five or six fragments
were amplified over the P1 and P2 fpgs promoters, respectively. Quantitation was
performed using real-time PCR. The data points were plotted at the midpoint of each
amplified region.
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Figure 2-23. Phosphorylation of RNAPII at serine 2 and 5 detected over
fragments of the P1 and P2 fpgs promoters in mouse liver. ChIP walking studies
were performed using an antibody against RNAPII (filled circles), antibodies raised
against the C-terminal domain heptad (YSPTSPS) repeat of RNAPII phosphorylated
at serine 2 (inverted triangles) and serine 5 (open circles), as well as an antibody
raised against IgG (open triangles) as a nonspecific control. Five or six fragments
were amplified over the P1 and P2 fpgs promoters, respectively. Quantitation was
performed using real-time PCR. The data points were plotted at the midpoint of each
amplified region. The data from two separate experiments are presented in A and B.
Ratios of enrichment signal of phospho-specific antibodies to total RNAPII signal
were calculated for points at +75 nt and +50 nt for P1 and P2, respectively (C and
D).
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Figure 2-24. Phosphorylation of RNAPII at serine 2 and 5 detected over
fragments of the P2 fpgs promoter in mouse brain. ChIP walking studies
were performed using an antibody against RNAPII (filled squares), antibodies
raised against the C-terminal domain heptad (YSPTSPS) repeat of RNAPII
phosphorylated at serine 2 (filled circles) and serine 5 (open circles), as well as
an antibody raised against IgG (X) as a nonspecific control. Quantitation was
performed using real-time PCR. The data points were plotted at the midpoint
of each amplified region.
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Figure 2-25. Presence of transcription factors over the mouse fpgs P2
promoter in L1210, liver and brain. ChIP analysis was performed using
antibodies directed against the sequence-specific transcription factor Sp1,
and general transcription factors TFIIB, TBP, TAF p250, and the NELF-A
protein. Quantitation was performed by real time PCR using primers
amplifying regions at -200 nt (A) and +200 nt (B) positions relative to the P2
transcriptional start site.
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Figure 2-26. Schematic diagram of proposed mechanism of transcriptional
interference occurring at the P2 promoter in mouse liver. In dividing cells,
the initiation occurs at the P2 promoter and generates abundant fpgs transcript
(Top). In mouse liver, transcriptional initiation occurs at the P1 promoter and
elongation RNAPII complexes travel down the fpgs locus. We propose that
RNAPII elongation complexes restricts assembly of a pre-initiation complex at
the P2 promoter, thus preventing robust transcription from the P2 promoter in
mouse liver.
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Chapter 3: Disruption of individual steps in the control mechanisms of the
mouse fpgs gene

INTRODUCTION
The studies presented in the previous chapter questioned how the two promoters of
the mouse fpgs gene are regulated in a tissue-specific manner.

Our data suggests that

epigenetic mechanisms and transcriptional interference are involved in the control of the
two mouse fpgs promoters.
A major challenge in further investigating these regulatory mechanisms is that the
experiments needed require model systems where a primary change, i.e. loss of DNA
methylation or loss of P1 activity, is established and the consequences on gene expression
and epigenetic modifications at the mouse fpgs gene are measurable. As our initial studies
were completed, two model systems became available that had single disturbances in the
processes we were aiming to test: 1.) a knock-out mouse where the P1 promoter is
completely removed was generated in our laboratory(263); and 2.) Cedar et. al engineered
a mouse embryonic fibroblast immortal cell line that is severely depleted in DNA
methylation (137).

126

Transcriptional Interference studies
In mouse liver, the upstream fpgs P1 promoter is active and the downstream P2
promoter is silenced. In previous studies, tracking the residence of RNAPII and general
transcription factors across P2 in liver argued that the accumulation of elongation
complexes restricted the assembly of pre-initiation complexes at this promoter. We took
this to suggest that a mechanism of transcriptional interference at the mouse fpgs gene was
involved in dictating the production of one isoform over a second in a tissue-specific
fashion.
Transcriptional interference is a very broad term that includes any mechanism
where the transcriptional activity of one gene impacts the activity at a second gene. TI
mechanisms have been most extensively studied through engineered in vitro systems (1,
83, 188). Evidence from genome-wide studies supports the idea that TI may alter the
expression of more genes than previously thought. Intergenic distances between genes
have been mapped on human chromosomes 6, 20, and 22 and in many cases were found to
be small, resulting in circumstances where regulatory regions frequently overlapped(233).
Likewise, over 50% of mammalian genes have recently been identified to use multiple
promoters(37). Whether and how TI is coordinating expression of either adjacent or multipromoter mammalian genes are important questions that will require analysis on a case-bycase basis.
TI has been best illustrated in vivo at the SRG1-SER3 locus in S. cerevisiae. The
intergenic transcription of the SRG1 gene represses the transcription of the adjacent SER3
gene through direct TI (155). Transcriptional repression of the SER3 gene was relieved in
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SRG1 mutants or in mutants where a transcription termination signal was placed between
the two genes (155). The TI mechanism was found to be promoter occlusion from studies
showing that SRG1 activity severely limited transcription factor binding to the SER3
promoter (155). Additional studies related this effect to amino-acid metabolism when it
was found that SRG1 expression was induced by high serine levels, which lead to the
silencing of SER3, a serine biosynthetic gene (156). This was one of the first examples
described in vivo where direct TI, or promoter occlusion, was proven to coordinate
eukaryotic gene expression.
In our studies, we have used the mouse fpgs gene to study mechanisms of TI at an
mammalian promoter in vivo. Lin-Ying Xie, a former student in the laboratory, generated
a knock-out mouse line, where the P1 promoter and the two upstream exons A1a and A1b
were deleted through homologous recombination (263).

Homozygous deletion mice

survived embryonic development, matured to adulthood, and reproduced normally (263).
Our studies on the phenotype of these mice are not yet complete but, to date, the mice
appear to be biologically normal.
In an effort to test our TI hypothesis, the address presented in this chapter
compared expression levels and transcription factor binding at the P2 promoter in mouse
liver harvested from wild-type and knock-out animals. We also used this mouse model to
assess changes in the patterns of histone acetylation and histone H3 lysine 4 methylation
across the mouse fpgs gene in the livers of genetically different mice. The P1 knock-out
mouse model is a unique reagent allowing us to approach the mechanism of TI at an
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endogenous locus by deletion of the proposed interfering gene; such studies have only
previously been done in yeast models.

DNA methylation studies
DNA methylation analysis of the two mouse fpgs promoters showed that the CpGsparse P1 promoter is differentially methylated between tissues, suggesting a role for DNA
methylation in the regulation of the P1 promoter. Likewise, loss of DNA methylation was
coincident with histone acetlyation and transcriptional initiation. These observations were
truly a surprise since at the time we were unaware of any example described where loss of
DNA methylation predicted the transcriptional activation of a tissue-specific CpG-sparse
promoter. We were very interested to explore the possibility that DNA methylation was a
primary determinant of transcriptional regulation at the P1 promoter.
Genome-wide studies have identified tissue-specific differentially methylated
regions in both mouse and human (58, 227, 256).

However, the primacy of DNA

methylation in the regulation of tissue-specific transcriptional control remains
controversial. The notion that CpG methylation may coordinate tissue-specific expression
has been proposed for the past two decades (40, 235), but little evidence has supported this
model (22, 206, 254). The methylation-mediated transcriptional repression of CpG-island
promoters during the process of transformation has been well described (120, 131)but,
tissue-specific promoters are now known to often be CpG-sparse and the ability for DNA
methylation and methyl-binding proteins to promote silencing of this class of genes is
poorly understood. Alterations of DNA methylation that parallel changes in expression at
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tissue-specific and developmentally coordinated genes with non-CpG island promoters
have been described in a few instances (75, 106, 112, 150). The maspin gene was one of
the first cases identified in vivo where tissue-specific loss of DNA methylation resulted in
production of mRNA.

A case for the importance of this epigenetic mechanism in

hematopoietic development has recently been made in several important studies at the
mammalian globin locus.

In this work, investigators tracked methylation and gene

expression patterns in mice during development, which has lead to the proposal that DNA
methylation and methyl-binding proteins may be involved in gene switching at this locus
(106, 203).
Central to the interpretation of tissue-specific patterns of methylation is an
understanding of how these genomic regions of differential methylation originate in
developed tissues. The distribution of methyl groups at CpGs throughout the genome
occurs at implantation with a phase of de novo methylation and is maintained throughout
normal development and differentiation (193, 206). As such, loss of DNA methylation at a
tissue-specific promoter must require a process of selective DNA demethylation. Whether
loss of DNA methylation is a passive event, requiring multiple rounds of DNA replication,
or an active process is a topic of controversy. However, there are an increasing number of
examples found in the literature where rapid and cyclical changes in DNA methylation
have been observed in mammalian cells in response to extracellular stimuli (126), leading
to the proposal that this gene was regulated by an active process demethylation (32).
Recent work illustrated an association between nucleotide-excision repair (NER) processes
and genome-wide DNA demethylation (14, 213).
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However, the universality of NER

mechanisms in shaping the tissue-specific patterns of demethylation observed in mammals
remains to be understood.

Likewise, there is still a great deal to learn about how the

timing and specifity of demethylation events are dictated, and whether or not DNA
demethylation is a primary event in transcriptional activation. Our studies at the P1
promoter focus on the sequence of events leading to transcriptional activation, histone
marks, and loss of DNA methylation at this region.
Methylation is the only known covalent modification of DNA in mammals and is
catalyzed by a family of enzymes collectively known as the DNA methyltransferases
(DNMTs) (131). These enzymes are classified based on a highly conserved catalytic
domain at the C-terminus and the N-terminal domains of these proteins tend to be highly
variable (131). To date, the identified mammalian DNMTs include: DNMT1, DNMT2,
DNMT3a, and DNMT3b (131). Studies have determined that DNMT2 is not required for
establishing or maintaining methylation patterns but instead, DNMT2 is a tRNA
methyltransferase (80, 179). DNMT1 was the first enzyme purified in this family and was
found to have activity towards nonmethylated and hemi-methylated DNA, with a
preference towards a hemi-methylated substrate (21). Genetic deletion of the DNMT1
gene in developing mice leads to genome-wide loss of CpG methylation and embryonic
lethality at E9.5 (142). Embryonic stem cells with DNMT1 mutant alleles retained
detectable levels of DNA methylation, which lead to the proposal that additional
methyltransferases were responsible for methylation in early stages of development (242).
Subsequently, DNMT3a and 3b were cloned and characterized as the enzymes required for
de novo methylation during development (177, 178). DNMT3L is a member of the de
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novo methyltransferase family of proteins, which does not have any catalytic activity that
cooperates with 3a and 3b to establish de novo methylation patterns (108). Current thought
proposes that DNMT3a and 3b establish methylation patterns during development and
DNMT1 uses a hemi-methylated substrate to maintain methylation in developed tissues
(22, 131).

How coordination of these enzymes affects tissue-specific patterns of

methylation is not well understood.
A major challenge in the field of DNA methylation has been developing model
systems to test the consequence of global loss of DNA methylation. It has been impossible
to generate cell lines either from embryos of knock-out mouse models or in human
carcinoma cells lines that are truly deficient in DNMT1. Previous literature predicts that if
DNMT1 null cells survive in culture, they are not completely deficient in DNMT1, but
instead are DNMT1 hypomorphs (44, 60).

Additionally, in cells where the catalytic

domain of DNMT1 has been conditionally deleted human carcinoma cells undergo mitotic
catastrophe and substantial cell death within two days (44). While these issues highlight
the importance of DNMT1 and DNA methylation for cellular survival, they have made it
very difficult to ask fundamental questions regarding the consequences of primary changes
in DNA methylation at specific CpGs.
An alternative approach to DNMT1 knockdown or knock-out animals or cell lines
has been the use of nucleoside DNMT1 inhibitors 5-azacytidine (5aza) and 5aza-2deoxycytidine (5daza) to pharmacologically induce loss of genome-wide patterns of DNA
methylation (122). These compounds are cytidine analoges that are incorporated into
DNA during replication. Binding of these analogues, once incorporated into DNA, to the
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catalytic site of DNMT1 is covalent and pseudo-irreversible and traps the enzyme on the
DNA, leading to depletion of cellular levels of DNMT1. As a result, these agents have
been shown to cause demethylation and reactivation of many genes (60). While treatment
with 5aza and 5daza has proven very useful, they have been shown to induce a DNA
damage response, which leads to the expression of p53, p21, and numerous downstream
targets (180). Distinguishing transcriptional effects caused by DNA damage vs. those
resulting from a primary loss of methyl-CpGs is complicated by the fact that so many
genes become activated during the DNA damage response.
In order to circumvent the problems generated by DNMT1 hypomorphs and
inhibitors discussed above, Howard Cedar’s group generated a fibroblast cell line that is
homozygous for the DNMT1 mutant allele used in the original knock-out studies (142),
and homozygous for a p53 mutant allele, resulting in a p53-/-Dnmt1-/- genetic background.
p53-/-Dnmt1-/+ animals were mated and the resulting embryos were harvested at E9.5,
when the p53-/-Dnmt1-/- embryos were identified by genotyping (137). In their report, they
assayed global DNA methylation in these cells using nearest neighbor analysis and
proposed that almost all CpG sites were unmethylated (137). This system was unique
because the hypomethylated cells remained viable and proliferative in culture due to the
loss of p53. Hence, these cells would support studies examining the primary effects of loss
of DNA methylation on gene expression and chromatin structure, which had not previously
been feasible. Likewise, a control cell line was easily available by generating mouse
embryonic fibroblasts from p53-/- mice.

With a primary change in DNA methyation,

Cedar’s group analyzed changes in histone acetylation and histone H3 lysine 4
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methylation, as well as changes in gene expression. In these studies, they identified two
classes of genes: those genes where loss of DNA methylation was coincident with an
increase in gene expression, histone acetylation, and histone H3 lysine 4 methylation, and
the second group of genes that required loss of DNA methylation and inhibition of histone
deacteylation to show an increase in transcriptional activity. Some of the studies discussed
in this chapter took advantage of this cell line to ask questions regarding the role of DNA
methylation in the regulation of the P1 mouse fpgs promoter.

Objectives of study
Our previous work left us with a large number of unanswered questions regarding
the histone PTMs, DNA methylation, and transcriptional interference involved in the
tissue-specific regulation of the mouse fpgs gene.

These questions include: 1. Is

transcriptional interference the primary mechanism silencing P2 in mouse liver? 2. Is
promoter occlusion the mechanism of transcriptional interference occurring at P2 in mouse
liver? 3. Is DNA methylation necessary and sufficient for the silencing of P1 in dividing
cells? and 4. Is DNA methylation across P1 necessary and sufficient to prevent histone
acetylation and histone H3 lysine 4 methylation at nucleosomes surrounding P1 in dividing
cell? The answers to these questions could not be pursued through observations of the
wild-type mouse. In the studies presented in this chapter we used two model systems with
primary disturbances in P1 activity and DNA methylation to explore the contribution of
these factors in the use of the two mouse fpgs promoters.
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MATERIALS AND METHODS
Materials
C57BL/6 mice were used in all the mouse studies and were originally obtained
from Charles River Laboratories. P1 knock-out mice were back-crossed with wild-type
C57BL/6 mice for six generations before they were used in the studies (263). Chemicals
and reagents were purchased from Sigma (St. Louis, MO) and Fischer (Pittsburgh, PA).
Antibodies were obtained from Upstate Biotechnology (Billerica, MA), Santa Cruz (Santa
Cruz, CA), Abcam (Cambridge, MA), and Imigenex (San Diego, CA) and will be
discussed individually in the sections to follow. 5-Aza-2’-deoxycytidine (A3656) and
Trichostatin A (TSA) (T8552) were purchased from Sigma-Aldrich.

Trizol reagent

(Invitrogen, cat no. 15596-026) was used to isolate RNA. The puregene DNA purification
system (Gentra, cat no. D-5000A) was used to isolate genomic DNA.

EZ DNA

Methylation-Direct Kit (Zymogen, cat. No D5020) was used for bisulfite conversion of
genomic DNA. DNA oligo primers (25 nmoles) were purchased for these studies from
Integrated DNA Technologies (IDT). Quanti-tect Sybr Green PCR Master Mix (product #
204143) was purchased from Qiagen (Valencia, CA) and used for all of the Real-time PCR
analysis. Superscript III Reverse transcriptase First-Strand Synthesis System for RT-PCR
(cat no. 1808-051) was used to generate cDNA. The Real-time PCR machines used in
these studies were BioRad DNA Engine Peltier Thermal Cyclers with a Chromo 4 RealTime Detector attachment. Opticon Monitor Software was used to analyze the Real-Time
data.
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Cell culture
P and PM MEFs were maintained in DMEM medium (Gibco/Invitrogen)
supplemented with 15% Fetal Bovine Serum (FBS). Cells were grown at 370C in 5% CO2.

Chromatin immunoprecipitation- P1 knock-out mouse liver studies.
The ChIP protocol described in chapter 2 for mouse liver was applied to profile
histone H3 acetylation and histone H3 lysine 4 tri-methylation across the mouse fpgs gene
and to assess Sp1, HNF4, and RNAPII binding to the P2 promoter in mouse liver from
wild-type and P1 knock-out animals. Cross-linked DNA fragments were sonicated down to
100-300 bp and DNA size distribution was monitored on agarose gel. Lysates were rotated
at 4ºC overnight with 8 µg of anti-RNAPII (Upstate Biotech, 05-623), 4 µg anti-IgG
(Upstate Biotech, 12-371), or 5 µg of antibodies against phosphoserine 5 peptide from
RNAPII (Abcam, ab5131), phosphoserine 2 peptide from RNAPII (Abcam, ab5095),
HNF4 (Santa Cruz sc-8987), acetyl histone H3 lysine 9 (Upstate Biotech, 07-352), trimethyl H3K4 (Upstate, 07473), or SP1 (Santa Cruz, sc-59). Real-time PCR was performed
with 1 µl of final sample dissolved in 100 µl of TE. The primer sets used to cover the
entire mouse fpgs gene and to amplify the P2 promoter at high-resolution were the same as
those described in chapter 2.

RNA isolation from P and PM cells
Tissue-culture (100 mm) dishes were plated with P or PM cells and grown to 85%
confluence. Pipettes and the workbench were wiped down with RNAse Zap solution
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(Invitrogen) to limit the amount of RNAses in the environment. The protocol supplied with
the trizol reagent was followed directly for the purification of RNA. The 100 mm dishes
were placed on ice, medium was decanted, and 3 mls of trizol reagent were added to the
plate. Cell lysates were taken up several times in a 1 ml filter pipette tip and transferred to
a 14 ml polypropylene round-bottom Falcon tube (Falcon, cat no. 352059).

The

homogenized samples were incubated for 5 minutes at RT to allow complete dissociation
of nucleoprotein complexes. Six hundred microliters of chloroform were added to each
tube and the tubes were capped tightly and shaken by hand for 15 seconds, followed by 2-3
min incubation at RT. The samples were centrifuged at 12,000 x g for 15 min at 40C. The
aqueous phase was transferred to a fresh Falcon tube and 1.5 mls of isopropyl alcohol was
added to each tube to precipitate RNA. Samples were incubated for 10 minutes at RT
followed by centrifugation at 12,000 xg for 10 minutes at 40C. A transluscent pellet was
visible at the bottom of the tube and the supernatant was carefully removed by decanting to
avoid disruption of the pellet. The RNA pellet was washed by adding 3 mls of 75%
ethanol in diethylpyrocarbonate (DEPC)-treated water and the tubes were vortexed and
spun down at 7500 x g for 5 minutes at 40C. The supernatant was again decanted and
inverted on the workbench to remove excess ethanol. The pellets were air dried for no
more than 2 minutes and resuspended in 100 µl of DEPC-treated water and transferred to a
RNAse-free 1.5 ml microcentrifuge tube. The samples were passed through a pipette tip to
ensure that the RNA was completely resuspended. If RNA was not completely in solution
(flakes or pellet could still be visualized) the samples were incubated at 550C for 10
minutes. Total RNA was quantified using the NanoDrop ND-1000 spectrophotometer.
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Five-hundred nanograms of each RNA sample were run on a 1% agarose gel stained with
ethidium bromide at 100 volts for 30 min to assess the integrity of the RNA by visualizing
the banding pattern of 28S RNA and 18S rRNA: if the 28S RNA band was approximately
2x more intense then the 18S rRNA, the RNA was considered to be intact. Purified RNA
was stored at -800C in 3x volume of 100% ethanol or isopropanol and 1/10th the volume of
NaAc at pH 5.2.

cDNA synthesis of RNA obtained from P and PM cells.
Total RNA (2.5 µg to 5 µg) from P and PM cells were used to synthesize cDNA
with the Superscript III First-Strand Synthesis Reverse transcriptase Kit (Invitrogen).
RNA was added to a RNAse-free 0.6 ml tube and combined with 1µl of 50µM oligo(dT)20
primer, 1µl of 10mM dNTP mix, and DEPC-treated water up to 10µl. The mixture was
incubated at 650C for 5 min to melt any RNA secondary structure. The oligo(dT) primer
was used in these experiments to selectively convert polyadenylated full-length mature
mRNA into cDNA. The samples were then placed on ice for at least 1 minute. In a
separate 0.6 mL tube the cDNA synthesis mix was prepared by adding the following
components, 20 µl of 10x RT buffer, 40 µl of 25mM MgCl2, 20µl of 0.1M DTT, 10 µl of
RNaseOUT (40U/µl), and 10µl of SuperScript III Reverse transcriptase (200U/µl) for 10
cDNA synthesis reactions. Ten microliters of cDNA synthesis mix was added to each
RNA/primer mixture and mixed gently by flicking the tube. The samples were collected
by brief centrifugation. The mixture was incubated at 500C for 50 minutes to allow first
strand cDNA synthesis. The reaction was terminated through incubation at 850C for 5
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minutes. Following termination, the samples were chilled on ice and were collected by
brief centrifugation. One microliter of RNAse H was added to each tube and incubated for
20 min at 370C. This step removes the RNA template bound to the newly synthesized
cDNA allowing for immediate use in PCR. In addition to the cDNA synthesis reactions
carried out using total RNA, two control reactions were performed in parallel: 1) One
reaction was prepared exactly as described above, except that only water was added to the
primer mixture instead of RNA (no template control). This reaction controls for RNA or
DNA contamination in the reagents of the kit. And 2) A second cDNA synthesis mixture
was prepared without the addition of the SuperScript III RT (-RT cDNA synthesis
mixture). Ten microliters of RNA/primer mixture was added to the –RT cDNA synthesis
mixture and processed following the protocol outlined above. This reaction controls for
the level of genomic DNA contaminating the RNA samples.

Primer design to amplify cDNA encoding mRNA generated at the P1 or the P2 mouse
fpgs promoters.
The fpgs transcripts generated from the two promoters of the mouse fpgs gene are
splice variants and we used this fact to design primers that would amplify one species over
another. The sense primer was used to distinguish between the two types of transcripts: to
select for P1-specific fpgs cDNA the sense primer was sequence within exon A1b (A1b
forward), whereas the P2-specific fpgs cDNA was amplified using a sense primer
positioned within exon 1 (Ex1 forward). The anti-sense primers used in these experiments
were complimentary to sequences within exon A1b (A1b reverse), exon 3 (Ex3b reverse),
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or exon 6 (Exon 6 reverse). The primers used in a given experiment are noted in the
Figure Legends. The primers were designed, purchased, and resuspended as described in
chapter 2.

Semi-quantitative PCR of cDNA generated from RNA of P and PM cells.
The semi-quantitative PCR experiments presented in this chapter were performed
following the same procedure described in chapter 2 with the following exceptions: 1) 1µl
of cDNA template was added to the 24 µl master mix. and 2) PCR reactions using primers
specific to fpgs cDNA generated at the P1 promoter were removed at cycles 30, 32, 34, 36,
and 38. GAPDH cDNA levels were used as a reference gene to control for variation in
RNA extraction and cDNA synthesis between samples.

PCR reactions amplifying

GAPDH cDNA were removed at 8, 10, 12, and 14 cycles in order to visualize the
production of products in the exponential range. The primers used to amplify the P1specific fpgs cDNA in the semi-quantitative experiments were A1b forwarnd and Exon 3
reverse.

Real-time PCR of cDNA generated from RNA of P and PM cells.
Real-time PCR reaction mixtures were prepared as described in chapter 2 and 3µl
of cDNA template was added to the 72 µl sub-master mix. Primers were designed to
amplify Slpi, cryaa, and GAPDH cDNA in the real-time experiments. Slpi and cryaa were
control genes for the P and PM cells and GAPDH was a reference gene used to compare
between cDNA samples (discussed above). The primers used to amplify the fpgs-specific
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cDNA species were A1b forward, A1b reverse, and Exon 6 reverse. The reactions were
pre-incubated at 95oC for 15 min and the amplification conditions for each primer pair
were 95oC for 45s; 58 oC for 45s, 72 oC for 45s followed by a final extension time at 72 oC
for 5 min. Forty PCR cycles were performed for the real-time studies and a plate read step
was programmed at the end of each cycle to capture the fluorescence in each tube. Melt
curve analysis was programmed at the end of the run to measure melting curves of each
PCR product in one degree increments between the temperatures of 50 oC- 100 oC. In PCR
reactions where A1b forward and Exon 6 reverse were used the annealing temperature was
set to 63 oC degrees. We found that amplification of P1-specific fpgs cDNA for forty
cycles generated multiple sized products that encoded species of fpgs cDNA that would not
generate a full-length protein due to the presence of pre-mature stop codons. These
products were detected in melt curve analysis and by visualization on an agarose gel. By
using an annealing temperature of 63 oC we were able to obtain single peak melt curves,
which reflected the desired product as visualized on an agarose gel. In these experiments,
a standard curve was not generated and the ΔCt method was used to analyze the real-time
data (see below).

Analysis of Real-time PCR data
Real-time data was analyzed using the ΔCt method. This method allows relative
quantification of a gene-specific cDNA relative to the level of the expression of a reference
gene. In our experiments, GAPDH levels were used as the reference. As discussed in
chapter 2, the threshold cycle number (CT), is the cycle number at which amplified product
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accumulates to a level where fluorescent signal is detected. The formula for the ΔCt
method is
Ratio = 2Ct(reference)-Ct(target)
The CT value determined from the amplification of the cDNA of interest, e.g. P1-specific
fpgs cDNA, was subtracted from the CT value collected from reactions where GAPDH
specific product was generated.

Chromatin immunoprecipitation-P and PM cells.
The ChIP protocol used in these studies was the same procedure described in
chapter 2, with minor modifications as discussed below. P and PM were plated in 100 mm
dishes and allowed to adhere to the plates overnight. The next day, cells were rocked for 8
minutes at RT with 1% HCHO in 10 mls of RPMI-1640 medium. Glycine was then added
to the media to achieve a final concentration of 0.125 M and the cells were rocked for an
additional 5 minutes. The media was aspirated from the plate and the cells were washed by
the addition of 5 mls of PBS + 1mM PMSF to the plates. The PBS was removed and an
additional 5 mls of PBS + 1mM PMSF was added to the plates. The cells were removed
from the plate by scraping and cell suspension was then placed in a 15 ml centrifuge tube.
The pelleted cells were washed and processed as described in chapter 2. Two million cells
were resuspended in 300 µL samples of lysis buffer and sonication was carried out in a
bath sonicator (Diagenode) to achieve 300-500 bp DNA. Additional sets of dishes were
plated with P or PM cells when these experiments were initiated.

The cells were

trypsinized, pelleted by centrifugation, and were counted using the Beckman coulter
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counter. The numbers obtained from these counts were used to estimate the number of
cells that were cross-linked and lysed. Two million P and PM cells were sonicated using
repeated cycles of 30 sec pulse and 30 sec off, followed by the addition of fresh cold ice
water to the bath for a total sonication time of 25 minutes. Lysates were rotated at 4ºC
overnight with 5 µg of antibodies against acetyl histone H3 lysine 9 (Upstate Biotech, 07352), tri-methyl H3K4 (Upstate, 07473), or IgG (Upstate Biotech, 12-371). Real-time PCR
was performed with 1 µl of final sample dissolved in 100 µl of TE. The primer sets used
to cover the entire mouse fpgs gene and to amplify at high-resolution the P2 promoter were
the same as those used in the studies described in chapter 2.

Treatment of P and PM cells with Trichostatin A (TSA).
P and PM MEFs were plated in 100 mm dishes and were treated when the plate
was approximately 70% confluent. Ten milliliters of fresh media were added to the plates
and half of the plates were treated with 0.06 µM of TSA. Three millimolar stock TSA
solutions were prepared in ethanol. TSA was diluted in PBS and filter sterilized prior to
use. The cells were exposed to drug for 12, 24, 48, and 72 hours and fresh drug was added
every 24 hours. We found that, when MEFs were treated with TSA for more than 24 hours,
the growth and viability of the cells were severely impacted. Hence, we focused our
studies on 12 and 24-hour time points.

At the indicated time points, RNA was isolated,

cDNA synthesized, and analyzed by either semi-quantitative or real-time PCR.
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Treatment of P and PM cells with 5-Aza-2’-deoxycytidine.
P and PM cells were plated in 100 mm dishes and were incubated overnight to
allow cells to adhere to the plates.

5daza stock solutions were prepared in sodium

phosphate buffer and resuspended to a final concentration of 1 mM, diluted in PBS and
filter sterilized prior to use. Ten milliliters of fresh media were added to the plates and half
of the plates were treated with 1µM 5daza for 24, 48, and 72 hours. Fresh media and drug
were added every 24 hours. At the indicated time points, either RNA or DNA were
isolated from the treated and untreated plates for future use in cDNA synthesis and
bisulfite sequence analysis, respectively.

Bisulfite sequencing analysis
We used bisulfite conversion sequence analysis to quantify the DNA methylation
present over the P1 mouse fpgs promoter in P and PM cells. Bisulfite treatment converts
unmethylated cytidine (C) to uracil, but methyl cytidine is not susceptible to this reaction
and remain unchanged. Amplification by PCR replaces the uracils with thymidines (T)
and sequence analysis is used to determine which cytidine residues were methylated and
unmethylated within a genomic region of interest.
Isolation of DNA
Genomic DNA was isolated from P and PM cells using the Puregene DNA
purification kit. Cells were trypsinized and pelleted by centrifugation at 500 x g for 5
minutes. The supernatant was removed leaving 100-200 µl of residual liquid. The cell
pellet was vortexed, resuspending cells to assist with lysis. Two to three million cells were
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resuspended in 600 µl of lysis solution and pipetted up and down to generate a
homogenous mixture. Cellular RNA was removed by the addition of RNAse A (3 µl of
4mg/ml stock) to the cell lysate. The sample was inverted 25 times and incubated at 37oC
for 30 min. The samples were placed on ice and cooled to room temperature and then were
transferred to 14 ml Falcon tubes.

Two-hundred microliters of protein precipitation

solution was added to the RNAseA treated cell lysate.

The samples were vortexed

vigorously for 20 seconds and then incubated on ice for 5 minutes. The incubation on ice
is not required, but I found that it helps the formation of a tight protein pellet after
centrifugation. Following incubation, the samples were spun at 2,000 x g for 10 minutes.
If the precipitated protein pellet was not tightly fixed to the bottom of the tube, the samples
were vortexed and re-incubated on ice for 5 minutes followed by centrifugation. The
supernatant was poured into a fresh Falcon tube containing 600 µl of isopropanol. The
tubes were inverted gently fifty times followed by centrifugation at 2,000 x g for 15
minutes. The supernatant was poured off and the tubes were inverted on the bench top to
drain additional liquid. The samples were washed in 600 µl of 70% ethanol, followed by
centrifugation at 2,000 x g for 10 minutes. The ethanol was decanted leaving a small
amount of residual liquid.

The pellets were transferred to a 1.5 ml DNAse-free

microcentrifuge tube. The samples were pelleted by centrifugation at 12,000 x g for 5 min.
The remaining ethanol was removed and the pellet was allowed to dry on the bench top for
5 minutes. One-hundred microliters of DNA hydration solution (Tris-EDTA solution) was
added to the tubes and the samples were placed at 650C for 1 hour and rotated end-over-
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end overnight at RT. If genomic DNA was not completely in solution following overnight
incubation, additional DNA hydration solution was added in 50 µl increments.
Bisulfite conversion
The EZ DNA methylation-Direct kit (Zymo research) was used for the bisulfite
coversion of genomic DNA isolated from P and PM cells. Two-hundred to five-hundred
nanograms of genomic DNA in a volume of 20 µl were added to 130 µl of CT conversion
reagent solution to a 0.2 ml PCR tube. The tubes were placed in a thermal cycler (Biorad),
which was programmed to incubate the samples at 98oC for 8 minutes, 64oC for 3.5 hours,
and 4oC for up to 20 hours. The zymo-spin IC column was placed in a collection tube and
600 µl of M-binding buffer was added to the column. The sample was loaded into the
column containing the M-binding buffer. The column was capped and inverted several
times. The sample was centrifuged at 10,000 x g for 30 seconds and the flow-through was
discarded. At this point, the bisulfite converted genomic DNA was bound to the column.
Desulphonation was carried out using 200 µl of M-desulphonation buffer and incubating
the samples at RT for 20 minutes, followed by centrifugation at 10,000 x g for 30 seconds.
The samples were washed with 200 µl of wash buffer to the column and spun down as
described previously. The column was placed in a 1.5 ml microcentrifuge tube and the
bisulfite converted DNA was eluted off the column using 10 µl of M-elution buffer. The
tubes were centrifuged at 10,000 x g for 30 seconds to collect the converted DNA.
Bisulfite-Specific primer design
Bisulfite converted genomic DNA will be rich in adenine (A) and thymidine (T)
bases, since all cytidine (C) residues will be converted to thymidines except for the few
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that are in the context of a CpG dinucleotide and methylated. To design primers for PCR
of bisulfite-treated DNA, I first converted the sequence of the genomic DNA of the P1
promoter in silico to reflect the bisulfite treated form. This made primer design and the
subsequent sequence analysis very straightforward. The genomic sequence of the mouse
fpgs gene was placed in a word document. The EDIT/REPLACE function was used to
replace CG with XY. Then the EDIT/REPLACE function was used to replace C with T
followed by replacement of the XY with CG.

This generated a sequence where all

cytidines were replaced by thymidines except for those in the context of a CpG
dinucleotide. Primers were designed to amplify four 150 bp to 400 bp sized fragments
from the -500 nt to +500 nt positions within the P1 promoter region relative to the
transcriptional start site. The primers were 20 to 30 bases in length with Tm between 510C
and 540C (the low Tm is a result of the AT-richness of the sequence) and did not include
any CG residues (**this is an important point: if one includes CG residues in the primer
design it is possible to preferentially amplify the methylated form of the desired product
and overestimate the methylation status of a particular residue). We generated primers with
at least 5-8 G residues to increase the Tm and the complexity of the primers in an effort to
minimize non-specific binding. We positioned primers to generate small amplicons (< 400
bp) in order to increase the probability of generating an abundant PCR product, since
fragmentation of genomic DNA does occur during bisulfite conversion. The fragments
amplified were between -502 nt and -230 nt, -132 nt and +200, +264 nt and +560 nt, +609
nt and 1000 nt positions relative to the P1 promoter transcriptional start site. Primers were
ordered and resuspended as described in chapter 2.
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One microliters of bisulfite treated DNA were added to a 25 µl PCR reaction using
the HotStarTaq (Qiagen) prepared as discussed in chapter 2. The AT-richness of the
genomic DNA can decrease the specificity of PCR reactions. We used a touchdown PCR
strategy to increase the specificity of the PCR amplifcation of the bisulfite converted DNA.
Touchdown PCR enhances the specificity of the initial primer–template duplex formation
by using initial annealing temperatures that are 5–10°C above the Tm of the primers. In the
following cycles, the annealing temperature was decreased by 0.50C/cycle until the Tm of
the primer is reached. This is followed by additional rounds of PCR using the annealing
temperature of the Tm of the primer. The touchdown program used for all four primer
pairs specific to bisulfite converted genomic DNA of the P1 promoter region was: 950C 15
min, 950C 30 sec, 620C->520C for 30 sec with a decrease of Tm 0.50C per cycle (20
cycles), 720C 30 sec, followed by 950C 30 sec, 520C 30 sec, 720C 30 sec, for 36 additional
cycles, with a final extension step at 720C for 5 minutes. Ten microliters of reaction were
visualized using 1% agarose gel stained with ethidium bromide. The touchdown PCR
protocol generated single products at the correct size, which could easily be excised from
the gel and purified.
Gel purification
The products of the bisulfite-specific PCR reaction were cut out of the agarose gel
using a clean razor blade while visualizing the bands using a long-wavelength UV lamp.
The gel slice was transferred to a pre-weighed 1.5 mL microcentrifuge tube and weighed
again. The weight of the gel slice was obtained by subtracting the weight of the empty
tube from the weight of the tube with the gel slice. The DNA was purified from the gel
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slice using the Promega Wizard SV Gel and PCR Clean-up system (Promega). Membrane
binding solution was added to the tube with the agarose gel slice (10µl/10 mg of gel slice).
The samples were vortexed and incubated at 550C for 10 minutes, with frequent mixing, so
that the gel slice was completely dissolved. The mixture was transferred to an assembled
SV minicolumn and incubated for 1 minute at room temperature, to allow binding of the
DNA to the column. This was followed by centrifugation of the column at 16,000 x g for
1 minute. The flow-through was discarded. Membrane wash solution (700 µl) was added
to the column and spun down as above, followed by a second round of washing using 500
µl of wash solution. The flow-through was discarded and remaining ethanol was removed
by a final spin at 16,000 x g for 1 minute. The column was placed in a fresh 1.5 mL
microcentrifuge tube and 50 µl of Nuclease-free water was added to the center of the
column and incubated for 1 min at room temperature.

The DNA was collected by

centrifugation for 1 minute at 16,000 x g in the microcentrifuge tube.
TOPO TA Cloning
The purified PCR products were cloned using the TOPO TA cloning system from
Invitrogen. This system takes advantage of the fact that Taq polymerase adds a single
deoxyadenosine to the 3’ ends of PCR products. The vector has an overhanging 3’
deoxythymidine residue, which allows efficient ligation of the PCR product into the
vector. The plasmid vector pCRIV-TOPO was used for sequencing. Four microliters of
PCR product were added to 1 µl of salt solution and Topo vector. The reaction was mixed
gently and incubated for 5 minutes at RT and were then placed on ice. A reaction was also
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prepared that only included vector, which served to control for random integration or religation events that would result in false-positive colony formation after transformation.
Transformation of chemically competent TOP10 cells (Invitrogen)
The TOPO cloning reactions prepared in the last section were transformed into
E.coli; uptake of the plasmid was detected through selection for antibiotic resistance.
Blue-white screening was used to select colonies with plasmids that were successfully
ligated. For each transformation one vial of TOP10 chemically competent cells (provided
at a transformation efficiency of 1 x 109 cfu/ug of supercoiled DNA) and two Luna-Bertani
(LB) agar plates formulated with 50 µg/ml of carbenicillin (Sigma) were used. SOC
medium (Invitrogen) was thawed and warmed to RT. The LB plates were warmed at 370C
for 30 minutes followed by the addition of 40 µl of X-gal (40 mg/ml) on each LB plate and
re-incubation at 370C.

The vials of one-shot TOP10 cells were thawed on ice. Two

microliters of TOPO-cloning reaction for each PCR product was added to the vial,
followed by gentle mixing. The TOP10 cells were incubated for 30 minutes on ice. The
E.coli were heat shocked at 420C for 30 seconds to allow uptake of the recombinant
plasmid. The tubes were transferred to ice and 250 µl of S.O.C. medium was added. The
samples were shaken at 370C for 1 hour at 200 RPM to allow expression of the plasmid
and 50 µl and 100 µl of each reaction (including the vector only control) were plated on
LB-agar plates with carbenicillin and X-gal. The plates were incubated overnight at 370C.
The transformation efficiency was controlled by for addition of 10 pg of puc19 plasmid to
a vial of TOP10 cells and plating 10 µl of this mixture on an LB-agar plate.
Picking colonies
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Blue-white screening increases the probability of selecting a colony that has
plasmid with the desired insert: transformants with recombinant plasmid will have a
disrupted lacZ-α gene and will not be able to metabolize X-gal, appearing as colorless
colonies on the plate, whereas those that have been transformed with plasmid not
containing an insert will metabolize X-gal and produce blue colonies. Ten white colonies
were picked for each transformation reaction and placed in 4 mls of LB with 4 µl of
carbenicillin (50 mg/ml stock). The bacteria were grown with shaking at 250 RPM at 370C
overnight. Recombinant plasmid was isolated using the Wizard Plus SV Mini-Prep Kit
according to the manufacturer’s instructions (Promega, cat no A1460). Isolated plasmid
from each clone was digested with EcoRI and the sizes of the digested products were
visualized on a 1% agarose gel stained with ethidium bromide. Verified plasmid (100
ng/ul) was sequenced through the Nucleic Acids Research Facility (VCU) using the ABI
3700 Prism 96 Capillary sequencer. The sequence data was best when either vector
specific M13 reverse primer or gene specific anti-sense primers were used.

Western blot analysis
Cellular lysate preparation
At the time of harvest, cells were washed with ice-cold PBS +1mM PMSF and
removed from the plates using a cell scraper. Scraping was performed on ice. Cells were
placed in a 15 ml conical and pelleted at 300 x g for 5 minutes at 4oC, and washed again
with 10 mls of ice-cold PBS + 1mM PMSF. Cells were again pelleted by centrifugation
and resuspended in 1ml of ice-cold PBS + 1mM PMSF. The cells were transferred to a
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pre-weighed 1.5 ml centrifuge tube and spun down at 12,000 x g for 5 minutes at 40C. The
supernatant was aspirated and the cell pellets were weighed and lysed in 10x volumes of
lysis buffer (62.5 mM Tris pH 6.8, 5% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 1x
protease inhibitor complete cocktail (Roche)). The samples were passed through a 21gauge needle several times, and debris was pelleted by centrifugation at 10,000 x g for 5
minutes at 4oC. This step was performed twice. We found that aspirating two times
increased the amount of protein obtained from the lysates. The supernatant was aliquoted
and stored at -800C. Protein concentrations were determined by the Biorad-Bradford
protein assay according to the manufacturer’s instructions against a standard curve
generated by measuring the absorbance of known concentrations of bovine serum albumin
at 595 nm.
SDS page and immunoblotting
Twenty micrograms of total cellular protein were diluted in 2x volume of Laemmli
sample buffer (Biorad 161-0737). Lysates were boiled for 5 minutes followed by brief
centrifugation to collect the samples. The pre-made SDS polyacrylamide gels (Biorad)
were assembled in a electrophoretic gel box unit (100 cm x 6.5 cm), and running buffer (25
mM Tris base, 250 mM glycine, 0.1% SDS) was poured into the apparatus. The combs
were removed and the wells were flushed with buffer to remove any debris. The samples
and a pre-stained protein standard ladder (Biorad) were added to the wells. The total
cellular proteins were resolved by electrophoresis on a 4-15% SDS polyacrylamide gel
(Biorad) in running buffer. Gels were run for approximately 1 hr at 100 volts.
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Proteins were transferred to an Immobilon polyvinylidene fluoride (PVDF)
membrane (Millipore) in 1x Towbin buffer (25 mM Tris, pH 8.3, 192 mM glycine, 10%
methanol, 0.04% SDS) using a semi-dry apparatus. Nine pieces of Whatman paper were
soaked in Towbin buffer and placed into the bottom of the transfer unit. The PVDF
membrane was soaked in 100% methanol and placed on top of the Whatman paper. The
gel was placed on top of the PVDF membrane and covered with six additional pieces of
Whatman paper. The transfer was run at 40 mAmps per gel for approximately 3 hours.
Following transfer, the membranes were dipped in methanol and allowed to dry at room
temperature for 15 minutes.

Non-specific protein binding was blocked using

StartingBlock Blocking Buffer (cat no. 37542, Pierce) for 1 hour at RT. Blots were
washed with 0.05% TBS-T (0.5M Tris pH 7.5, 0.14M NaCl, 2.7 mM KCl, 0.05% Tween
20) three times for 5 minutes at RT. Primary antibodies were diluted in Startblocking
buffer and incubated at 40C overnight. The primary antibodies used were DNMT3a (cat
no. IMG-266A, Imgenex) at 1:250, DNMT3b (cat no. IMG-184A, Imgenex) at 1:250, and
DNMT1 (ab19905, Abcam) 1:1000. Following incubation, the blots were washed three
times in TBS-T for 5 minutes and membranes were incubated with goat-anti mouse
(DNMT3 blots) or goat-anti-rabbit (DNMT1 blots) secondary antibody with horseradish
peroxidase conjugate (1:10,000) for 1hr at room temperature (Pierce) in StartingBlock
Buffer.

The blots were again washed as described above. Chemiluminescence was

detected using the SuperSignal West Pico and West Dura Chemiluminescent Substrate Kits
(Pierce).
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RESULTS
The studies presented in chapter 2 left us with a series of questions that could not
be pursued through observations of the wild-type mouse. We have designed a series of
experiments using two model systems with primary disturbances in P1 activity and DNA
methylation to address these remaining questions.

Transcriptional interference studies:
The studies presented in this chapter addressing the contribution of transcriptional
interference to the regulation of the P2 promoter of the fpgs gene in mouse liver have been
pursued in collaboration with Lin-Ying Xie, a former student in the laboratory. She has
generated the critical tool for these experiments: the P1 knock-out mouse (263).

Histone H3 acetylation is less abundant across the fpgs gene in knock-out liver.
We questioned if P1 activity was causative of histone H3 acetylation across P1 and
P2 mouse liver by comparing the levels of histone H3 acetylation found in wild-type tissue
with those detected in the P1 promoter knock-out mouse liver. ChIP analysis using an
antibody raised against H3K9Ac was performed as and fragments of the fpgs gene were
amplified using Q-PCR described in chapter 2. The amplicons were spaced 1.5-2.0 kb
apart and the genomic region probed in these experiments spanned from -2 kb upstream to
+ 15 kb downstream of the P1 promoter transcriptional start site. Amplification of P1 in
wild-type animals was not included in these studies, since these sequences were not
present in the knock-out animals. The degree of H3K9 acetylation throughout the fpgs
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gene was markedly lower in liver from the P1 knock-out mouse than in wild-type mouse
liver (Figure 3-1).

This observation is in agreement with the concept that histone H3

acetylation is commonly localized at nucleosomes surrounding active or poised genes (87).
Surprisingly, the relative patterns of H3K9Ac between the two samples were almost superimposable, and the profile determined in knock-out mouse liver was significantly different
than the patterns previously described in L1210 cells or mouse brain (Fig 2-12). It should
be noted that in knock-out liver, there was a measurable increase in H3K9Ac starting 2 kb
upstream of the P2 transcriptional start site and peaking at promoter, whereas in wild-type
liver H3K9Ac between these two amplicons remained constant (Figure 3-1). We took this
change to reflect the increase in transcriptional activity observed at the P2 promoter in the
liver of P1 knock-out animals. These data suggested that P1 transcriptional activation
caused the high levels of histone H3 acetylation across the fpgs gene in mouse liver, but it
appeared that additional tissue-specific mechanisms were involved in dictating the pattern
of histone acetylation found in mouse liver.

Histone H3 lysine 4 tri-methylation across the fpgs gene in knock-out and wild-type
mouse liver.
An enrichment of histone H3 lysine 4 tri-methylation has been associated with
nucleosomes surrounding promoter regions bound by RNAPII complexes engaged in
active transcription or in a poised state in both mammals and yeast (13, 186). We probed
the fpgs gene in wild-type and knock-out mouse liver for this histone PTM and found
patterns not entirely predicted by previous studies. H3K4me3 was found to be higher over
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the P2 promoter region in knock-out mouse liver than in wild-type tissue (Figure 3-2); this
supports the observation that P2 expression increases in the P1 knock-out mouse liver.
Abundant levels of H3K4me3 between -2 kb and + 2 kb relative to the P1 transcriptional
start site were detected in wild-type mouse liver, but were completely lost with the removal
of P1 activity in knock-out mouse liver samples (Figure 3-2), suggesting that H3K4me3 of
the nucleosomes surrounding this region was directly linked to the level of P1
transcriptional activity. The substantial level of H3K4me3 detected at + 3.5 kb relative to
the P1 transcriptional start site in knock-out mouse liver was very surprising and implied
that RNAPII complexes were binding to this region of the fpgs gene (Figure 3-2). We
considered the possibility that loss of P1 activity permitted transcriptional initiation at a
cryptic promoter in this tissue not previously identified through 5’ RACE and RPAs (202,
244).

P2 expression and levels of the general transcription factor Sp1 and of HNF4, a
tissue-specific factor, at the fpgs gene in wild-type and knock-out mouse liver.
In the previous chapter, we proposed that the activity of the P2 promoter in mouse
liver was restricted by transcriptional interference through a mechanism of promoter
occlusion. Using Q-Rt-PCR, Lin Xie determined that P2 expression in knock-out mouse
liver increased between 4 and 6-fold when compared to the level of P2 expression in wildtype mouse liver (263). These data represent the influence of transcriptional interference
on P2 expression in mouse liver. Interestingly, the level of P2 expression detected is at
least two orders of magnitude lower than the amount of P2-specific transcript generated in
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actively dividing cells, i.e. L1210 cells. In order to confirm that promoter occlusion was
occurring at P2 in mouse liver, we probed for Sp1 at positions -200 and + 200 relative to
the P2 transcriptional start site in wild type and knock-out mouse liver. Sp1 residence at
P2 was negligible when compared to the non-specific IgG control in wild-type liver
(Figure 3-3 A). In contrast, amplification of these fragments of P2 was enriched in knockout liver (Figure 3-3 A). These data, coupled with Lin Xie’s analysis of expression
directly supported the idea that P1 activity repressed the P2 promoter by preventing the
assembly of a PIC, through a mechanism of promoter occlusion.
In silico analysis of the mouse fpgs gene revealed consensus DNA binding
sequences for hepatic nuclear factor 4 (HNF4) within the regions of the P1 and P2
promoters. HNF4 is a tissue-specific factor involved in directing the cell-type specific
expression patterns detected in differentiated hepatocytes. HNF4 occupancy has been
shown to recruit HATs, chromatin remodeling complexes, and general transcription factor
components of the PIC (215). The role of HNF4 in the regulation of the mouse fpgs gene
has not previously been studied. As discussed in the preceding chapter, the P2 promoter in
wild-type mouse liver is not completely silenced, but the level of expression is extremely
low when compared to L1210 cells (< 0.75%). As a starting point to understanding if
HNF4 was involved in regulating P2, we assessed the residence of this factor at P2 (Figure
3-3 B).

We detected HNF4 at positions -200 nt and +200 nt relative to the P2

transcriptional start site at similar levels in both wild-type and knock-out mouse liver, both
substantially above the non-specific IgG control (Figure 3-3 B). Additionally, since the
levels of HNF4 between the wild type and knock-out samples were comparable it appeared
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that the residence of HNF4 at the P2 promoter was not affected by the transcriptional
activity of the P1 promoter. This was quite a surprise, since Sp1 occupancy at the P2
promoter was found to inversely correlate with P1 activity in mouse liver (Figure 3-3 A).
How molecules of HNF4, but not Sp1, were able to bind to the P2 promoter in wild-type
mouse liver is a very interesting question that remains to be understood.

Occupancy of RNAPII across the P2 promoter in wild-type and knock-out mouse
liver.
In our previous work, we mapped the residency of RNAPII across the P2 promoter
region in mouse liver, L1210 cells, and mouse brain using high-resolution ChIP walking.
The profiles determined for the three tissues were remarkably different (Figures 2-22 thru
24). We were interested in determining if the increase of P2 transcriptional activity
observed in knock-out mouse liver would alter the pattern of RNAPII binding across the
P2 promoter. We used ChIP walking to assess the residence of RNAPII across this region
in knock-out mouse liver (Figure 3-4). P2 was divided into six overlapping fragments as
described in Figure 2-18. ChIP analysis was performed on liver from wild-type and
knock-out animals using antibodies generated against total, phospho-serine 5, and
phospho-serine 2 RNAPII. As discussed in chapter 2, antibodies generated against the
CTD of RNAPII phosphorylated at either serine 5 or serine 2 are often used as markers of
early and late stages of elongation, respectively (81, 133). Total RNAPII was again
detected across the P2 promoter region at similar levels in wild-type mouse liver (Figure 34 A) as in previous experiments (Figure 2-23). The occupancy of RNAPII complexes
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phosphorylated at serines 5 and 2 reflected the levels of total RNAPII detected across P2 in
wild type tissue (Figure 3-4 A). ChIP using knock-out liver showed total levels of RNAPII
gradually increasing across P2 and peaking between the +1 and +200 positions relative to
the P2 transcriptional start site (Figure 3-4 B).

The level of RNAPII complexes

phosphorylated at Serine 5 also reached a maximum between the +1 and +200 positions,
reflecting an increase in total RNAPII levels (Figure 3-4 B). In contrast, the amount of
RNAPII phosphorylated at Serine 2 did not increase with total RNAPII and remained fairly
constant throughout the entire P2 promoter region in knock-out mouse liver (Figure 3-4 B).
Since loss of P1 caused an increase in P2 transcriptional activity, we took the profiles of
RNAPII detected in knock-out liver to represent complexes engaged in initiation and the
early stages of elongation. The patterns of RNAPII complexes detected in knock-out
mouse liver were different than those determined across the active P2 in L1210 cells
(Figures 3-4 B and 2-22). In fact, the profile was more closely related to those previously
described in mouse brain (Figures 3-4 B and 2-22), a tissue where RNAPII complexes are
poised for activation.

The studies using tissues from the knock-out animals are

preliminary, but it is interesting to consider that the level of transcriptional activity
generated at P2 may determine the distribution of RNAPII across the region. Also, since
the levels of P2 expression in knock-out mouse liver were orders of magnitude lower than
those detected in L1210 cells, it may be the case that a proportion of the RNAPII
complexes detected across P2 in this tissue were actually poised but inactive as in mouse
brain.
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Overall, our studies confirm that transcriptional interference plays a role in
silencing P2 in mouse liver, but other mechanisms are most likely involved in enhancing
P2 activity to the levels observed in L1210 cells. Sp1 binding to the P2 promoter increased
substantially in mouse liver when P1 activity was eliminated. This is one of the first pieces
of data directly supporting a regulatory mechanism of promoter occlusion at a mammalian
gene in vivo.

DNA methylation studies
We previously identified the P1 promoter of the mouse fpgs gene as a tissuespecific differentially methylated region: the CpGs within this promoter were methylated
in tissues where P1 is silent, i.e. L1210 cells, and hypomethylated in tissues where P1 is
active, i.e. mouse liver (Figure 2-9). We took this to suggest a role for DNA methylation
in the regulation of the tissue-specific expression patterns generated from the P1 promoter.
In order to test this hypothesis we designed a series of experiments using a model system
generated by Cedar et. al (137), a mouse embryonic fibroblast (MEF) cell line reported to
have low levels of global DNA methylation due to the homozygous disruption of the
DNMT1 endogenous loci (PM cells). These cells are p53-deficient, which enables these
cells to maintain viability after several passages in culture.
experiments was a MEF cell line that is p53-deficient (P cells).
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The control for these

Expression of control genes and activity of the P2 mouse fpgs gene promoter in P and
PM cells.
In the study published by Cedar et. al using the PM cell line, two groups of genes
were defined that appeared to be regulated by DNA methylation. Group A included genes
that were transcriptionally silent in P cells but active in PM cells, where global DNA
methylation is greatly suppressed.

In contrast, the genes within group B were only

expressed in PM cells that were treated with a histone deacetylase inhibitor, trichostatin A
(TSA) (137). The investigators concluded that genes in Group A were primarily regulated
by DNA methylation, but additional mechanisms were involved in controlling the
expression of genes within group B, since demethylation was not sufficient to activate
transcription from the genes in this population (137). Dr. Cedar kindly sent us a flask of P
and PM cells and we initiated our studies by measuring the expression of a gene within
either group A (Slpi) or group B (Cryaa) to repeat the work Cedar published in the original
paper. RNA was isolated from P and PM cells and was converted to cDNA and the
expression of Cryaa and Slpi was assessed using Q-PCR. The ΔCt method was used to
analyze Cryaa and Slpi expression relative to the expression of our chosen reference gene,
glyceraldehydes-3-phosphate dehydrogenase (GAPDH). The results from this initial study
were quite surprising (Figure 3-5). Slpi expression increased in PM cells, when compared
to P cells by approximately 9-fold (Figure 3-5), as predicted by the fact that this gene was
placed within group A. However, the increment of expression observed was much less
than the 50-fold change reported previously for Slpi by Cedar’s group. The cryaa gene
was originally classified as a group B gene by Cedar et. al and thus we expected that little
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to no change in expression levels would be detected between P and PM cells. In striking
contrast, cryaa expression dramatically increased over 2000-fold in our experiments
(Figure 3-5). These observations have been repeated, the primers have been checked, and
the PCR products visualized on an agarose gel stained with ethidium bromide to verify that
the product generated was the size predicted by the genomic sequence. Additionally,
parallel experiments performed by Erica Peterson in Dr. Taylor’s laboratory confirmed that
the PM cells obtained from Cedar had markedly lower levels of DNMT1 than the P cells,
confirming that we were working with the correct cell lines (data not shown).

We

concluded that the cryaa gene in our hands was clearly not a gene that should be classified
within group B, but rather represented a gene within group A.
In dividing mouse cells, fpgs mRNA is generated from the sole use of the P2
promoter (244). We measured the level of fpgs cDNA complimentary to mRNA
originating from transcriptional initiation at the P2 promoter in both P and PM cells. We
applied real-time PCR and used the ΔCt method to analyze P2 expression relative to
GAPDH (Figure 3-5). The level of P2 expression in the P and PM cell lines was found to
be identical, suggesting that any transcriptional activity at P1 in PM cells was not
interfering with initiation at P2.

Changes in P1 expression observed in the hypomethylated PM cell line.
To test our hypothesis that DNA methylation was involved in regulating the
expression of the P1 promoter, we questioned if the global loss of DNA methylation
observed in PM cells by Cedar et. al altered the expression of the P1 promoter. In the
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experiments presented in Figure 3-6, cDNA encoding P1-specific fpgs mRNA was
amplified using semi-quantitative PCR and real-time PCR analysis. Semi-quantitative PCR
showed that P1-specific cDNA levels appeared at earlier cycles in PM cells than in P cells,
suggesting that the amount of P1-specific cDNA in PM cells was slightly higher than in P
cells (Figure 3-6 A). The amount of GAPDH cDNA determined by semi-quantitative PCR
was very similar between P and PM cells, as judged by visualization of the products on an
agarose gel stained with ethidium bromide (Figure 3-6 A).

Real-time PCR analysis

showed that in PM cells the P1-specific cDNA levels ranged from 2.5-5.0-fold higher than
those detected in P cells (Figure 3-6 B). We used the two PCR approaches because we
found that in P cells multiple products were generated at later PCR cycles. These products
were clearly different sizes than the expected fragments, and sequencing of the products
determined that they included varying segments of the intron between A1b and exon 1, and
some of the products also included part of exon 1. All of the alternate species generated in
P cells that were sequenced contained premature stop codons and were not predicted to
generate full-length FPGS protein.
The alternate products posed a problem for analysis by real-time PCR, and
therefore we designed primers within exon A1b to estimate of the difference between the
levels of P1-specific fpgs cDNA in P and PM cells. This approach was flawed for a couple
of reasons: 1) It is always a risk to amplify cDNA using primers within the same exon,
since even small levels of contaminating genomic DNA can substantially influence the
data.

And 2) The multiple pseudo-products generated from P1 in P cells were still

measured using this approach, and thus the levels calculated in P cells were most likely an
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over estimate of the levels of correct fpgs cDNA transcript generated from P1 in P cells.
However, we have verified the real-time data using semi-quantitative PCR and in later
studies incorporating the use of an anti-sense primer complimentary to exon 6, which
generated single products when the annealing temperature was set to 63oC or above. As
such, the combined data confirmed that, in PM cells, P1 expression increased on average
between 2.5-5.0 fold compared to the levels determined in P cells.

Bisulfite sequencing of the P1 promoter region revealed a surprising pattern of DNA
methylation in PM cells.
We performed bisulfite sequencing analysis of the 19 CpG dinucleotides within 1.5
kb of the P1 promoter spanning the region -500 nt to +1000 nt relative to the P1
transcriptional start site in P and PM cells. We sampled this region by designing primer
pairs to amplify four 300-350 bp fragments. The CpGs within the P1 promoter in P cells
were almost completely methylated, in agreement with the DNA methylation profile across
P1 previously described for other murine dividing cells, i.e. L1210 cells (Figure 3-7, closed
circles). However, the pattern of DNA methylation detected in PM cells across this region
was very surprising: P1 remained abundantly methylated (Figure 3-7), in spite of the fact
that genomic DNA from PM cells were found previously to be largely unmethylated (137).
Remarkably, significant differences in the level of methylation at individual CpG residues
throughout the region were apparent, and it appeared that loss of DNA methylation was
reserved for the CpGs at positions -500, -250, and +50 nt relative to the P1 transcriptional
start site. The methylation of the CpG at +50 nt approached zero, and its proximity to the
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transcriptional start site was extremely interesting. Additionally, the methylation of the
CpGs between +750 and +1000 nt was also decreased in PM cells compared to P cells by
approximately 40%.

However, the methylation levels across this 250 bp fragment

remained substantially higher than the level of DNA methylation determined at these CpGs
in mouse liver, which were found methylated in only 25% of the sequenced clones. How
the DNA methylation is maintained across this region in PM cells remains an open
question. It should be noted that work in Dr. Taylor’s laboratory has shown that there are
residual levels of DNMT1 in PM cells, supporting the idea that the PM cell line should be
considered a DNMT1 hypomorph, rather than a complete knock-out cell line. These data
suggested that the loss of CpG methylation at a few residues within the 1.5 kb region was
sufficient to cause the increase observed in the transcriptional activity of P1 in PM cells.

Histone H3 acetylation and lysine 4 tri-methylation across the mouse fpgs promoters
in P and PM cells.
The interplay between DNA methylation and several histone PTMs has been well
described, but in many cases the causative epigenetic modification remains unknown (74).
In chapter 2, we determined that loss of DNA methylation at P1 in mouse liver was
coincident with an increase in P1 transcriptional activity and H3Ac and H3K4me3 of
regional nucleosomes. In these studies, we used the P and PM cells to question if loss of
DNA methylation was sufficient to cause an increase in H3Ac and/or H3K4me3. ChIP
experiments were performed using P and PM cells with antibodies generated against
H3K9Ac and H3K4me3. Real-time PCR was used to amplify regions of genomic DNA
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within the P1 and P2 promoters and enrichment at the P2 promoter was used as a positive
control. As expected, the histones surrounding the P2 promoter in both cell lines were
decorated with abundant levels of H3Ac and H3K4me3 (Figure 3-8), reflecting the
transcriptional activity of this promoter in these dividing cells. Histone H3 acetylation was
also detected across the P1 promoter in both P and PM cells when compared to the nonspecific IgG control (Figure 3-8). We were very surprised by the high levels of histone H3
acetylation detected over P1 in P cells. Histone acetylation at this promoter in L1210 cells
was previously detected, but the levels found in P cells are more abundant. We are not yet
clear on the cause of this increase in acetylation at P1 in P cells, but it may very well be a
consequence of the p53-null status of the P cells. Interestingly, the amount of H3Ac found
over P1 in PM cells was 1.5x higher than that observed in P cells, a factor that was
calculated by normalizing the levels of H3Ac measured over P1 to those observed over the
P2 promoter in the respective cell lines. We took this to suggest that the changes of DNA
methylation patterns at the P1 promoter observed in PM cells were impacting the level of
H3Ac across the promoter.
The presence of H3K4me3 across a promoter region in both yeast and mammals
has been tightly linked to the presence of RNAPII complexes (13, 87, 186).

The

transcriptional activity of P1 was found to increase slightly in PM cells (Figure 3-6),
however H3K4me3 was not detected across P1 in the hypomethylated PM cells (Figure 38). From these data, it appeared that the altered patterns of DNA methylation observed at
positions -250 nt and +50 nt (Figure 3-5), and/or the slight increase in P1 activity detected
in PM cells (Figure 3-6) were not sufficient to enhance H3K4me3 across this promoter; it
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appeared that H3K4me3 at the P1 promoter was more tightly correlated with
transcriptional activity, rather than DNA methylation patterns.

Inhibition of histone deacetylase activity enhances P1 activity in P and PM cells, but
more substantially in PM cells.
Methyl-binding proteins are recruited to methylated CpG dinucleotides and often
serve as a scaffold for large repressor complexes that include chromatin remodeling and
HDAC enzymes (123, 170). As a result, histone deacetylation and DNA methylation have
been shown to cooperate in mediating transcriptional silencing at several CpG-dense
promoters. It was not clear if the link between DNA methylation and HDAcs would
translate to the CpG-sparse P1 promoter. As Cedar’s group described, a large proportion
of mammalian genes require both loss of methylation and inhibition of histone
deacetylation to achieve transcriptional activation. We questioned if HDAC inhibition
would enhance the P1 transcriptional activity in P and PM cells. Cells were treated with
0.06 µM TSA for 12, 24, 48, and 72 hours and P1-specific fpgs cDNA was measured using
semi-quantitative and real-time PCR as described for Figure 3-6. Slpi expression was
measured as a control. The growth of the two cell lines was significantly impacted by
treatment with TSA for 48 and 72 hours, and to minimize the influence of secondary drug
effects these cells were not processed. Treatment with TSA for 24 hours increased the
expression of Slpi 7-fold and 22-fold in P and PM cells, respectively (data not shown).
However, this treatment did not reproducibly alter the level of P1 transcriptional activity in
either P or PM cells (data not shown). Slpi expression was also increased when cells were
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treated for 12 hours with TSA but to a lesser extent than observed after 24 hours of
treatment: expression increased 4-fold in P cells and 6-fold in PM cells (Figure 3-9). On
the other hand, the level of P1 activity appeared to increase in both P and PM cells when
cells were treated with TSA for 12 hours (Figure 3-9). P1-specific fpgs cDNA levels
increased in P cells approximately 4-fold and increased in PM cells approximately 8-fold
above the levels of P1 expression detected in the respective cell lines without TSA
treatment (Figure 3-9). As such, HDAC inhibition coupled with the changes in DNA
methylation appeared to further enhance P1 activity in PM cells. It is interesting to note
that the level P1 expression detected in P cells treated with TSA approached the amount of
P1-specific fpgs cDNA found in PM cells relative to GAPDH expression (Figure 3-9).
Since DNA methylation was not substantially lost across P1 (Figure 3-7), we considered
the possibility that the effect of TSA treatment on the expression of P1 in PM cells would
be enhanced if the methyl groups of the CpGs across P1 were further depleted.

5-aza-deoxycytidine treatment of P and PM cells for 24 and 48 hours.
We could not fully understand the role of DNA methylation in the control of the
tissue-specific expression pattern of the P1 promoter without further depleting the CpG
dinucleotides in this region of methyl groups. We questioned if further inhibition of DNA
methyltransferase activity would result in loss of DNA methylation and enhanced
transcriptional activity at the P1 promoter in PM cells. To test this we treated P and PM
cells

with

1µM

of

5-aza-deoxycytidine

(5daza),

an

inhibitor

of

the

DNA

methyltransferases, for 24, 48, and 72 hours. The growth and viability of the P cells were
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substantially impacted by treatment with 5daza for 48 and 72 hours, however PM cells
appeared to grow normally and were unaffected by the presence of 5daza in the medium.
The resistance of DNMT1 hypomorphs to 5daza treatment has been previously described
in HCT116 cells (60). This observation is not surprising since the major target of this
drug, DNMT1, is already substantially reduced in PM cells. In these studies, we isolated
RNA and DNA from the treated P and PM cells for expression analysis and bisulfite
sequencing.
Following 24 and 48-hour treatment with 5daza the expression of P1-specific fpgs
transcript was measured in P and PM cells (Figures 3-10 and 3-11).

P1 activity did not

increase in PM cells treated for 24 hrs (Figure 3-10), however following 48 hours of
treatment the level of P1 activity measured by fpgs cDNA increased approximately 5-fold
compared to the amount of P1-specific fpgs cDNA detected in untreated PM cells (Figure
3-10). The doubling time of the PM cells is approximately 18 hours, and the effect of
DNA methyltransferase inhibition on the transcriptional activity of the P1 promoter
appeared to require two-rounds of DNA replication. It is possible that a substantial loss of
DNA methylation across P1 in PM cells does not occur until 48 hours after treatment.
Bisulfite sequencing analysis was performed using genomic DNA isolated from
PM cells after 24 hours of treatment with 5daza. We have also planned to perform this
analysis using DNA harvested from PM cells treated for 48 hours with 5daza. The level of
DNA methylation was in PM cells 24 hrs after treatment with 5daza (Figure 3-12 A, open
circles). However, the change in DNA methylation was reserved to a cluster of CpGs
between +100 nt and +750 nt positions relative to the P1 transcriptional start site, when
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compared to the level of DNA methylation found in untreated PM cells (Figure 3-12 A,
closed circles). The CpGs upstream of position -250 nt and downstream of +750 nt were
methylated in a remarkably similar manner to the same residues in untreated PM cells
(Figure 3-12 A).

The distinctly localized change in DNA methylation observed in PM

cells treated with 5daza reflected the punctate pattern of hypomethylation found at
individual CpGs in the untreated PM cells (Figure 3-12 A, closed circles).

These data

identify four categories of CpGs within the P1 promoter, based on their sensitivity to loss
of DNA methyltransferase activity: 1) CpGs located between -500 and -250 on average
maintained methylation in PM and PM+5daza conditions, 2) CpGs within the region
between -250 and +50 nt were the most sensitive to loss of DNMT1, 3) the fragment
between +70 and + 700 included CpGs that were sensitive to 5daza treatment, and 4) CpGs
between 750 and 1000 nt were moderately sensitive to the reduction of DNMT1 in PM
cells, but were not affected by further DNA methyltransferase inhibition with 5daza
treatment after 24 hrs. The factors determining the difference in sensitivity of individual
clusters of CpGs within this promoter region remain unclear. However, since the level of
P1 activity did not increase in PM cells after 24 hours of treatment with 5daza it appeared
that the methylation status of the CpG residues between +70 and +750 nts was not
involved in determining the transcriptional activity of this promoter. These data stress the
importance of the CpG residues at the -250 nt and +50 nt positions in the transcriptional
regulation of P1.
The effects of 5-daza treatment on P1 transcriptional activity and CpG methylation
was also assessed in P cells (Figure 3-12 and 3-11). These data were very surprising. The
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level of P1-specific fpgs cDNA increased approximately 20-fold and more than 100-fold
following 24 and 48 hours of treatment, respectively (Figure 3-11). Relative to the P1
activity measured in PM cells under the same conditions, the level found in P cells was 3fold and 10-fold greater than the amount of P1-specific fpgs cDNA detected in PM cells
following 24 and 48 hours of treatment with 5daza, respectively (Figures 3-10 and 3-11).
Bisulfite sequencing of genomic DNA from P cells treated with 5daza for 24 hours
revealed loss of methlaltion at individual CpGs (figure 3-12, open circles). Remarkably,
the CpG residue at the +50 nt and between +300 nt and +550 nt positions relative to the P1
transcriptional start site appeared the most sensitive to DNA methyltransferase inhibition
(Figure 3-12). In contrast, the genomic regions upstream of -250 nt and downstream of
+750 nt remained almost 100% methylated (Figure 3-12). Because the increment in P1
activity is substantial in P cells after treatment with 5daza for 48 hours we are very
interested in determining if this change in expression correlates with loss of DNA
methylation throughout the P1 promoter under these conditions.

Measurment of DNMT3a and 3b levels in P and PM cells
The level of DNA methylation remaining in PM cells was substantial (Figure 3-7),
and even after treatment with 5daza for 24 hours methylation levels remained (Figure 312). It is very likely that following 48 hours of treatment with 5daza, DNA methylation is
reduced across the P1 promoter in PM cells, since transcription originating at this promoter
increased at this time point (Figure 3-10). However, we were not convinced that the low
levels of DNMT1 present in PM cells would be sufficient to maintain the abundant levels
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of DNA methylation detected at P1 in these cells. We proposed that perhaps either
DNMT3a or DNMT3b were coordinating the methylation of CpG dincucleotides within
the P1 promoter. Cedar’s group drew the conclusion that in these MEFs the levels of
DNMT3a and 3b were likely to be quite low, since these enzymes are expressed in ES cells
and their major function is de novo methylation during embryonic development (177). We
designed primers to measure the expression levels of DNMT3a and DNMT3b in P and PM
cells (Figure 3-13 A). The difference between the cDNA levels encoding DNMT3a and
DNMT3b between P and PM cells was remarkable. DNMT3a expression was up regulated
approximately 9-fold in the hypomethylated PM cell line (Figure 3-13).

Similarly,

DNMT3b levels were 4-fold higher in PM cells than the levels detected in P cells.
Western blot analysis performed in collaboration with Erica Peterson, a member of Dr.
Taylor’s laboratory, confirmed that the amount of DNMT3a and DNMT3b protein levels
in PM cells were substantially greater than the levels found in P cells (Figure 3-13 B).
Interestingly, DNMT1, DNMT3a, and DNMT3b were all sensitive to 24-hour treatment
with 1µM 5-daza, however DNMT3a appeared less sensitive than DNMT1 in PM cells
(Figure 3-13 B and C).

These data suggest that DNMTs 1, 3a, or 3b are potential

candidates for the regulation of DNA methylation across the P1 promoter in PM cells. We
know that the activity of DNMT 3a and 3b in PM cells is not able to compensate for the
loss of DNMT1 globally, since genome-wide DNA methylation analysis has found these
cells to be severely hypomethylated (137). However, it may be the case that DNMT3a or
3b activity sustains methylation of P1 in PM cells. It should also be noted that the level of
DNMT3a in P cells is remarkably high, considering MEFs were not predicted to have any
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detectable levels of de novo methyltransferases. Perhaps DNMT3a is responsible for the
methylation of P1 in both P and PM cells, suggesting a new role for de novo
methyltransferases in the methylation of tissue-specific promoters.
DISCUSSION
The results presented in chapter 2 suggested that epigenetic and transcriptional
interference mechanisms were involved in coordinating the use of the two promoters. We
sought to determine if these epigenetic factors are causative or consequential of the tissuespecific control of the mouse fpgs gene. In order to approach this question, we used a
model system that caused a primary disturbance in DNA methylation at P1, and a P1promoter knock, in which transcriptional interference at P2 was impossible and in which
cross-talk between histone modifications and promoter activity could be tested. The
patterns of DNA methylation at the P1 promoter are more complicated than we previously
thought, but our data suggest that CpG methylation facilitates transcriptional silencing of
the P1 promoter. Likewise, our studies supported transcriptional interference/occlusion at
P2 in mouse liver, but also indicated other mechanisms enforcing tissue-specific restriction
of P2 expression in liver.
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Studies using the P1-knock-out mouse model
Tissue-specific patterns of histone marks are not simply a consequence of
transcriptional activity.
Studies in yeast have best shown the functional consequences of individual histone
PTMs in transcription (38, 128), but classifying histone PTMs as either causative or
consequential of a particular transcriptional state at mammalian genes in vivo have been
difficult. In the studies presented in this chapter, we used the P1 knock-out mouse model
to determine if the distinct patterns of histone PTMs observed between mouse liver, brain,
and L1210 cells were the consequence of P1 transcriptional activity in mouse liver. The
levels of histone H3 acetylation across the fpgs gene in P1 knock-out liver were much
lower than those detected in wild-type mouse liver, but the profiles described between the
two genetically different tissues were remarkably similar (Figure 3-3). Furthermore, the
pattern of histone H3 acetylation at the fpgs locus in knock-out liver was surprisingly
different then those determined in L1210 cells and mouse brain, in spite of the fact that P1
activity was absent in all three of these tissues. Hence, it appeared that additional tissuespecific mechanisms were driving the positioning of histone acetylation across the coding
region of the fpgs gene, and that transcriptional activity at P1 served to enhance the histone
acetylation at those pre-determined positions. Our data suggests that histone marks across a
tissue-specific gene are more than simply a consequence of transcriptional activity and
support a functional role for these epigenetic modifications in the control of tissue-specific
expression.

Support for this concept has recently been furnished in studies mapping

chromatin marks across enhancer and insulator elements at high resolution in several
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human cell lines (102).

These studies showed that insulator elements share similar

epigenetic marks between different cell-types, but the chromatin signatures found across
enhancer elements are often unique to a specific cellular background. Enhancers are cis
acting elements that, when bound by sequence-specific DNA binding proteins can impact
transcriptional activity from long range distances (>10 kb) and when positioned either
upstream or downstream of the targeted promoter (26).

We consider that enhancer

elements present within the fpgs gene may be responsible for dictating the pattern of
acetylated nucleosomes and perhaps tissue-specific expression at the fpgs gene in mouse
liver.
The enrichment of histone H3 lysine 4 tri-methylation at regional nucleosomes has
been clearly linked to the presence of RNAPII at the 5’ end of genes in an active or poised
state (13, 87). The abundant peak of H3K4me3 detected in wild-type mouse liver adjacent
to P1 was absent in P1 knock-out mouse liver, presumably due to the lack of
transcriptional initiation occurring at this region (Figure 3-2). However, we detected a
substantial enrichment of H3K4me3 approximately 4 kb downstream of the +1
transcriptional start site of the P1 promoter in knock-out mouse liver. This peak was not
detected in other tissues where P1 activity was also absent, i.e. L1210 cells and mouse
brain. We took this to suggest that the genomic region 4 kb downstream of P1 in knockout liver is permissive to RNAPII binding, and may represent a cryptic promoter that has
previously not been identified. This occurrence may very well be related to the histone
acetylation present at the fpgs gene in knock-out liver. Histone acetylation enhances the
availability of cis DNA-binding elements to cellular trans factors (249). As such, in the
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absence of P1 activity, the level of histone acetylation across the fpgs gene in mouse liver
may be sufficient to permit binding of RNAPII at the +4 kb position.

Promoter occlusion at the P2 promoter of the mouse fpgs gene
We used the P1 knock-out mouse model to determine if transcriptional interference
was involved in selecting the production of one FPGS isoform over another in mouse liver.
Knock-out of P1 activity did indeed result in an increase in the transcriptional activation of
the P2 promoter, confirming our previous conclusions in studies using wild-type mouse
liver. In our laboratory, Lin-Ying Xie estimated that the increase in P2 activity in knockout liver ranged between 4 to 6-fold when compared with levels of P2 expression found in
wild-type liver (263). Removal of P1 activity was coincident with an increase in the
binding of the transcription factor Sp1 to the P2 promoter in liver, supporting the idea that
transcriptional initiation at the P2 promoter in wild-type tissue was blocked as a
consequence of high levels of transcriptional activity originating at the P1 promoter
(Figure 3-3). Interestingly, the expression of P2 in mouse kidney, a tissue that also uses
P1, increased only approximately 1.5-fold in P1 knock-out tissue. We took this to suggest
that the degree of transcriptional interference at P2 in mouse kidney was less than that
occurring in mouse liver. This finding may be explained by previous data from RPAs,
which showed that the amount of transcript generated from P1 was lower in kidney than in
liver (Figure 2-2); this decrease in P1 activity in kidney was coincident with a higher level
of detectable P2 expression in this tissue compared to liver (244). Taken together, it
appears that the degree of transcriptional interference at P2 reflects the level of P1
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transcriptional activity. It would be very interesting to determine if elongating RNAPII
complexes accumulate over the P2 promoter in mouse kidney as they do in mouse liver.
Overall, our studies using the P1-knock mouse liver concluded that a mechanism of
promoter occlusion was limiting the P2 activity in wild-type mouse liver. This is one of
the first proven cases where promoter occlusion was shown to control promoter usage of a
mammalian gene in vivo.

Multiple control mechanisms of the P2 promoter
The P2 promoter represents a unique case where a CpG-island promoter is not
broadly expressed, as is often the situation, since CpG-island promoters are often found at
the 5’-ends of housekeeping genes. We proposed that P2 in mouse liver was controlled by
transcriptional interference, however relief from transcriptional interference increased
transcription at P2 only 4-6 fold, but was still 30-50 times lower than the level of P2
expression measured in dividing cells. Why is the P2 promoter not fully activated in
knock-out mouse liver? One possibility is that the level of trans factors present in dividing
cells causes robust transcriptional activation of the P2 promoter necessary to accommodate
high levels of cellular proliferation. Perhaps enhancer elements along the length of the
fpgs gene are differentially used to generate the dividing-cell specific levels of fpgs
expression, as suggested by the genome-wide studies discussed previously (102). It may
also be the case that repressive mechanisms, in addition to transcriptional interference, are
restricting P2 expression in mouse liver. However, the fact that we detected HNF4 at P2 in
mouse liver argues that transcriptional activation, rather than repression is the favored
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transcriptional state of this promoter in mouse liver. HNF4 is also expressed in mouse
kidney, and we believe that the redundant tissue-specific factors between liver and kidney
may explain why measurable levels of P2 activity are detected in these tissues, compared
to other differentiated tissues, such as mouse brain, where no fpgs transcripts are found
(244).
In mouse brain, the P2 promoter was found to be poised for transcriptional
activation (Figure 2-24), representing an additional mechanism of transcriptional
regulation of this promoter. We are interested in determining if the poised state of the P2
promoter exists across multiple mouse tissues where P2 is silent. Genome-wide studies in
human and mouse samples have shown that poised RNAPII complexes are common to a
large number of genes and P2 appears representative of this class of promoters (13, 87).
A comprehension of the multitude of transcriptional mechanisms coordinating the
expression of the P2 promoter of the mouse fpgs gene is critical to our understanding of the
regulation of the human fpgs locus. In human tissue, fpgs mRNA is expressed in heart,
liver, lung, and skeletal muscle (71, 244). Surprisingly, human fpgs mRNA is generated
from the sole use of the P2 promoter (244). Since the effectiveness of antifolate-based
chemotherapeutic regimens depend on the presence of FPGS protein in sensitive tumor
cells, an awareness of the transcriptional mechanisms involved in coordinating the
expression patterns of the P2 promoter in mouse tissues, might have important clinical
implications.
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DNA methylation studies
The studies described in this chapter using the P and PM cell lines were designed to
ask the question: Is loss of DNA methylation sufficient to transcriptionally activate the P1
promoter in mouse dividing cells? Previous work demonstrated that methylated CpG
dinucleotides were severely depleted in PM cells due to a substantial reduction of DNMT1
protein levels (137). Our interpretation of the results we obtained with these cells was
complicated by the fact that the PM cells were not a simple case of a hypomethylated cell
line existing in culture, as had previously been thought. However, we have made some
surprising and interesting observations regarding the epigenetic control of the P1 promoter
and the transcriptional regulation of the levels of DNMT3a and DNMT3b.

Mechanisms controlling the P1 promoter: epigenetics and tissue-specific factors
We tested the consequences of changes in epigenetic mechanisms on the activity of
the P1 promoter using a PM MEF cell line and through the use of pharmacological agents,
which lead to alterations of the cellular levels of DNA methylation and histone acteylation.
The substantial increase in P1 transcriptional activity following 48 hours of treatment with
5daza in both P and PM cells suggest that loss of DNA methylation is sufficient for
transcriptional activation of the P1 promoter. However, the levels of P1 activity detected
in the treated P cells are at least three orders of magnitude lower than the levels found in
mouse liver, suggesting that other mechanisms are involved in regulating this promoter. In
support of this idea, recent experiments have determined that HNF4 is present at the P1
promoter in mouse liver. One possibility is that loss of DNA methylation permits basal
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activation of the P1 promoter, but tissue-specific activators are required to achieve the
levels of transcription measured in the liver. Whether loss of DNA methylation is required
in order for trans factors to affect the transcriptional activity of P1 is a very interesting
question and is currently being explored.

How are the methylation patterns across the P1 promoter established?
The data presented in this chapter stress that we are far from understanding the
entire story linking DNA methylation and tissue-specific gene expression. The manner in
which the pattern of DNA methylation across P1 is altered with loss of DNMT1 is
remarkable: individual CpGs appear to lose methyl groups at dramatically different rates
throughout the entire genomic region sampled in our bisulfite analysis. These data suggest
that the mechanisms responsible for DNA methylation across the P1 promoter are
multifaceted and methylation of individual CpGs within the same genomic region may be
controlled differently. To the best of our knowledge, reduced levels of DNMT1 have been
shown to cause loss of DNA methylation within CpG-rich promoter regions in a uniform
fashion (60, 194), making the P1 promoter an interesting exception to this general rule.
We do not yet understand how these patterns are established or their functional
consequences, but our data argues that the rules dictating DNA methylation at CpG-rich
promoters may be different than those of CpG-sparse promoters.
In PM cells, CpGs adjacent to the transcriptional start site of the P1 promoter are
severely hypomethylated, yet the rest of the region retains high levels of methylation. One
explanation for this pattern is that the remaining DNMT1 enzyme activity in PM cells
180

maintains the methylation of most of the P1 region, but is not able to methylate the sites
adjacent to the transcriptional start site. However, DNMT1 has been shown to methylate a
hemi-methylated substrate in vitro in a processive manner, arguing that partial methylation
of CpG residues within a region of genomic DNA is unlikely mediated by this enzyme
(250).
Alternatively, loss of methylation observed in PM cells at P1 may be a
consequence of the hypomethylated state of these cells.

The global levels of gene

expression are altered in these cells and the pattern of methylation observed may be the
result of a block in methylation caused by trans-acting factors binding. In this model, the
transcription factor is expressed in PM cells but not P cells.

Prevention of DNA

methylation through transcription factor binding has previously been described (97, 235).
Treatment of PM cells with 5daza caused further loss of DNA methylation across
the P1 promoter region. However, the effects of 5daza are not specific to DNMT1 and the
levels of DNMT3a and DNMT3b were also affected by treatment with this agent. As such,
the change in methylation observed in PM cells after 24-hour treatment with 5daza may be
a consequence of the loss of DNMT 1, 3a, 3b, or a combination of the proteins.
When P cells were treated with 5daza for 24-hours, expression of P1 was increased
and loss of methylation was observed in a pattern highly specific to individual CpG
dinucleotides, similar to the profile found in PM cells. Subsequently, treatment for 48
hours resulted in a substantial increase in P1 expression that was higher than the levels
observed in PM cells treated with 5daza. The difference in P1 expression between P and
PM cells following 5daza treatment was suprising, since we expected that P1 might be
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more sensitive to loss of DNMT1 levels in PM cells, where this protein had already been
severely diminished. We have not yet explained this discrepancy, but we are strongly
considering that alternate DNMT enzymes are involved in regulating the methylation
across the P1 promoter. This is a divergent concept from the current thought that DNMT1
is the sole enzyme responsible for maintaining DNA methylation in differentiated cells or
tissues.

Are DNMT3 protein levels regulated by DNA methylation or cellular levels of DNMT1?
The expression of the genes encoding the de novo methyltransferase enzymes,
DNMT3a and DNMT3b, occurs most abundantly at early stages of embryonic
development in the mouse (177). In the characterization of the PM cell line, Cedar et. al
reported that the contribution of the de novo enzymes to genome-wide methylation in these
cells were likely to be minimal. However, we detected higher levels of DNMT3a and
DNMT3b at both the transcript and protein levels in PM cells when compared to P cells,
suggesting that these genes may be regulated by DNA methylation or cellular levels of
DNMT1. Additional reports have found that one of the two promoters within the DNMT3a
locus is hypomethylated in HCT116 cells that are DNMT1 hypomorphs; however, the
levels of DNMT3a transcript or protein were not measured (60). The coordination of
DNMT expression through DNA methylation has previously been described at the
DNMT3L locus, where methyl groups deposited by DNMT3a and DNMT3b activity led to
the silencing of this gene (108). Whether the de novo enzymes DNMT3a and DNMT3b
are regulated by mechanisms linked to cellular DNMT1 levels is not known.
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An

appreciation for how these enzymes are over-expressed in PM cells may shed light on this
potentially important connection.

Are de novo methyltransferase enzymes responsible for methylation of P1?
The over expression of the de novo methyltransferase in PM cells may be
responsible for maintaining the methylation levels observed across P1 in our studies.
DNMT1 knock-out animal studies have clearly shown that the de novo enzymes are not
compensatory for loss of DNMT1 on a genome-wide level (142), but a subset of genes
may remain silenced in DNMT1 hypomorphs due to the activity of DNMT3a or DNMT3b
that has not previously been identified. Interestingly, reasonable levels of DNMT3a but
not DNMT3b were also found in P cells. This is in agreement with previous literature that
showed the full-length form of DNMT3a at low levels in somatic tissue, but not DNMT3b
(177). Is it possible that one of the de novo methyltransferases may be responsible for the
methylation of P1 in PM cells and perhaps also P cells? Literature precedent suggests that
DNMT3a may be a candidate enzyme regulating P1 methylation: 1) DNMT3a, but not
DNMT3b, is detected in P cells and is also found at low levels in normal somatic tissues
(177).

2) DNMT3b catalyzes the addition of methyl groups through a processive

mechanism, similar to DNMT1, and loss of this protein is unlikely to cause the discrete
hypomethylation of individual CpGs (82). And, 3) Dnmt3a has been shown to methylate
DNA substrates in vitro in a distributive manner, resulting in products that are methylated
in a non-uniform fashion. This has lead to the proposal that DNMT3a may require
targeting to individual CpG sites (103). Perhaps a distributive enzyme would be more
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easily used for the methylation of CpG-sparse promoters, but the processive DNMT1 for a
CpG island promoter. As such, reduction of this protein may impact individual CpGs
within a small genomic region differently.

In vitro data also supports the idea that

cooperation between the DNMTs may function to methylate the CpG-sparse promoter of
the fpgs gene (67). An appreciation for how the DNA methylation patterns are established
at the P1 promoter in P and PM cell lines is important to our understanding of the
happenings at this promoter in vivo.
A class of promoters exists in both humans and mice that is methylated in a tissuespecific fashion, which inversely correlates with transcriptional activity. An awareness of
how these differentially methylated regions are established is central to our ability to test
their functional importance. We initiated these studies in the P and PM cells thinking that
changes in DNMT1 would allow us to determine the contribution of DNA methylation to
the control of the P1 promoter. Clearly, we underestimated the complexity of the patterns
of methylation previously described at P1.

We are eager to determine how DNA

methylation is coordinated at P1 and if our observations are universal to tissue-specific
CpG-sparse promoters genome-wide.
In this chapter, we used model systems with single genetic disturbances to study
the impact of changes in P1 activity and DNA methylation on the use of the two mouse
fpgs promoters. These studies are preliminary but, in spite of this fact, we have made
some very interesting observations that require explanations.

Future studies will be

designed to address some of the remaining questions including: 1) Why is the P2 promoter
not fully activated in P1 knock-out mouse liver? 2) What mechanism is determining the
184

tissue-specific patterns of histone marks found in mouse liver independent of the
transcriptional activity at P1? 3) Why is P2 able to produce transcript in mouse liver and
kidney, but not brain? 4) How are different methylation patterns of P1 established in adult
mouse tissues, and why are certain CpGs sensitive to loss of cellular levels of DNMTs?
And, 5) Are tissue-specific factors involved in the coordination of the P1 promoter and if
so is loss of DNA methylation required for these trans factors to activate the P1 promoter?
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Figure 3-1. Histone H3 acetylation across the mouse fpgs gene in wild-type
and P1 promoter knock out mouse liver. Chromatin from wild-type (closed
triangles) and P1 knock out (closed circles) mouse liver was cross-linked,
sonicated, and immunoprecipitated with an antibody against acetyl-H3K9
(closed symbols) or non-specific IgG (open symbols). The content of DNA for
various segments of the fpgs locus was determined by real-time PCR. The two
transcriptional start sites are shown as the cross-hatched bars.
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Figure 3-2. Histone H3 lysine 4 tri-methylation across the mouse fpgs gene
in wild-type and P1 promoter knock out mouse liver. Chromatin from wildtype (closed triangles) and P1 knock out (closed circles) mouse liver was crosslinked, sonicated, and immunoprecipitated with an antibody against H3K4me3
(closed symbols) or non-specific IgG (open symbols). The content of DNA for
various segments of the fpgs locus was determined by real-time PCR. The two
transcriptional start sites are shown as the cross-hatched bars.
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Figure 3-3. Residence of trans factors at positions the P2 promoter in wildtype and P1 knock out mouse liver. Chromatin from wild-type (black and dark
grey vertical bars) and P1 knock out (light grey bars) mouse liver was crosslinked, sonicated, and immunoprecipitated with an antibodies against Sp1 (A),
HNF4 (B) or non-specific IgG (A and B). The content of DNA at -200 nt and
+200 nt relative to the P2 promoter transcriptional start site was determined by
real-time PCR.
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A.

B.

Figure 3-4. RNAPII occupancy across P2 in wild-type and P1 knock out
mouse liver. Chromatin from wild-type (A) and P1 knock out (B) mouse liver
was cross-linked, sonicated, and immunoprecipitated with an antibodies
against total RNAPII (closed circles), phospho-serine 5 RNAPII (open
circles), phospho-serine 2 (inverted triangles) or non-specific IgG (open
triangles). The DNA content was determined by real-time PCR by amplifying
six overlapping fragments. The points were plotted at the midpoint of each
fragment.
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Figure 3-5. Expression of Slpi, Cryaa, and the P2-specific fpgs transcript
in PM cells relative to levels detected in P cells. RNA was isolated from P
(black vertical bars) and PM (grey bars) cells. 2.5 µg to 5 µg of RNA was
converted to cDNA using Superscript III Reverse transcriptase kit. 1 µl of
cDNA was added to a 25µl PCR reaction. cDNA content was measured
using gene-specific primers in real-time PCR. The level of GAPDH cDNA
was measured as a reference and the ΔCt method was used to assess the
amount of gene-specific cDNA in each cell line relative to the amount of
GAPDH. In these experiments, the level of Slpi, Cryaa, or P2-specific
cDNA measured in P cells was normalized to 1.0.
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Figure 3-6. P1 transcriptional activity in P and PM cells. RNA was isolated from
P (black vertical bars) and PM (grey bars) cells. 2.5 µg to 5 µg of RNA was converted
to cDNA as in Figure 3-5. 1 µl of cDNA was added to a 25µl PCR reaction. (A)
Semi-quantitative PCR was performed and reactions were terminated at 30, 32, 34, 36,
and 38 cycles to quantify the level of P1-specific fpgs cDNA in P and PM cells. The
primers used to detect this fpgs cDNA were specific for regions in A1b and exon 3.
PCR reactions using primers specific for GAPDH cDNA were quenched at 8, 10, 12,
and 14 cycles. (B) P1-specific fpgs cDNA was measured using real-time PCR with
primers specific for regions within exon A1b. The level of GAPDH cDNA was
measured as a reference and the ΔCt method was used to assess the amount of genespecific cDNA in each cell line relative to the amount of GAPDH.
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Figure 3-7. CpG methylation across the P1 promoter in P and PM
cells. Genomic DNA was isolated from P (closed circles) and PM
(closed triangles) cells. 200-500 ng of genomic DNA underwent bisulfite
conversion. The P1 promoter was amplified in four fragments using
bisulfite specific PCR primers. The region sampled spanned from -500
to +1000 nt relative to the P1 transcriptional start site. PCR products
were gel-purified, cloned, and the sequences of 7-10 colonies were
determined for each amplified region. At the position of each CpG
dinucleotide in the genomic sequence, the percentage of clones
containing a methylated cytosine is represented in the graph, plotted
relative to the positions of exons A1a and A1b (cross-hatched vertical
bars).
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Figure 3-8. Histone H3 acetylation and lysine 4 tri-methylation at the two
promoters of the mouse fpgs gene in P and PM cells. Chromatin from P (A)
and PM (B) cells was cross-linked, sonicated, and immunoprecipitated with an
antibodies against H3K9Ac (black bars), H3K4me3 (light grey bars) or nonspecific IgG (dark grey bars). The midpoint of each amplified region was at +50
nt and -200 nt relative to the P1 and P2 promoter transcriptional start site,
respectively. Real-time PCR determined the DNA content.
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Figure 3-9. Inhibition of histone deacetylases activates transcription
at P1 and Slpi in P and PM cells. Cells were treated with 0.06 µM TSA
for 12 hours. RNA was isolated from P and PM cells and cDNA was
synthesized as described in Figure 3-5. The primers used to detect P1specific fpgs cDNA were specific for regions within exon A1b. Semiquantitative PCR was also performed (data not shown). The level of
GAPDH cDNA was measured as a reference and the ΔCt method was
used to assess the amount of gene-specific cDNA in each cell line
relative to the amount of GAPDH.
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Figure 3-10. P1 transcriptional activity increases in PM cells
after 24 and 48 hours of treatment with 5daza. RNA was isolated
from PM cells (black bars) and PM cells treated with 1µM 5daza
(grey bars) for 24 and 48 hrs. cDNA was generated as described in
Figure 3-5. 1 µl of cDNA was added to a 25µl PCR reaction. The
level of P1-specific cDNA at 24 hrs was measured using primers
specific to regions within exon A1b. cDNA obtained from the 48 hr
time point was amplified using a forward primer in exon A1b and a
reverse primer in exon 6 of the mouse fpgs gene. Similar results were
also collected using Semi-quantitative PCR. The level of GAPDH
cDNA was measured as a reference and the ΔCt method was used to
assess the amount of gene-specific cDNA in each condition relative
to the amount of GAPDH.
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Figure 3-11. P1 transcriptional activity increases in P cells at
after 24 and 48 hours of treatment with 5daza. RNA was isolated
from P cells (black bars) and P cells treated with 1µM 5daza (grey
bars) for 24 and 48 hrs. cDNA was generated as described in Figure
3-7. 1 µl of cDNA was added to a 25µl PCR reaction. The level of
P1-specific cDNA at 24 hrs was measured using primers specific to
regions within exon A1b. cDNA obtained from the 48 hr time point
was amplified using a forward primer in exon A1b and a reverse
primer in exon 6 of the mouse fpgs gene. Similar results were also
collected using Semi-quantitative PCR. The level of GAPDH cDNA
was measured as a reference and the ΔCt method was used to assess
the amount of gene-specific cDNA in each condition relative to the
amount of GAPDH.
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Figure 3-12. CpG methylation across the P1 promoter in PM and P
cells treated with 1µM of 5daza for 24 hours. Bisulfite sequencing
was carried out as described in Figure 3-6 using genomic DNA isolated
from P (B) and PM (A) cells treated with 1µM 5daza for 24 hrs.
Sequences of 6-10 colonies were determined for each amplified region
across the P1 promoter in P and PM cells. At the position of each CpG
dinucleotide in the genomic sequence, the percentage of clones
containing a methylated cytosine is represented in the graph, plotted
relative to the positions of exons A1a and A1b (vertical bars).
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Figure 3-13. DNMT3a and DNMT3b are overexpressed in PM cells
compared to P cells. (A) RNA was isolated from P and PM cells and
cDNA was synthesized as described in Figure 3-5. The level of GAPDH
cDNA was measured as a reference and the ΔCt method was used to
assess the amount of gene-specific cDNA in each cell line relative to the
amount of GAPDH. (B and C) Whole cell lysates were prepared using
2% SDS lysis buffer. 20µg of total protein were run on a 4-15% SDSPAGE gel. Proteins were transferred to Immobilon-P PVDF membrane
using a sem-dry apparatus. PVDF membranes were blocked in Blotto
solution, probed with primary antibody (1:500) overnight, washed with
TBST, incubated in with secondary antibody for 1hr, and developed
using Pierce chemiluminescence kit.
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Chapter 4: Antifolates active against de novo purine synthesis have a marked
spillover effect on inhibition of mTORC1 and activation of AMPK.

INTRODUCTION
The concept of molecular based therapeutics is founded on the idea that genetic
alterations between normal and neoplastic cells are distinguishing features, that when
targeted by chemotherapeutic agents will affect only those cells in a cancerous state. In
theory, this drug development strategy should result in the generation of compounds that
cause substantial regression of tumors, while having little, if any, secondary affects on the
surrounding normal tissue or normal stem cells. The cell signaling pathways responsible
for the coordination of cellular proliferation depend on the effector molecule, the
mammalian target of rapamycin (mTOR), and are rich in proteins commonly dysregulated
in human cancers and other proliferative disorders.

As such, mTOR is often found

unchecked in a number of human pathologies, and a great deal of effort has been directed
towards generating direct and indirect inhibitors of this protein as strategies for
molecularly targeted therapeutics.

Cell growth, translation, and mTOR
Protein translation is a substantial energy burden to the cell and several signaling
pathways responding to growth factor stimulation and nutrient availability converge on the
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mTOR protein and coordinate mTOR activity, to ensure that the energy demands of
protein synthesis are met by the available cellular resources (149). mTOR is a 289 kD
serine/threonine kinase that is a member of the phosphatidylinositol 3-kinase related kinase
family (PIKK), sharing structural similarity to ATM, ATR, and DNA protein kinase (78).
The amino-terminal domain of the protein is composed of HEAT repeats, which are
thought to enhance protein-protein interactions (78). The remaining portions of mTOR
include a FAT domain (signature of all PIKK kinases) at the C-terminal end, a FKBP12rapamycin-binding domain (FRB), and a kinase domain (78). In the cell, mTOR exists in
two large multiprotein complexes, mTORC1 and mTORC2, with functionally distinct
consequences (Figure 4-1). mTORC2 is composed of mTOR, mLST8, and rictor (208)
and its activity has been linked to the phosphorylation of Akt at Ser473 (209) and the
control of the actin cytoskeleton (116). The mTORC1 complex is activated in response to
abundant cellular nutrients and growth factors and stimulates protein translation; this
complex includes the subunits mTOR, Raptor, and mLST8 (129) and is specifically
inhibited by rapamycin (see below) (Figure 4-1). Raptor facilitates the positioning of the
substrates of mTOR to enhance phosphorylation (174).

PRAS40 (Proline-rich AKT

substrate) has also recently been shown to bind to and inhibit mTORC1 prior to its
phosphorylation by Akt, which causes the release of PRAS40 from the complex (248). The
events leading to mTORC1 activation represent an integration of growth factor signaling
and nutrient availability (149) (Figure 4-1).
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Downstream effectors of mTORC1:
mTORC1 activates translational initiation through the phosphorylation of two key
downstream targets 4E-binding protein 1 (4EBP1) and the 40S ribosomal protein S6 kinase
(S6K1) (Figure 4-1) (78). Several residues within 4EBP1 (T37, T45, T70, S65) serve as
substrates for mTORC1 (78).

The hypophosphorylated form of 4EBP1 prevents the

assembly of the translation initiation complex through its binding with the elongation
initiation factor 4 E (eIF4E) when it is positioned at the 5’ cap of mature mRNA (78).
Activation of mTOR phosphorylates 4EBP1, disrupting its interaction with eIF4E, and
facilitates the activation of cap-dependent protein translation (78) (Figure 4-1). eIF4E is an
important mediator of translation of mRNAs involved in cell cycle progress, angiogenesis,
and survival such as mRNAs for cyclin D1, Bcl-2, Bcl-xl, and vascular endothelial growth
factor (VEGF) (151).
Under basal, non-stimulated conditions the hypophosphorylated form of S6K1
interacts with elongation initiation factor 3 (eIF3) (105). Activation of mTOR leads to the
phosphorylation of T389 and the dissociation of the two proteins. The free S6K1 interacts
with phophoinositide-dependent kinase 1 (PDK1), which phosphorylates S6K1 at T229,
and fully activates the kinase activity of this protein (149).

The active S6K1

phosphorylates several targets including insulin receptor substrate-1 (IRS-1), the 40S
ribosomal subunit S6, eukaryotic initiation factor 4B (eIF4B), and programmed cell death
4 (PDC4), which is accompanied by the enhancement of translational initiation, ribosome
biogenesis and cellular proliferation (149). In particular, the phosphorylation of eIF4B
stimulates its interaction with eIF3 and recruitment to the translational pre-initiation
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complex (105). The translocation of eIF4B to the initiation complex stimulates the RNA
helicase activity of eIF4A, which enhances the translation of transcripts with 5’
untranslated regions with high secondary structure; mRNAs of this nature typically encode
proteins involved in cell-cycle progression and proliferation (257)(Figure 4-1).
Upstream regulators of mTORC1:
TSC1/TSC2 complex and Rheb
The mTORC1 complex associates with and is directly activated by the GTP-bound
form of the small G protein, Rheb (152)(Figure 4-1). The interconversion between a GTP
and GDP bound state of Rheb is determined by the GTPase (GAP) activity of the upstream
negative regulator of mTORC1, TSC2 (152)(Figure 4-1). TSC2 exists in the cell as a
heterodimer with TSC1 and together these proteins are the primary determinant of the
cellular activity of mTORC1.

Multiple upstream signaling inputs phosphorylate the

TSC1/TSC2, dictating the GAP activity of TSC2, and thus mTORC1 (Figure 4-1, see
below).
Activators of mTORC1:
A major upstream regulator of mTORC1 activity is the serine/threonine kinase Akt.
Akt activity is stimulated by growth factors, such as insulin and epidermal growth factor
(EGF), and by the activity of phosphatidylinositol 3-kinase (PI3K) (Figure 4-1) (48). A
balance of Akt activity is reached in the cell by the activity of the phosphatase and tensin
homolog (PTEN), which dephorylates phosphatidylinositol-3,4,5-trisposphate (PIP3), to
phosphatidylinositol-4,5,-bisphosphate (PIP2), preventing the recruitment of Akt to the
membrane and activation of the protein by phosphorylation by PDK1 (Figure 4-1). Akt
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has several cellular targets that coordinate cell growth and proliferation, one of which is
TSC2.

The GAP activity of the heterodimer is inactivated by the Akt-mediated

phosphorylation of three residues, S939, S981, and T1462, within TSC2 (114). As a
consequence, Rheb-GTP levels are increased and mTORC1 activity is stimulated. As
discussed previously, recent studies have uncovered an additional link between mTORC1
and Akt through the Akt-mediated phosphorylation of PRAS40 (248). In normal cells, Akt
mediated activiation of mTORC1 is tightly controlled by a negative feedback inhibitory
loop mediated by the kinase activity of S6K1 (246). S6K1 phosphorylates IRS1 and
stimulates the degradation of this protein, limiting the activation of Akt through the PI3K
pathway (Figure 4-1) (93, 98). As a result, in some instances drug-induced mTORC1
inhibition has led to the activation of Akt due to the loss of this negative feedback loop
(57). There are several additional signaling pathways that stimulate mTORC1 and the
major players involved are outlined in Figure 4-1.
Inhibitors of mTORC1
Since the downstream targets of mTORC1 lead to the activation of processes
requiring substantial levels of cellular energy it is no surprise that several mechanisms
exist to inhibit mTORC1 in cells depleted of energy stores. Original studies suggested that
mTOR itself sensed levels of ATP and thus served as a metabolic sensor (52). However,
several lines of investigation determined that in a low energy state mTORC1 is inhibited
through the activation of the AMP-activated protein kinase (AMPK), also known as the
energy sensor of the cell (36). AMPK is activated in response to cellular stress, which is
often signaled by an increase in cellular levels of AMP (96). One mechanism of AMPK205

mediated inhibition of mTORC1 is accomplished by phosphorylation of TSC2 on position
S1345, which activates the GAP activity of this protein and reduces the activation of
mTORC1 through Rheb-GTP (113, 115). Recent studies have discovered that AMPK also
directly targets mTORC1 by phosphorylating the Raptor component of the complex (89).
This post-translational modification enhances the interaction of Raptor with protein
binding partner 14-3-3 and decreases overall mTORC1 activity (89). The importance of
the AMPK/TSC/mTORC1 axis in maintenance of cellular survival under stress conditions
has been highlighted in studies where cells deficient in either TSC2 or resistant to AMPKmediated phosphorylation underwent rapid induction of apoptosis in response to conditions
of energy depletion (115).
Regulation of AMPK
AMPK exists in the cell as a heterotrimeric complex composed of a α-catalytic
subunit and two regulatory subunits, β and γ. Each subunit is encoded by at least two
genes (α1, α2, β1, β2, γ1, γ2, γ3), creating the potential for a large number of AMPK
isoforms to exist mammal tissues (95). A number of these isoforms have been identified
but the functional consequences of the different complexes are not entirely understood.
The α-subunits are composed of a conserved serine/threonine kinase domain at the Nterminus and the C-terminal portion facilitates binding to the other two subunits (95). The
β subunits complex with α and γ and bind glycogen through the C-terminal domain and
central domain of the protein, respectively (95). AMP and ATP bind to the γ subunits
through two bateman domains, regions of protein defined to bind molecules containing
adenosine, located at the carboxy-terminal end of the protein (95).
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LKB1 is the major upstream kinase coordinating activation of AMPK in intact cells
through the phosphorylation of AMPK at the residue T172 within the α-catalytic subunit
(100, 220). Phosphorylation of this residue is a post-translational modification that is
required for the activation of AMPK (101). LKB1 functions in a heterotrimeric complex
as a tumor suppressor and is required for the AMPK-mediated inhibition of mTORC1
(100, 219, 220). As such, mouse embryo fibroblasts with mutant LKB1 have elevated
levels of mTORC1 activity (219). AMPK activation occurs as a consequence of both
phosphoryaltion of the α-subunit and the binding of AMP to the γ-subunit (95). In vitro
enzyme assays have determined that AMP binding to the γ-subunit both allosterically
activates AMPK and prevents dephosphorylation of the catalytic subunit by cellular
phosphatases, e.g. PP2Cα (95, 204, 231). Aminoimidazole-4-carboxamide ribonucleotide
(ZMP) has also been shown to stimulate AMPK activity in a similar manner to AMP, and
administration of aminoimidazole-4-carboxamide ribonucleoside to cells has been used
extensively to define the role of AMPK in energy metabolism (49, 231). A second class of
upstream kinases of AMPK has been identified, the calmodulin-dependent protin kinases
(CaMKKs) (94).

However, the CaMKKs are expressed in a highly tissue-restricted

manner and appear to respond to levels of Ca+2 and not AMP. This is supported by the
observation that when Hela cells, deficient in LKB1 but expressing CaMKK, are treated
with agents that increase cellular AMP levels the phosphorylation of AMPK is not
enhanced (94).
In addition to the affects on mTORC1 activity, AMPK activation is primarily
responsible for shifting the metabolic focus of the cell from anabolism to catabolism. As
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such, glucose uptake, glycolysis, and fatty acid oxidation are all stimulated, while fatty
acid synthesis, gluconeogenesis, and lipolysis are largely inhibited (94). Additionally,
another very important consequence of AMPK activation is the induction of a p53dependent metabolic check-point, which results in cells arrested in the G1 phase of the cell
cycle (124). This effect appears to be coordinated by the phosphorylation of p53 at serine
15 and induction of two cyclin-dependent kinase inhibitors, p27 and p21 (124, 145).
Interestingly, studies in HCT116 cells suggest that a link between LKB1-AMPK and p53
may be required for the p53-mediated transactivation (268). These data argue that AMPK
activation may have substantial impact on the control of rapidly dividing tumor cells,
independent of its inhibitory effects on mTORC1.

The mTOR pathway and disease
The upstream and downstream proteins involved in the mTOR pathway are
common tumor suppressors or oncogenes that are dysregulated in a number of proliferative
disorders and human cancers.

For the sake of clarity, the proteins and their role in

transformation have been left out of the discussion above and are presented in Table 4-1.

Consequences of mTOR inhibition in vitro and in vivo
Inhibitors of mTOR have been extensively sought as ideal candidates for molecular
targeted therapeuitic agents because of the common phenotype of mTOR dysregulation
found in several human cancers. Rapamycin is the prototypical mTORC1 inhibitor that
was originally identified as an antifungal agent (25, 217).
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This agent is bound

intracellularly to the immunophilin, FK506 binding protein-12 (FKBP12), which binds to
the FKBP12-rapamycin binding (FRB) domain of mTOR, leading to the selective
inhibition of mTORC1 activity and downstream signaling events, with no apparent effects
on mTORC2 (78). Currently, rapamycin is clinically used as an immunosuppressant to
prevent kidney transplant rejection and is being tested for efficacy in the use of treatment
of graft versus host disease (240).
In the early 1980’s, rapamycin was evaluated by the developmental therapeutic
branch of the national cancer institute and was found to be “a non-cytotoxic agent that had
cytostatic activity against several human cancers in vitro and in vivo”(63). However, the
insoluble nature of rapamycin limited the utility of this compound as an anticancer drug
and developmental efforts were halted. Over the course of the past fifteen years, secondgeneration water-soluble rapamycin analogues, termed rapalogs, have been designed and
their utility as chemotherapeutic agents explored both in vitro and in vivo (63). The
lessons learned from the pre-clinical and clinical studies using direct mTOR inhibitors
have shed light on the cell signaling pathways linked to mTOR activity and the anticancer
potential of mTOR inhibitors beyond those directly targeting the enzyme.
In vitro experiments have suggested that a variety of tumor types including
glioblastoma, rhabdomyosarcoma, small cell carcinoma, prostate, and breast may be
sensitive to mTOR inhibition in vivo (56).

The determinants of a particular cellular

response as an affect of mTOR inhibition appear to depend largely on the genetic
background of the treated cell-type (25). A clear example described where a particular
genotype predicted the anticancer activity of mTOR inhibition has been shown in studies
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in mice and human tumors that are deficient in PTEN; the activity of Akt was elevated in
cells where PTEN was deficient and the growth of cells with this genotype both in vivo and
in vitro were preferentially blocked by inhibition of mTOR (171, 185, 221). Similarly,
unchecked PI3K signaling, either as a result of PTEN loss or dysregulated growth receptor
activity, has been shown to sensitize breast cancer cells to mTOR inhibition (173). These
data argue that screening for PTEN status and aberrant PI3K/Akt signaling, two
derangements commonly found in human cancers, may identify a subpopulation of patients
that will respond to treatment based on mTOR-inhibition.
The cellular response to rapamycin is largely the result of the hypophosphorylation
of the two major targets of mTORC1, 4EBP1 and S6K1. Cells exposed to rapamycin
display a minor decrease in overall protein translation, however the predominant cellular
affect is substantial G1 growth arrest (63). One mechanism involved in coordinating this
signature block involves the decrease in cellular proteins tightly linked to cell cycle
progression, e.g. cyclin D1 and c-myc, in response to loss of phosphorylation of S6K and
4EBP1 and their downstream signaling (56, 76, 99). This decline in protein levels is
accompanied by the stabilization of p27, which inhibits the activity of the cyclin-dependent
kinases 4 and 6 and reinforces the G1/S-phase block (127, 176). Likewise, the presence of
p53 and p21 has also been linked to the rapamyacin induced growth affects, and cell lines
mutant in p53 have been shown to undergo apoptosis, rather than cell-cycle arrest
following treatment with an mTOR inhibitor (109).
Tumor growth suppression has also been shown in a number of cases to be a
consequence of anti-angiogenesis effects in response to mTOR inhibition. The
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microenviornment of tumors tends to be hypoxic and tumor survival and metastasis is
often dependent upon ongoing processes of angiogenesis. Mouse models with endothelial
cell-specific loss of PTEN have dysfunctional angiogenesis and developing embryos die at
E 11.5 as a consequence of bleeding and cardiac failure, linking the PTEN/PI3K/mTOR
pathway to the control of vascular development (91). The connection between the mTOR
pathway and angiogenesis is defined by the substantial cross-talk between the two
processes; mTOR activation induces the expression of HIF1α mRNA that leads to the
induction of vascular endothelial growth factor (VEGF), a critical regulator of
angiogenesis (85); likewise, VEGF has been shown to stimulate the P13/AKT/mTOR
pathway (63, 85).

The consequences of this connection on tumor progression were

realized when the observation was made that rapamycin treatment inhibited metastatic
tumor growth and angiogenesis in vivo (85).
Several cases have been described where mTOR inhibition has resulted in the
induction of apoptosis in human cancer cell lines (25), but the causative events are not
entirely defined. In spite of this fact, it is very clear that the genetic backgrounds of the
affected cells play a major role (56). For example, in cells with mutant p53 the tendency
towards a G1 arrest following rapamycin treatment is disrupted and apoptosis is initiated
(109); this p53 mutant-mediated apoptosis is dependent upon expression of 4EBP1 and
loss of p21 (110). Additional studies have also correlated null-PTEN status and Akt
hyperactivity with a predisposition to apoptosis following treatment with rapamyacin (56).
Further understanding of the signaling events and genetic backgrounds driving cells toward
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apoptosis are critical to identifying cancer types where single agent therapy with mTOR
inhibitors will cause tumor regression rather than slowed tumor progression.

Potential of mTOR inhibition in the treatment of human cancers
The efficacies of three rapamycin analogs temsirolimus, everolimus, and AP23573
as single agent therapy in the treatment of a number of different cancer types and several
proliferative disorders are currently being tested in clinical trials. Success of the rapalogs
has been found in the treatment of a variety of lymphomas including refractory mantle-cell
lymphoma and non-mantle-cell-non Hodgkins lymphoma, as well as, in the control of
facial angiofibromas and renal angiolypomas, common features of profilerative disorders
(160). Recently, mTOR inhibitors were approved by the FDA as first-line therapy for
poor-prognosis renal cell carcinoma (RCC); phase III clinical trial data showed that the
number of patients responsive to treatment with tesmirolimus was double that effected by
treatment interferon, which is the current therapy for RCC (160). It has been surprising to
clinicians that rapalogs have not shown clinical activity in a substantial number of the
tumor types tested. This may be the result of the dominant cytostatic cellular response to
mTOR inhibition observed in pre-clinical studies, and it may suggest that the use of these
compounds may be best in combination with cyotoxic agents. Pre-clinical studies have
shown potential for mTOR inhibitors in combination with radiation (CR) and clinical trials
are currently underway to test their utility in a variety of different clinical diseases (160).
The full clinical benefit of mTOR inhibitors has yet to be determined, but current data
suggests that the responsive tumor types may define certain genetic features, including
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PTEN loss and cyclin D1 overexpression, as predictors of sensitivity to mTOR inhibition
(160). Thus, the anticancer potential of mTOR inhibitors identified in pre-clinical studies
appears to hold true for certain cancers with specific genetic disruptions.

Antifolates targeting de novo purine synthesis
As discussed in chapter 1, drug development efforts to identify highly selective
inhibitors of folate metabolism lead to the synthesis of the two diasteromers 6R- and 6S- 5,
10-dideaza-5,6,7,8-thetraydrofolate (DDATHF) (237)(Figure 1-4).

These compounds

were determined to inhibit the first-folate dependent step of de novo purine synthesis,
glycinamide ribonucleotide formyltransferase (GART) (18, 165)(Figure 1-3). DDATHF
was found to be an excellent substrate for FPGS (18) and polyglutamated form targeted
GART much more efficiently than the parent compound (205). Mouse leukemic cells
treated with DDATHF were growth inhibited and the ATP and GTP levels within these
cells were substantially reduced (18); these effects were completely reversed by the
addition of a purine source, such as hypoxanthine, to the medium (18). Further studies,
determined that the effects of DDATHF on de novo purine synthesis caused substantial
cytotoxicity on human colorectal carcinoma cells exposed to drug (226). In spite of the
potential suggested through pre-clinical data of DDATHF as an anticancer drug, the
clinical utility of this compound was limited because it caused severe thrombocytopenia in
patients during phase I and II clinical trials (191).
The Eli Lilly compound, 231514 (pemetrexed) (Figure 1-4), was originally
designed as a fourth generation de novo purine synthesis inhibitor, was identified as a
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potent cytotoxic agent and was advanced as clinical candidate following the failure of
DDATHF in the clinical setting (224, 238). Pemetrexed is the first antifolate drug
approved by the FDA in the past 20 years for the treatment of cancer and is currently
approved for first line therapy in combination with cisplatin for non-small cell lung cancer
and mesothelioma (61, 148, 211).
As previously discussed, in vitro experiments determined that the primary target of
this compound was thymidylate synthase, but also found that the folate-dependent
enzymes in de novo purine synthesis, GART and to a much lesser extent AICART, were
inhibited by the drug (224). These studies concluded that the polyglutamated forms of
pemetrexed were 50-200 times more potent inhibitors of thymidylate synthase than of
either GART or AICART (224). In agreement with this data, the ATP and GTP pools
found in CEM cells following treatment with pemetrexed were not depleted, as they were
after treatment with DDATHF (45). Taken together, these data imply that the inhibition of
the secondary targets by pemetrexed play a minor role in the cellular effects mediated by
this compound. However, pemtrexed has acted as an effective cytotoxic agent towards
cells that have been confirmed to be resistant to ralitrexed, a pure thymidylate synthase
inhibitor, supporting the idea that the multiple targets of pemetrexed are involved in
mediating its cellular effects (45). It is clear that the mechanism of action of pemetrexed is
more complicated than antifolate compounds targeting a single folate-dependent enzyme,
and understanding the cellular consequences has become increasingly important with the
recent success of this compound in the clinic. The studies presented in this chapter have
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discovered that pemetrexed, through its action on de novo purine synthesis, leads to the
activation of AMPK and the inhibition of mTOR.

Objectives
We have designed a series of experiments to determine if a link between antifolate
therapy and mTOR inhibition exists. More specifically, we hypothesized that changes in
nucleotide pools within the cell induced by antifolate compounds inhibiting either of the
two folate-dependent enzymes in de novo purine synthesis, GART or AICART, result in
the inhibition of mTORC1 through the activation of AMPK. To address this question we
performed cell culture experiments using DDATHF, the prototypical GART inhibitor, and
a pemetrexed analogue found in our laboratory to primarily inhibit AICART.
Furthermore, we expanded our findings by including pemetrexed in our experiments and
determined a new potential mechanism explaining the antitumor activity of this compound
for lung carcinomas, an unusual activity of antifolates. As we will demonstrate in this
chapter, pemetrexed exerts a strong inhibitory effect on mTOR as an indirect effect of
AICART inhibition. This is the first time such an effect has been found.
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MATERIALS AND METHODS
Materials
Antibodies were obtained from Cell Signaling Technology (Beverly, MA) and will
be discussed individually in the sections to follow. Compound C (P54996-[4-(2-piperidin1-yl-etoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]pyrimidine)

was

purchased

from

Sigma-Aldrich. Starting Block Buffer (37542) was purchased from Pierce. 10x Trisglycine transfer buffer was obtained from Bio-rad (161-0734). Goat anti-rabbit secondary
antibody was purchased from Thermo-scientific (35560). SuperSignal West Pico and Est
Dura Chemiluniescent Substrate Kits were purchased from Pierce. Pemetrexed, 6RDDATHF, and Lilly AICART inhibitor (LCA) were obtained from Eli Lilly and Co
(Indianapolis, IN). All other culture reagents were from Sigma Aldrich and were of
highest available quality.

Cell culture
CCRF-CEM human lymphoblastic leukemia cells were maintained at a density
between 105-106 cells/ml in RPMI 1640 medium (Gibco/Invitrogen) supplemented with
10% dialyzed fetal bovine serum. HCT116 human colorectal carcinoma cells were grown
in RPMI 1640 medium (Gibco/Invitrogen) supplemented with 10% dialyzed fetal bovine
serum. All cells were grown at 370C in 15% CO2.
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Drug treatment of HCT116 cells or CEM cells.
HCT116 cells were plated at 2.5 x 106 cellsl in 10 mls in 100 mm dish and were to
allowed cells to adhere to the plate overnight. Ten milliliters of fresh media were added to
the plates and drug was added simultaneously with the appropriate amount of reversal
agents.

Pemetrexed, DDATHF, LCA, thymidine, AICA, AICAR, and inosine were

prepared in PBS and sterilized filtered prior to use. Hypoxanthine was prepared in 75 mM
HCl.

Compound C was dissolved in DMSO and diluted into PBS. The cells were

exposed to drug for 24 or 48 hours and harvested as described in chapter 3. CEM cells
were treated at a density of 1 x 105 cells/ml and, during treatment, the media was
supplemented with 20 mM HEPES and 40 mM MOPS. Since CEM cells are grown in
suspension, at the time of harvesting they were pelleted by centrifugation and then washed
and lysed as described in chapter 3.

Reversal experiments using HCT116 cells.
Cells were plated in 12-well plates at a concentration of 2 x 104/ml in 2 ms of
media. The cells were incubated overnight to allow cells to become adherent. The
following day fresh media was added to the plates with the appropriate amount of drug and
rescue agents. The plates were examined every 24 hours microscopically cell morphology
and death were noted. After 96-hours of treatment, the supernatant was aspirated and
morphology washed the wells with 1 ml of 1x PBS. Each well was trypsinized and the
cells were pelleted by centrifugation. The cell pellets were resuspendend in 1 ml of PBS
and 500 µl of cell suspension was added to 9.5 ml of PBS for counting using the Beckman
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Coulter Counter. Each condition was performed in duplicate and the average cell number
was plotted.

Immunoblot analysis.
Cells were lysed in buffer containing 62.5mM Tris, pH 6.5, 5% glycerol, 2% SDS,
5% 2-mercapothethanol, 50mM NaF, 0.2 mM Na3VO4 and 1x protease inhibitor complete
mixture (Roche Applied Science).

Protein concentrations were determined using the

Bradford assay, against a standard of BSA using reagents from Bio-rad laboratories. Total
cellular protein CEM cells (40 µg) and HCT116 cells (20 µg) were resolved on 7.5%, 415%, and 15% SDS-polyacrylamide gels and were transferred to an Immobilon-P
polyvinylidene fluoride membrane (Millipore) using a protocol for wet-transfer in
Tris/Glycine transfer buffer Biorad. Western blot analysis using some antibodies and
cellular lysates obtained from CEM cells were challenging, and we found that increasing
the total level of protein loaded to 40 µg helped in obtaining successful blots. Prior to
transfer, the protein gels and PVDF membrane (which was dipped first in methanol) were
rinsed in water and then soaked in cold 1x transfer buffer prepared using the manufacturer’s
protocol (Biorad) for 30 minutes. The pre-cast mini-gel transfer apparatus from Biorad was
used to carry out the wet transfer. The “transfer sandwich” was prepared as follows: a
sponge pre-soaked in transfer buffer was placed on the white plate, followed by three pieces
of whatman paper, the PVDF membrane, the gel, three additional sheets of Whatman, and a
second sponge. All items in the sandwich were soaked in transfer buffer prior to assembly.
The transfer was run at 100 V for 1 hour. Membranes were blocked with either 5% milk or
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Starting Block Buffer (Pierce), washed, and probed with antibodies against AMPKα
(1:1000) (cell signaling, #2532), phospho-AMPKα (T172) (cell signaling, #2531)(1:250),
4EBP1 (9452) (1:1000), phospho-4EBP1 (T70) (cell signaling, #9455) (1:1000), S6 kinase
(1:1000) (9202), phospho-S6 kinase (T389) (cell signaling #9205) (1:250 and 1:500), acetyl
CoA carboxylase (1:1000) (cell signaling #3662), Raptor (cell signaling #24C12) and
phospho-Raptor (S792) (cell signaling #2083) (1:1000), phospho-acetyl-CoA carboxylase
(S79) (cell signaling #3661) (1:1000) at 40 C overnight. All antibodies were purchased from
Cell Signaling. Washes were carried out as described in chapter 3, but used 0.1% TBST.
This change usually decreased the background on these blots. Membranes were incubated
with goat anti-rabbit secondary antibody with horseradish peroxidase conjugate for 1hr at
room temperature (Pierce). Chemiluminescence was detected using the SuperSignal West
Pico and West Dura Chemiluminescent Substrate Kits (Pierce). Washing with these
antibodies is critical and if upon developing the blots were dirty we repeated washing 3x for
5 minutes or longer and re-developed. Below are the conditions we found to work best for
these antibodies.

Unfortunately, changes in cell lines may result in the need for re-

optimization. If these do not work, for another cell line, it is suggested than an optimization
experiment should be performed with several conditions, varying primary and secondary
concentrations, as well as diluting solutions. The differences that small changes make in
the signal obtained from a particular antibody are remarkable.

For optimization of

antibodies, I always started out with the least sensitive developing agent, i.e. West Pico, and
then went to more sensitive reagents as needed. West dura is very strong and diluting it 1:5
has proven to also be very useful.
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Blocking
1:1000 5%
BSA

Primary

5% milk

Secondary

1:250

Startblock

1:1000

1:1000 5%
BSA

Startblock

1:1000

Startblock

1:250

1:2000

5% milk

1:10,000

Startblock

1:2000

5% milk

1:10,000

Startblock

1:2000

Startblock

1:2000

30 sec-1 min

Pico

Pico

ECL

Table 4-1: Antibody conditions for the total and phosphorylated forms of
AMPK, 4EBP1, S6K1, and ACC
Antibody
5% milk

5% BSA

5% milk

Dura

Pico

Pico

Pico

Pico

1:1000 5%
BSA

1:2000

ACC and
phosphoACC

5% milk

Startblock

Phospho4EBP1

Startblock

PhosphoS6K1

4EBP1

5% milk

Startblock

PhosphoAMPK

5% milk

S6K1

AMPK

220

RESULTS
The direct link between mTOR dysregulation and a larger number of human
cancers has generated a great deal of interest in identifying therapeutic strategies that target
the mTOR complex either directly or indirectly. The studies described in this chapter were
initially designed to test if de novo purine synthesis inhibition by antifolate compounds
targeting the folate-dependent enzymes, GART or AICART, caused inhibition of the
mTOR pathway. Treatment of mammalian cells with inhibitors of de novo purine synthesis
has been shown to cause depletion of ATP and GTP pools and as a result induced rapid
growth arrest (18). Previous studies have identified AMPK, a kinase whose activity leads
to the inhibition of the mTORC1 complex, as a sensor of cellular energy that becomes
activated when ATP levels decline. We hypothesized that nucleotide imbalance induced
by a de novo purine synthesis blockade may lead to the activation of AMPK and inhibition
of the mTORC1 complex, which would represent a novel and clinically relevant
consequence of antifolate compounds targeting this biochemical pathway.

Targets of 6R-DDATHF and LCA by end-product reversal experiments.
End-product growth-inhibitory reversal experiments have been used in several
instances to define the folate-dependent enzymes targeted by antifolate compounds.
Growth rescue by inclusion of thymidine (TdR) or hypoxanthine (Hx) distinguishes
between antifolates that primarily target thymidylate synthase and de novo purine
synthesis, respectively. In order to determine whether the first or second folate dependent
enzyme of de novo purine synthesis, GART or AICART, is affected by drug, the effects of
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aminoimidazolecarboxamide (AICA) on the growth of cells exposed to drug is assessed.
AICA is metabolized to the corresponding ribonucleotide, AICAR monophosphate (also
known as ZMP) by adenine phosphoribosyltransferase (APRT) and, thus, inclusion of
AICA in growth medium introduces a purine pathway intermediate into the cell that is
downstream of GART, but upstream of AICART (Figure 4-3). If GART is inhibited,
inclusion of AICA in the medium should reverse growth inhibition (18, 165) whereas, if
AICART is inhibited, no effect on growth would be expected.
We were interested in testing the effect of GART and AICART inhibition on the
mTOR pathway. Prior studies have shown that the major site of action of 6R-DDATHF is
the first folate-dependent step in de novo purine synthesis, GART (18, 165). We had
several antifolate compounds in house and Dr. Moran performed a series of end-product
reversal experiments to identify compounds targeting AICART. In these experiments the
data generated using 6R-DDATHF represents the results expected of a pure GART
inhibitor (Figure 4-2). Growth inhibition by 6R-DDATHF was not affected by the addition
of thymidine to the medium, but was completely reversed by the addition of hypoxanthine
(Figure 4-2). Cells treated with 6R-DDATHF supplemented with AICA (320 µM) are
substantially less growth inhibited than cells grown in drug alone (Figure 4-2), in
agreement with concept that this compound is a GART inhibitor.

The inclusion of

thymidine in the medium of cells treated with the compound Lilly AICART inhibitor
(LCA) did not affect cell growth, but hypoxanthine partially rescued the growth inhibitory
effect (Figure 4-2). However, the combination treatment of hypoxanthine and thymidine
completely rescued cells treated with LCA (Figure 4-2).
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Taken together, these data

suggest that this compound targets primarily de novo purine synthesis and secondarily
thymidylate synthase. The addition of AICA with or without thymidine in growth medium
had no effect on cell growth, identifying AICART as the enzyme targeted by LCA in de
novo purine synthesis.
Recent studies performed by a current student in the laboratory, Scott Rothbart,
have supported the idea that LCA inhibits AICART by showing that abundant levels of
ZMP, the substrate of the AICART reaction (Figure 4-3), accumulates to high levels (1-4
mM) in both CEM and HCT116 cells treated with 1µM of LCA. The accumulation of
ZMP behind the AICART block added an additional link between LCA and mTOR
inhibition outside of the realm of nucleotide depletion; the expansion of cellular ZMP
pools following treatment with the ribonucleoside analoge of AICA, AICAR, has been
shown to activate AMPK, resulting in mTORC1 inhibition, and substantial cytotoxic
effects (49, 88). ZMP is capable of binding to the γ-subunit of AMPK similar to AMP,
which supports the activation of AMPK by enhancing the phosphorylation of T172 within
the α-catalytic subunit of the protein (95). Thus, it appeared that LCA had potential to
activate AMPK kinase through two mechanisms: depletion of ATP and accumulation of
ZMP pools within cells.
We had in our hands two compounds, 6R-DDATHF and LCA, that targeted the
first and second-folate dependent steps in de novo purine synthesis, respectively. We were
in a unique position to question if treatment with these compounds impacted the mTOR
pathway and if cellular effects of nucleotide depletion and ZMP accumulation were
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different. The steps of de novo purine synthesis blocked by 6R-DDATHF and LCA are
illustrated in Figure 4-3.

End-product reversal studies of HCT116 cells treated with LCA.
In our initial studies we repeated end-product reversal studies with LCA using
HCT116 cells and the data from these experiments are shown in Figure 4-4. The growth
of HCT116 cells was partially inhibited by LCA at a concentration of 10 nM and was
completely blocked when treated with 100 nM or higher concentrations of drug (Figure 44). The growth inhibition observed in cells treated with LCA was not affected by the
addition of thymidine (TdR) (5.6 µM) to the medium, which would be expected to reverse
the cellular affects attributed to thymidylate synthase inhibition. However, inclusion of
inosine (IR) (100 µM), a nucleoside source of purines, substantially lessened the level of
growth inhibition observed when compared to the growth of cells treated with drug alone
or with TdR (Figure 4-4). In contrast to the studies performed in CEM cells, the addition
of both TdR and IR to the medium did not enhance the reversal of growth inhibition by IR
alone, suggesting that any potential secondary effects of LCA on thymidylate synthase
were minimal and not contributing to the growth patterns observed of the treated HCT116
cells (Figure 4-4).

Inhibition of de novo purine synthesis blocks mTOR activation.
HCT116 colorectal carcinoma cells were exposed to 6R-DDATHF and LCA to
question if mTORC1 inhibition was a consequence of the de novo purine synthesis
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blockade mediated by these compounds. We studied the activity of mTOR by monitoring
the phosphorylation status of two primary targets of the mTORC1 complex S6K1 and
4EBP1 (Figure 4-5). mTOR-mediated phosphorylation of S6K1 and 4EBP1 results in an
overall increase in protein translation and cellular growth (148). A 1µM concentration of
6R-DDATHF and LCA inhibited mTORC1 activity in HCT116 cells, demonstrated by the
reduced level of phosphorylation detected in western blot analysis using phospho-specific
antibodies against T389 of S6K1 and T70 of 4EBP1 (Figure 4-6). The effect of LCA on
mTOR appeared to be more substantial than that of 6R-DDATHF, since phosphorylation
of both S6K1 and 4EBP1 were completely eliminated by the former and only partially
reduced by the latter treatment (Figure 4-6). Likewise, the lower migration of total 4EBP1
found in cells treated with LCA suggested that the phosphorylation of the additional
mTOR-sensitive residues in this protein may also be more affected by LCA than 6RDDATHF (Figure 4-6). Interestingly, the effect of LCA on mTORC1 activity was also
more potent than that observed when HCT116 cells were treated with AICAR, a known
inhibitor of mTOR through the activation of AMPK (49).

mTORC1 inhibition is specific to the effects of 6R-DDATHF and LCA on de novo
purine synthesis.
We tested if the effects of LCA and 6R-DDATHF observed on the mTORC1
pathway were reversed by the addition of a purine source, such as inosine, to the medium
containing drug (Figure 4-7); inosine is converted to inosine mono phosphate (IMP) in
cells through the action of inosine kinase and serves as the substrate for synthesis of
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adenosine mono-phosphate (AMP) and guanosine mono-phosphate (GMP) (Figure 4-3).
Since the growth reversal studies showed that LCA inhibited thymidylate synthase as a
secondary target (Figure 4-2), we also included thymidine in the media of cells treated with
this compound to separate out any effects of thymidylate synthase on the mTOR pathway
(Figure 4-7). The hypophosphorylation of 4EBP1 and S6K1 in response to 6R-DDATHF
treatment was completely eliminated when cells were grown in the presence of inosine
(Figure 4-7); likewise LCA-mediated mTORC1 inhibition appeared relieved by the
presence of purines in the medium (Figure 4-7). Initially, we took this to suggest that the
contribution of ZMP accumulation towards the inhibition of mTORC1 in cells treated with
LCA was minimal, since repletion of nucleotide pools was sufficient to rescue the
observed effects. However, studies discussed later in this chapter demonstrated that the
addition of a purine source to the medium of cells treated with an AICART inhibitor
prevented the accumulation of ZMP behind the block, most likely as a consequence
feedback inhibition mediated by AMP, GMP, or IMP on the rate-limiting enzyme in the de
novo purine synthesis pathway, glutamine PRPP amidotransferase.

Thus, the effects

observed on mTORC1 activity in cells exposed to LCA were either due to ATP depletion,
ZMP accumulation, or a combination of the two. Substantial hypophosphorylation of the
mTORC1 targets S6K1 and 4EBP1 was retained in cells treated with LCA and thymidine
(Figure 4-7), suggesting that the effects observed on mTORC1 were specific to de novo
purine synthesis inhibition. These studies confirmed our hypothesis that a de novo purine
synthesis block results in mTORC1 inhibition, and suggested that treatment with LCA has
more potent consequences on mTORC1 activity than 6R-DDATHF. We had yet to
226

determine the mechanism of this cellular affect, but considered the activation of AMPK as
a likely candidate.

AMPK is activated when de novo purine synthesis is inhibited in HCT116 cells.
We assessed if the proposed mechanism of AMPK activation was responsible for
the inhibition of mTORC1 observed when HCT116 cells were treated with either 6RDDATHF or LCA (Figure 4-8) AMPK activation in these studies was monitored by
assessing the phosphorylation of the α-subunit at position T172, a requisite posttranslational modification for the induction of the kinase activity of this protein (101). The
phosphorylation of AMPK was stimulated when cells were exposed to either 6R-DDATHF
or LCA for a period of 24-hours (Figure 4-8). In agreement with the rescue of mTORC1
activity (Figure 4-7) observed in cells grown in the presence of both inosine and 6RDDATHF, cellular levels of phospho-AMPK remained low under these conditions (Figure
4-8).

Interestingly, this was not the case in cells exposed to LCA and inosine; the

phosphorylation of AMPK was detected at equal levels in cells grown in medium
containing LCA with or without the addition of thymidine or inosine (Figure 4-8). We are
not yet clear how mTOR activity persists in spite of the fact that AMPK is phosphorylated
when cells are treated with LCA and inosine, but measurement of AMPK activity under
these conditions may shed light on this mechanism.
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mTOR inhibition occurs in cells treated with pemetrexed, a novel consequence of this
antifolate compound.
The impact of treatment with 6R-DDATHF and LCA on the mTOR pathway was
very interesting to us because of the therapeutic benefits direct inhibitors of mTOR have
had in the treatment of several human cancer types in clinical trials (160). The notion that
antifolate compounds targeting de novo purine synthesis could lead to the inhibition of
mTOR had not previously been described in the literature, but the clinical implications of
this observation on the use of this class of antifolates in the treatment of several human
malignancies was potentially huge. At this point in our experiments, we focused our
attention on determining if treatment with pemetrexed, a multi-targeted antifolate,
currently used as first line therapy for mesothelioma and non-small cell lung cancer caused
the inhibition of mTOR. The primary target of this drug is thymidylate synthase, however
in vitro enzyme assays and cell culture experiments have shown that the secondary target
of this compound is de novo purine synthesis. Understanding the potential mechanisms
responsible for the anti-tumor activity of a drug in widespread clinical use is of obvious
importance.
The studies described in the sections to follow were performed in collaboration
with two current students in the laboratory, Scott Rothbart and Cortney Heyer. In our
initial experiments, we questioned if pemetrexed-mediated inhibition of de novo purine
synthesis caused activation of AMPK and inhibition of mTORC1, similar to the effects
mediated by 6R-DDATHF and LCA on this cell-signaling pathway (Figure 4-9). The
activation of AMPK by pemetrexed and thymidine was assessed in CEM cells after 24 and
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48 hours of exposure. The western blot data presented in Figure 4-9 were generated from
whole cell lysates harvested after 48 hours of treatment.

We monitored the

phosphorylation of the α-subunit of AMPK as an indication of the kinase activity of this
protein, but we also used the phosphorylation status of a direct target of AMPK, acetylCoA carboxylase (ACC), as a direct indicator of the activity of AMPK in intact cells (258).
A 1µM concentration of pemetrexed promoted activation of AMPK as demonstrated by
both direct phosphorylation at T172 and by an enhanced phosphorylation of ACC at
residue S79 (Fig. 4-9). Activation of AMPK is known to cause inhibition of mTOR by
phosphorylation of TSC2, upstream of mTOR, as well as a direct phosphorylation of the
Raptor component of the mTORC1 complex (Figure 4-5 and 9) (89, 115). Accordingly, a
robust hypophosphorylation of 4EBP1 and S6K1 was seen in pemetrexed-treated CEM
cells (Fig 4-9), as well as an increase in phosphorylation of S792 of Raptor (Figure 4-9).
As in our previous experiments using LCA, we observed a lower and broader migration
pattern of total 4EBP1 in pemetrexed-treated cells, suggesting that phosphorylation status
of this protein was severely affected by drug treatment (Figure 4-9).

Thymidine was

included in these experiments to separate the effects of inhibition of thymidylate synthase
from any effect caused by de novo purine synthesis inhibition. The effects of pemetrexed
on activation of AMPK and inhibition of mTOR, as observed by the phosphorylation of
AMPK and the hypophosphorylation of the downstream targets of mTOR were dose
dependent starting at concentrations as low as 0.1 µM of pemetrexed (Figure 4-9). These
studies determined that treatment with pemetrexed in the presence of thymidine resulted in
AMPK activation and mTORC1 inhibition.
229

The second target of pemetrexed is the second folate-dependent step in de novo purine
synthesis, AICART and results in ZMP accumulation.
We sought an understanding of the mechanism behind the AMPK activation
observed and to prove if the mTORC1 inhibition detected was, in fact, a direct
consequence of AMPK activity. In order to address these processes we needed to know if
pemetrexed inhibited GART, and was most likely causing nucleotide depletion, or
AICART, resulting in accumulation of ZMP levels. The field was conflicted on this point:
in vitro enzyme assays suggested that the second target of pemetrexed was GART (224).
Dr. Moran performed growth inhibition reversal experiments in CEM cells to determine
whether the second target of pemetrexed was GART or AICART (Figure 4-11). This
growth inhibition of CEM cells by pemetrexed was not reversed by hypoxanthine (Hx), but
inclusion of thymidine in the culture medium did reverse the growth inhibitory effects of
pemetrexed, shifting the concentrations of drug needed to affect growth by about 12-fold,
as shown for the CEM human leukemia cell line in Figure 4-11.

Inclusion of both

thymidine and hypoxanthine reversed the effects of pemetrexed at even high
concentrations (Figure 4-11), in agreement with previous literature (224, 238). The critical
piece of data in this experiment was that the addition of AICA (320 µM) in the presence of
thymidine did not reduce the growth inhibitory effects of pemetrexed. We concluded that
the secondary target of pemetrexed was not GART, and was most likely AICART.
These observations were further expanded when studies performed by Scott
Rothbart determined that the ZMP pools increased substantially in pemetrexed-treated
cells, further supporting the idea that an effect of pemetrexed or its metabolites was
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predominantly on AICART (Figure 4-11). If inhibition of GART played a role in the
secondary effects of pemetrexed, ZMP accumulation would not have been observed
(Figure 4-11). To this point, ZMP accumulation did not occur in 6R-DDATHF-treated
CEM cells (Figure 4-11). The level of ZMP in pemetrexed treated cells accumulated in a
dose-dependent fashion and was maximal after 48 hours of treatment, reaching cellular
levels approximating 1.5 mM.

ZMP accumulates in pemetrexed treated cells correlates with the degree of AMPK
activation and mTOR inhibition observed in treated cells.
We initially considered the possibility that the AMPK activation observed in cells
treated with pemetrexed and thymidine was a consequence of the depletion of nucleotide
pools by AICART inhibition. However, direct measurment of ATP levels in studies
performed in our laboratory by Scott Rothbard and others by hplc indicated that the levels
of ATP did not decrease, but actually increased slightly in cells treated with pemetrexed
(data not shown). In light of these data, it appeared that the activation of AMPK observed
in the presence of pemetrexed and thymidine was solely linked to the level of ZMP
accumulation forced by the pemetrexed-induced AICART block.
We took advantage of the fact that AICA enters the de novo purine synthesis
pathway after being converted to ZMP through the activity of APRT (Figure 4-3) to further
increase the degree of ZMP accumulation found under conditions where the AICART
enzyme was inhibited by pemetrexed. The administration of AICA (320 µM) for 48 hours
caused the levels of ZMP in pemetrexed treated carcinoma cells to rise to concentrations
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approaching 4 mM, whereas the levels in cells exposed to AICA in the abscense of an
AICART block were undetectable (data not shown). We generated whole cell lysates from
cells treated under these conditions for 48 hours and found that the expansion of the ZMP
pool observed appeared to enhance the effects of pemetrexed on AMPK activation and
mTORC1 inhibition (Figure 4-12). The phosphorylation of the direct targets of AMPK,
ACC and to a greater extent Raptor, were increased by the addition of AICA to the
medium containing pemetrexed and thymidine (Figure 4-12).

Likewise, the

hypophosphorylation of 4EBP1 was markedly reduced in AICA treated cells, as evidenced
by the low level of protein detected using the phospho-specific antibody generated against
the T70 residue, and the broader migrating species detected with the pan-4EBP1 antibody
(Figure 4-12). Since the hypophosphorylation of S6K1 was substantial in pemetrexed
treated cells, a further loss of phosphorylation as a consequence of an increase in ZMP
levels was difficult to detect (Figure 4-12). These data greatly supported the notion that
the activation of AMPK and the inhibition of mTORC1 observed in pemetrexed-treated
CEM cells were directly correlated with the degree of ZMP accumulation behind the
AICART block.

The effect of pemetrexed on the AMPK-mTOR pathway is prevented when the levels
of ZMP are forced to remain low.
In our studies using 6R-DDATHF and LCA we determined that the addition of
purines reversed the inhibition of mTORC1 (Figure 4-7). We questioned if a source of
preformed purines, such as hypoxanthine, would also reverse the effects of pemetrexed on
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the AMPK-mTOR pathway (Figure 4-13).

Cells were treated with pemetrexed and

thymidine with or without hypoxanthine (32 µM) for 48 hours.

The level of

phosphorylation of ACC and Raptor detected in cells treated with pemetrexed and
thymidine with the addition of hypoxanthine were not increased above the levels found in
the control samples treated with thymidine and hypoxanthine only (Figure 4-13),
indicating that the activation of AMPK induced by pemetrexed was prevented when
hypoxanthine was present in the medium.

As would be predicted, the abscense of

detectable AMPK activity was coincident with loss of mTORC1 inhibition (Figure 4-13);
the hypophosphorylation caused by pemetrexed of S6K1 and 4EBP1 was completely
prevented by the inclusion of hypoxanthine in the medium (Figure 4-13).

ZMP

measurements confirmed that the mechanism of this hypoxanthine reversal of the
secondary target of pemetrexed was most likely due to the prevention of the accumulation
of ZMP, presumably due to the known feedback effects of an expanded purine pool on
early steps in purine synthesis (39, 260).

mTOR inhibition observed in pemetrexed specific cells is dependent upon AMPK
activation.
The accumulation of ZMP in pemetrexed-treated cells and the activating effects of
ZMP on AMPK suggested that the inhibition of mTOR by pemetrexed was mediated by
ZMP-dependent activation of AMPK. To determine the intermediacy of activation of
AMPK in this mechanism, the effects of an inhibitor of AMPK, compound C (20), on the
pemetrexed-induced mTOR inhibition was studied (Figure 4-14). The experiment was
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performed at two concentrations of compound C, 10 µM and 1 µM. Cell treated with 10
µM of compound C and pemetrexed were substantially growth arrested, and at this
concentration compound C appeared to have substantial effects on the mTOR pathway as a
single agent, as judged by the hyperphosphorylation of S6K1 (Figure 4-14). When a 1 µM
dose of compound C was used, secondary effects on cell growth and the mTOR pathway
were undetectable (Figure 4-14).

As expected, compound C inhibited the enhanced

AMPK activity in cells treated with pemetrexed and thymidine, as judged by an inhibition
of the phosphorylation of ACC (Figures 4-14). The effects of 10 µM and 1 µM compound
C on AMPK blocked the inhibition of mTOR by pemetrexed, as judged by the
hyperphosphorylation of S6K1 in the presence of pemetrexed and compound C (Figure 414), a striking contrast to the marked hypophosphorylation of S6K1 caused by pemetrexed.
Interestingly, the phosphorylation of AMPK in the presence of pemetrexed and compound
C was greater than that seen with pemetrexed, in spite of the fact that compound C
diminished the level of ACC phosphorylation; this suggested that compound C was
blocking the activity of AMPK while allowing phosphorylation of the α-subunit of
AMPK. Overall, we concluded that the effects of pemetrexed on the mTOR signaling
pathway were caused by the activation of AMPK following the accumulation of ZMP.

DISCUSSION
The search for new therapeutic agents useful against cancer has focused on
molecularly-targeted small molecules. Such strategies have rarely been identified, although
the Gleevec-sensitive BCR-Abl and Iressa-selective mutations in the EGFR protein are two
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well-studied cases (55, 182). One of the most promising approaches seems to be the design
of therapeutic agents that affect pathways dependent on tumor suppressor genes, whose
function is often eliminated or dramatically altered during transformation. The mTOR
pathway responsible for the balance of energy metabolism, protein and lipid synthesis, and
growth involves a series of upstream controlling proteins recognized as tumor suppressor
proteins, including LKB1, PTEN, TSC1 and 2, and others recognized as cellular oncogenes,
such as AKT and PI3 kinase (48).
In the studies presented in this chapter we identified a new action of a select class of
antifolates that inhibit de novo purine synthesis: inhibition of mTORC1. Our studies showed
that a block of either the first or second folate-dependent steps of purine synthesis results in
an inhibition of mTORC1 that is prevented by supplementation with a purine source or
inhibition of AMPK activity. Thus, the effect on mTORC1 observed appears to be a direct
consequence of AMPK activation in response to changes in purine nucleotide pools
following the inhibition of the GART or AICART enzymes. Furthermore, we determined
that the activation of AMPK under GART and AICART inhibition occurred by seemingly
different mechanisms. Previous studies have determined that GART inhibition results in a
reduction of ATP and GTP levels in CEM leukemic cells (18) and HCT116 cells (Woodard
and Moran, unpublished data), and we attribute the stimulation of AMPK following
treatment with 6R-DDATHF, a pure GART inhibitor, to this consequence. On the other
hand, AICART inhibition results in the accumulation of its substrate ZMP, which itself is an
activator of AMPK by mimicking the effect of AMP on the γ-subunit of AMPK (94, 231).
A rather striking observation was made with the discovery that pemetrexed, a multi-targeted
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antifolate currently in clinical use for the treatment of mesothelioma and non-small cell lung
cancer, has as one of its targets mTORC1. The ramifications of this observation in the clinic
have yet to be fully determined, but those studies are currently underway.

GART inhibition vs. AICART inhibition
We were able to observe the effects of both ATP depletion and ZMP accumulation
on the AMPK-mTORC1 pathway through the use of GART and AICART inhibitors,
respectively. Previous studies have determined that ZMP is an allosteric activator of
AMPK, in a manner similar to AMP, but is substantially (20x) less potent than the adenine
nucleotide (49). This supports the idea that an inhibitor causing ATP depletion and a
change in the AMP:ATP cellular ratios would be a more potent activator of AMPK than
compounds causing the expansion of ZMP pools. Rather surprisingly, we found that
mTORC1 inhibition as a consequence of an AICART block appeared more effective than
that observed following GART inhibition, as evidenced by a more substantial decrease in
phosphorylation of 4EBP1 and S6K1 under the former conditions (Figure 4-6). We took
this as an indication that AMPK activation was higher in AICART treated cells. It was
possible that treatment with the AICART inhibitor resulted in depletion of ATP levels, and
that the enhanced activation of AMPK was a consequence of both effects. However,
ongoing experiments by Scott Rothbart in this laboratory, as well as a published study
(45), indicate that ATP pools do not decrease after pemetrexed. We propose that the levels
of ZMP detected in cells treated with the AICART inhibitor (2-4 mM) were sufficiently
high to make any effect of changes in AMP:ATP levels on the activity of AMPK minimal.
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These data suggest that ZMP pool expansion as a consequence of an AICART block is a
more effective mechanism of mediating mTORC1 inhibition than ATP depletion by GART
inhibitors.
Our analysis raises the question of whether GART or AICART would be the ideal
target of a new generation of antifolates specifically selected as indirect inhibitors of
mTORC1. While GART inhibitors showed substantial potential as anticancer drugs in preclinical studies, their use in the clinical setting was limited by the complication of severe
thrombocytopenia in treated patients (191). This and the other side effects were most
likely attributable to the multitude of consequences resulting from substantial depletion in
purine nucleotide pools in normal highly proliferative cells, a common type of problem
faced when treating patients with non-targeted agents. In contrast, while secondary effects
of ZMP have been described on mitochondrial function (88), current thought is that the
cellular effects of ZMP are mediated predominately through AMPK. As such, ZMP
accumulation as a result of an AICART block may represent a method of targeting
transformed cells that are hypersensitive to mTORC1 inhibition, e.g. cells deficient in
PTEN, while preserving genetically normal cells. We propose that new drug development
efforts towards the design of antifolates inhibitory of mTORC1 will have effects that are
more selective and specific through a mechanism of action based on ZMP accumulation,
rather than ATP depletion. Thus, the screening and selection of novel compounds in this
class of antifolates should be based on their activity against the AICART enzyme.
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Does AMPK activation impact the cytotoxicity of de novo purine synthesis inhibitors?
Previous studies have determined that antifolates targeting de novo purine synthesis
have cytotoxic effects, but they appear to be less potent than antifolates targeting
additional folate-dependent steps, such as thymidylate synthase (226). GART inhibition in
human colorectal carcinoma cells was found to be cytotoxic, but the commitment to cell
death was substantially lower than the cells treated with an inhibitor of thymidylate
synthase (226). Interestingly, antifolate GART inhibitors only killed 1.5-2 logs of WiDR
cells, whereas inhibitors of thymidylate synthase, i.e. raltitrexid, killed down to mutant
frequencies. Likewise, these investigators noted that the morphology of the cells under the
two conditions were remarkably dissimilar, suggesting that the mechanisms driving the
cytotoxic effects were different (226).

In those same studies, it was found that the

cytotoxicity induced by methotrexate treatment in was substantially enhanced when
purines were added to the media, eliminating any affects on purine synthesis (226). The
polyglutamated derivatives of methotrexate have been shown to inhibit AICART in
addition to DHFR, and it appears from these studies that the purine effect was protective to
the cells grown in drug (4). Why would purine depletion protect cells from methotrexate?
The activation of AMPK often results in the induction of autophagy or growth arrest to
prevent cells from undergoing apoptosis (34, 115, 124). Authophagy is a process induced
by nutrient and energy depletion and results in the lysosomal degradation of cellular
material to promote cell survival in a time of stress (8). In a recent study, p27, a cyclindependent kinase inhibitor, was shown to promote autophagy in response to nutrient
withdrawal. p27 is phosphorylated in an AMPK-dependent manner, which results in the
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stabilization and accumulation of this protein within the cell (145). The investigators
determined that under conditions of energy depletion knockdown of p27 drove cells
towards an apoptotic state rather than the autophagic state observed in cells under the same
conditions with wild-type levels of p27 (145). The induction of autophagy in response to
anticancer agents has been described and how this affects the efficacy of a particular
therapeutic strategy is currently being explored (8). It is clear, however that the cellular
decision to induce growth arrest, autophagy, or apoptosis depends on the activity of several
proteins within the mTOR pathway, and AMPK has been suggested to be a major player.
With this in mind, it seems likely that activation of AMPK in response to de novo purine
synthesis inhibition caused the induction of autophagy in the methotrexate and GART
inhibited cells. From these studies, one may predict AICART inhibitors to have more of a
cytostatic rather than cytotoxic effect on tumor cells.

Compound C effect on AMPK phosphorlyation at T172
In the experiments performed using compound C, an AMPK inhibitor (270), we
made some surprising observations that should be further discussed.

We used this

inhibitor to test if the effects of pemetrexed on mTORC1 activity were a direct
consequence of AMPK activity. The hypophosphorylation of S6K1 and 4EBP1 resulting
from pemetrexed treatment were prevented when cells were exposed to 1 µM or 10 µM
compound C. Likewise, the phosphorylation of ACC, a direct target of AMPK, was also
prevented by the addition of compound C to the medium, supporting the idea that
inhibition of AMPK activity by compound C blocked the effect of pemetrexed on the
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mTOR pathway. Rather strikingly, in cells exposed to either concentration of compound C
and pemetrexed a substantial increase in the phosphorylation of AMPK at T172 was
observed.

How the phosphorylation of AMPK was enhanced while allowing a block of

AMPK enzyme activity remains unclear. Recent studies have determined that the binding
of AMP leads to the accumulation phospho-AMPK within the cell by preventing the
dephosphorylation of the α-subunit of AMPK by cellular phosphatases (204).

One

possible explanation for the increase in phospho-AMPK observed after treatment with
pemetrexed

and

Compound

C

is

that

the

AMPK-inhibitor

further

prevents

dephosphorylation of the α-subunit by phosphatases through a conformational change or
by direct inhibition of the phosphatases themselves. Interestingly, when cells were treated
with AICAR and compound C the increase in phospho-AMPK was not observed (data not
shown). Since ZMP was responsible for the activation of AMPK in both pemetrexed and
AICAR treated cells, these observations suggest the affects observed were specific to
pemetrexed treatment.

AMPK as a drug target
We have identified that the class of antifolates targeting de novo purine synthesis
causes the activation of AMPK. The positioning of AMPK upstream of several key
signaling pathways involved in cellular metabolism and proliferation has brought forth the
idea that AMPK may be a potential drug target for the treatment of diseases such as type II
diabetes, atherosclerosis, and most recently human cancers (94).

Current data has

uncovered that the activity of AMPK is central to p53-mediated checkpoints, as well as,
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the induction of autophagy and apoptosis under conditions of cellular stress (34, 124, 145).
These affects are both the consequences of the AMPK-mediated inhibition of mTORC1
and represent additional mechanisms of AMPK that are not necessarily tied to mTOR.
The cross-talk between AMPK, mTORC1, and p53 is evident by recent studies
showing that p53 supports the activation of AMPK and the inhibition of mTORC1 by the
transactivation of target genes whose products either lead to the enhancement of AMPK
activaton, i.e. sestrins, or the up-regulation of proteins responsible for reducing mTORC1
activity, such as PTEN (33, 68, 69). Likewise, AMPK activity has been shown to induce
the phosphorylation of p53 at the serine 15 position, a post-translational modification
required for the induction of p53-mediated growth arrest (124). These data place the
AMPK regulator at the center of p53 and mTORC1 mediated cellular events, two factors
whose dysregulation account for most of the pathologies causing human cancers. Thus,
exploring the efficacy of AMPK activation as an anticancer target is of substantial
importance.
The vast number of tumor suppressors and oncogenic proteins (Figure 4-1 and table
4-1) linked to AMPK predicts that the cellular response and sensitivity to AICART
inhibition will depend on the genetic background of the tumors exposed to drug. A direct
correlation between PTEN deficiency, as well as, PI3K hyperactivity and the cytotoxic
effects of rapamycin has been described in mouse tumors in vivo and in breast cancer cells
lines in vitro (171, 173, 185, 221). As such, we predict that cells with mutations in the
PTEN/PI3/Akt pathway will be particularly sensitive to treatment with de novo purine
synthesis inhibitors. Proliferative disorders often result from loss of function of either
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LKB1 or TSC1/TSC2 and the morbidities associated with these diseases have been
reduced when treated with direct mTORC1 inhibitors (48, 160). It is of interest to test the
efficacy of AICART inhibitors in the treatment of these pathologies. Likewise, the link
between AMPK-mTOR activation and the induction of HIF-1α, in response to hypoxia
(see introduction) also suggests that AICART inhibitors may have anti-angiogenesis
properties.
The potential for AMPK activation in the treatment of human malignances has
begun to be addressed both in vitro and in vivo. The treatment of breast cancer cells with
metformin, an activator of AMPK by mechanisms that remain unknown, resulted in
AMPK-dependent growth inhibition (265).

In vivo studies demonstrated that tumor

development in mice heterozygous for a PTEN deficiency, were affected by LKB1 levels
and the onset of tumor formation in PTEN +/- mice was delayed when activation of AMPK
was induced pharmacologically (111).

New targets for the multi-targeted antifolate, pemetrexed
Our studies have suggested that a drug currently in clinical use as a
chemotherapeutic agent may be working through mechanisms linked to AMPK activation.
Pemetrexed was shown to inhibit the second-folate dependent enzyme in de novo purine
synthesis, AICART. The resulting metabolic block causes the accumulation of ZMP
leading to the activation of AMPK and the inhibition of mTORC1. The clinical utility of
pemetrexed has largely been attributed to its effect on thymidylate synthase, but in vitro
experiments have highlighted the importance of the secondary targets of pemetrexed in
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mediating its cytotoxic effects (45). We are very interested in determining the extent of
how AMPK activation and mTORC1 inhibition has played a role in this compounds
clinical utility.

Interestingly, the combination of pemetrexed and cisplatin was more

efficacious in the treatment of non-small cell lung cancer than gemcitabine and cisplatin
except when patients had squamous cell carcinoma (61). This finding is remarkable and
investigators have postulated that this observation was a consequence of the overexpression of thymidylate synthase in squamous cell tumors (61). The studies presented in
this chapter offer an alternative explanation, whereby the distinction between squamous
cell carcinoma and the other non-small cell cancers is the status of the mTORC1 pathway.
The assessment of the phosphorylation status of 4EBP1 and S6K1 has been used to
assess mTORC1 inhibition in the clinical trials of direct mTOR inhibitors (160).
Retrospective analysis of the status of these proteins in tumor samples from patients treated
with pemetrexed will be useful in understanding if our observations are relevant to the
clinical setting. Additionally, pre-clinical and clinical data obtained from studies using
rapaloges may assist in identifying tumor types likely to be sensitive to treatment with
pemetrexed. To this point, current rapalogs have also shown activity against human lung
cancers in clinical trials (84, 181). Likewise, Rad001, a direct mTOR inhibitor, has
recently been approved as first line therapy for the treatment of renal cell carcinoma (160).
It may very well be the case that the effect of pemetrexed on the AMPK-mTOR pathway
has been largely responsible for the selective use of this compound in the treatment of
NSLC.
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Genetic alterations that lead to proliferative disorders
Gene
PTEN
TSC1
TSC2
AMPK
LKB1

Presentation
Hamartomatous
tumor
syndromes
Hamartomas

Syndrome
Cowden syndrome

Aetiology
PTEN loss,
hyperactive PI3K

Tuberous sclerosis
complex

Abnormal
growths in lungs
(smooth muscle)
Cadiomyopathy

Lymphangioleiomyomatosis

TSC1 mutation,
hyperactive
mTORC1
TSC2 mutation,
hyperactive mTOR

Gastrointestinal
polyps

Familial hypertrophic
cardiomyopathy
Peut-Jeghers syndrome

Loss of AMPK
Loss of LKB1

Tumor suppressor/oncogenic proteins involved in cancer
Gene/protein
Genetic alteration
Cancer type
PTEN
Deletion, silencing, Endometrial,
loss of function
glioblastoma,
hepatocellular
carcinoma
PI3K
Increased PI3K
Endometrial,
activity
glioblastoma, heptocarcinoma, thyroid,
prostate, lung
eIF4E
Overexpression
Breast, squamous
cell,
adenocarcinoma
LKB1
Mutation, silencing Non-small cell lung
cancer
Akt
Gene amplification, Breast, ovarian,
overexpression
colon, ovarian,
breast
S6K1
Gene amplification
Breast, ovarian
Table 4-2. Common mutations within the mTOR pathway that lead to
proliferative disorders or cancer. Adapted from Faivre et. al, vol. 5, pages 671688, August 2006, Nature Reviews Drug Discovery. Italicized text represent tumor
suppressors and bold represent oncogenic proteins.
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Figure 4-1. mTOR signaling network. Adapted from Merc-Bernstam
et. al, Journal of Clinical Oncology, vol. 27, no. 13, May 2009
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A.

B.

LCA, µM

Figure 4-2. End product reversal studies in CEM cell growth treated
with the de novo purine synthesis inhibitors 6R-DDATHF (A) and
LCA (B). CEM cells were treated with the indicated concentrations of 6RDDATHF (A) and LCA (B) alone (no addition) or in the presence of
Thymidine (TdR, 5.6 µM), Hypoxanthine (Hx, 32 µM), or a combination
of TdR with either Hx or AICA (320 µM). Drug and modifying agents
were added simultaneously and cells were incubated in media for 96 hours.
This work was performed by Dr. Richard Moran.
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Figure 4-3. The folate dependent steps of de novo purine synthesis and the
targets of DDATHF and LCA. De novo purine synthesis consists of ten
sequential enzymatic reactions starting with 1-phosphoribosyl-5-pyrophosphate
(PRPP) of which two, GART and AICART, are folate-dependent. The figure
depicts the substrate of the GART reaction, glycinamide ribonucleotide (GAR),
and the product of this reaction formylglycinamide ribonucleotide (FGAR), as
well as the salvage of AICA, AICAR, and hypoxanthine catalyzed by adenine
phosphoribosyltransferase (APRT), adenosine kinase (AK), and hypoxanthineguanine phosphoribosyltransferase (HGPRT), respectively. Inosine monophosphate (IMP) is converted to AMP and GMP.
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LCA, µM

Figure 4-4. Reversal of HCT116 cell growth inhibition by addition of
purines supported the observation that the target of LCA is de novo purine
synthesis not thymidylate synthase. HCT116 cells were treated with the
indicated concentrations of LCA alone (no addition, green small circles) or in the
presence of Thymidine (TdR, 5.6 µM, black squares), Inosine (IR, 100 µM, blue
triangles), or a combination of TdR and IR (red large circles). Drug and
modifying agents were added simultaneously and cells were incubated in media
for 96 hours. Cell growth was determined after 96 hours and cell number is
expressed.
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Figure 4-5. AMPK/TSC/mTORC1 axis studied.
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Figure 4-6. De novo purine synthesis inhibition causes a decrease in
phosphorylation of 4EBP1 and S6K1, two major downstream targets of
mTORC1. Western blots of total and phosphorylated S6K1 and 4EBP1 protein
levels following treatment with 1 µM of DDATHF or LYLCA. The molecular
masses of these bands were 62 kD (AMPK), S6K1 (70 kD), and 15-20 kD
(4EBP1). Equal levels of total HCT116 protein (20 µg) was loaded in each lane;
use of actin as a control demonstrated equal loading between lanes in this and the
following figures (not shown). AICAR was used at 320 µM of 1 µM in the
4EBP1 or S6K1 blot, respectively.
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Figure 4-7. Reversal of mTOR inhibition induced in HCT116 cells by
DDATHF and LCA by the addition of purines. Cellular activity of mTOR
was assessed by the phosphorylation of S6K1 and 4EBP1 after treatment with
DDATHF (A) and LYLCA (B). HCT116 cells were exposed to drug and
modifying agents for 24 hours and IR was used at 100 µM and TdR was used at
5.6 µM.
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Figure 4-8. mTORC1 inhibition following treatment with de novo purine
synthesis inhibitors correlates with activation of AMPK by phosphorylation
at position T172. Phosphorylation of AMPK at the Thr172 position was
assessed by western blot analysis following treatment of HCT116 cells with
1µM of DDATHF (A) and LCA (B). Cells treated with DDATHF were also
exposed to 100 µM of IR as a rescue agent. Cells treated with LCA were
exposed to 5.6 µM of TdR or 5.6µM of TdR and 100 µM of IR. The
phosphorylation of AMPK appeared to be reversed using IR in cells treated with
DDATHF, but not in those exposed to LCA. HCT116 cells were exposed to drug
and modifying agents for 24 hours as in Fig. 4-6.
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Figure 4-9. Effects of pemetrexed on activation of AMPK and inhibition of
mTOR. (A and B) Western blot analysis of total and phosphorylated AMPK,
ACC, Raptor, S6K1, and 4EBP1. The molecular masses of these bands were 62
kD (AMPK), 280 kD (ACC), 150 kDa (Raptor), S6K1 (70 kD), and 15-20 kD
(4EBP1). Equal levels of total protein (40 µg) was loaded in each lane; use of
actin as a control demonstrated equal loading between lanes in this and the
following figures (not shown). Vehicle was PBS, pemetrexed was used at 1 µM,
AICAR was at 250 µM, and TdR was 5.6µM; drug exposure was 48 hours.
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Figure 4-10. Dose-dependent activation of AMPK and inhibition of
mTOR upon treatment of CEM cells with pemetrexed. AMPK
activity was assessed by western blot analysis of phosphorylation of ACC
and Raptor, and the activity of mTOR was indicated by the
phosphorylation of S6K1 and 4EBP1. CEM cells were exposed to drug
at .01 µM, .1 µM, and 1.0 µM with 5.6 µM TdR for 48 hours; conditions
for western blots were as in Fig. 4-9.
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Figure 4-11. Reversal of CEM cell growth inhibition by AICA and
accumulation of cellular levels of ZMP indicated that the second target of
pemetrexed is AICART, not GART. (A) CEM cells were treated with the
indicated concentrations of pemetrexed alone (no add) or in the presence of TdR
(5.6 µM), Hx (32 µM), AICA (320 µM), or a combination of TdR with either Hx
or AICA. Drug and modifying agents were added simultaneously and drugcontaining medium was changed at 48 hours. Cell growth was determined after
96 hours and cell number is expressed relative to controls without drug. (B)
Increased cellular ZMP pools in pemetrexed-treated but not (6R)-DDATHFtreated CEM cells. Cells were exposed to drugs for 48 hours, nucleotides
extracted and ZMP separated by hplc. This work was performed by Dr.
Moran (A) and Scott Rothbart (B).
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Figure 4-12. Expansion of the ZMP pool by AICA enhances the effect
of pemetrexed on the AMPK-mTOR pathway in CEM cells. AMPK
activity was assessed by western blot analysis of phosphorylation of ACC
and Raptor, and the activity of mTOR was indicated by the
phosphorylation of S6K1 and 4EBP1. CEM cells were exposed to drug
and modifying agents for 48 hours as in Fig. 4-9 and AICA was used at
320 µM; conditions for western blots were as in Fig. 4-9.
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Figure 4-13. Reversal of secondary effects of pemetrexed on the
AMPK-mTOR pathway by the addition of purines. Cellular activity
of AMPK was assessed by western blot analysis of phosphorylation of
ACC and Raptor, and the activity of mTOR was indicated by the
phosphorylation of S6K1 and 4EBP1. CEM cells were exposed to drug
and modifying agents for 48 hours as in Fig. 4-9 and Hx was used at 32
µM; conditions for western blots were as in Fig. 4-9.
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Figure 4-14. Prevention of the secondary effects of pemetrexed on the
mTOR pathway by inhibition of AMPK. When CEM cells were exposed to 1
µM pemetrexed and 5.6 µM thymidine for 48 hours, 10 µM (A) or 1 µM (B) of
Compound C (CC) in the medium prevented the cellular activity of AMPK by
pemetrexed without interfering with the phosphorylation of AMPK. Vehicle (V)
was DMSO.
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Chapter 5: Perspectives

Throughout the course of this dissertation, I have addressed the epigenetic,
transcriptional, and cell signaling mechanisms involved in the actions of folate antimetabolites. In chapter 2, I presented evidence that the control of the multi-promoter
mouse fpgs gene involves epigenetic, transcriptional interference, and promoter-proximal
pausing mechanisms to coordinate the tissue-specific expression patterns detected in adult
differentiated tissues and normal and neoplastic proliferative cells.

In chapter 3, I

perturbed those controls to study the response of the integrated system. In chapter 4, I
presented evidence to suggest that antifolates inhibiting the second folate-dependent
enzyme of de novo purine synthesis, AICART, may represent a class of folate antimetabolites that have potential as molecularly targeted therapies in the treatment of human
cancer. Our studies have lead to several conclusions and generated a number of new
questions that remain to be answered, as discussed below.

The mouse fpgs gene: a model of tissue-specific transcriptional control mechanisms
The field of transcriptional control mechanisms is in a time of great expansion. The
realization that a relatively small number of eukaryotic genes are controlled to generate the
vast number of diverse proteins found in mammals has called into question the relevance
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of basic transcriptional mechanisms once considered to be fundamental. Genome-wide
technologies have identified the overwhelming prevalence of multi-promoter genes in
mammals and greatly expanded the fields of microRNAs and epigenetics. During the
course of this dissertation a major paradigm shift was caused by the discovery that a large
proportion of mammalian genes are regulated not at the level of transcriptional initiation,
but at a stage in transcriptional elongation (87). In this new framework, our studies at the
mouse fpgs gene have highlighted the importance of several recently identified
transcriptional processes in tissue-specific patterns of regulation, and the multitude of
control mechanisms coordinating this gene continues to surprise us.
We consider the mouse fpgs gene an excellent model system to expand the
genome-wide observations regarding tissue-specific and multi-promoter gene regulation to
a mechanistic understanding of the interplay of these events at a single genetic locus. The
work presented in this dissertation and generated from previous members of the laboratory
have dissected several interesting aspects of this gene, and with our knowledge base we are
in a unique position to address highly relevant and current topics using an in vivo model
system. The areas of interest include tissue-specific patterns of DNA methylation and
histone post-translational modifications, the mechanisms responsible for establishing
poised elongation complexes, and the fundamental differences between CpG-sparse and
CpG-island promoter regulation.
To further address these fields at the fpgs gene the next phase of in vivo studies will
benefit from observations made that suggested that the fpgs gene undergoes promoter
switching during the course of mouse developmental. The premise for this hypothesis
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rests on data presented in Dr. Fiona Turner’s dissertation where she analyzed the use of the
two fpgs promoters in developing mouse tissues. Interestingly, in neonatal mouse liver
fpgs mRNA was detected from both the P2 and P1 promoters (243). Likewise, following a
partial hepatectomy, performed to induce hepatocyte cellular division, P2 was also found
to be active. A separate study determined that detectable levels of FPGS protein were
found in developing mouse brain, but not in differentiated tissue, which suggested that the
P2 promoter is active in brain during development but silent in adult animals (12). Our
studies have determined the P2 promoter in brain is silenced through a mechanism of
promoter-proximal pausing. Tracking changes in promoter usage, DNA methylation status,
and histone post-translational modifications throughout the course of development may
provide insight into the sequence of events dictating the transcriptional, epigenetic, and
poised states at the fpgs promoters in differentiated tissues. The rules defined will most
likely be applicable to additional tissue-specific multi-promoter genes.
Of particular interest is the establishment of DNA methylation patterns at the P1
promoter in mouse liver.

Is the P1 promoter silent and methylated in developing

hepatocytes and if so, when is methylation lost? Tremendous insight has been gained
towards understanding the meaning of certain histone modifications and DNA methylation
through genome-wide studies using mammalian pluripotent stem cells (159, 161).
However, patterns of DNA methylation across CpG-sparse promoters are difficult to
obtain with the current strategies used to analyze genome-wide methylation. As such,
monitoring methylation at fpgs P1 during development may be uniquely informative.
Additionally, the field addressing processes of DNA demethylation is rapidly changing.
262

Current thought suggests that active de-methylation may occur through processes linked to
nucleotide excision repair (213). The concept that DNA demethylation may define tissuespecific patterns of methylation has only been proposed and pursuing studies focused at the
P1 promoter may shed light on this topic.
Literature precedent shows that primary events controlling genes are often defined
from studies in vitro, but the promoter switching and poising occurring during
development at the mouse fpgs may allow us to distinguish mechanisms in vivo.

Antifolates as molecularly targeted therapies
The use of antifolate drugs as chemotherapeutic agents was initiated in the early
1940’s and remains first line therapy for several human pathologies including acute
lymphocytic leukemia, rheumatoid arthritis, and sarcoidosis. These compounds target
enzymes involved in nucleotide synthesis and amino acid metabolism and thus have
proven to be very effective at eliminating highly proliferative tumor cells that depend on
these reactions for cellular survival. Previously, a place for antifolates in targeted
chemotherapy had not been realized, but our studies have defined a potential for folate
antimetabolites in this arena. AICART inhibitors indirectly target mTOR, a protein central
to several signaling pathways aberrantly regulated in human cancers. Thus, these agents
are akin to direct mTOR inhibitors, which are currently used as immunosuppressant agents
following kidney transplant and have recently been approved as first-line therapy in the
treatment of renal cell carcinoma (160, 240). Several questions remain regarding the utility
of AICART inhibitors as molecularly targeted therapies.
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What tumor types will be

sensitive to AICART inhibition? How will this class of compounds compare to direct
mTORC1 inhibitors? Will these compounds be useful in combination with cytotoxic
agents?
We propose that AICART inhibitors will have clinical success in the treatment of
human cancers in combination therapy.

Direct mTOR inhibitors have shown either

additive or synergistic anti-tumor activity in combination with paclitaxel, cisplatin,
doxorubicin, and carboplatin (160).

Pre-clinical studies have suggested that mTOR

inhibition may be beneficial in circumstances where an aberrant PI3/Akt pathway causes
tumor resistance to first-line chemotherapeutic strategies.

For example, the cytotoxic

effects of trastuzumab, a monoclonal antibody blocking the Erb2 tyrosine kinase receptor,
on breast cancer tumors are eliminated when cellular PTEN levels are lost, resulting in
high levels of Akt activity (147).

Co-administration of trastuxumab and Rad001, a

mTORC1 inhibitor, has been shown to increase the sensitivity of resistant breast cancer
cells to trastuxumab therapy by eliminating the downstream consequence of Akt
stimulation, mTORC1 activation (147).
A clinically relevant consequence of mTORC1 inhibition is the activation of Akt,
which occurs through the prevention of the feedback inhibition of Akt mediated by S6K1
activity on IRS-1 (Figure 4-1) (57). This has been shown to attenuate the anti-tumor
effects of mTORC1 inhibition. Pre-clinical studies have shown that the combination of
direct mTORC1 and IGF-R inhibitors alleviates this unwanted secondary consequence of
mTORC1 inhibition and enhances antitumor activity (223). IGF-R and mTOR inhibitors
are currently being tested in clinical trials (160). Akt activation will most likely also occur
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in response to mTORC1 inhibition induced by an AICART block and the combination
strategies successful with direct mTORC1 inhibitors should be considered when selecting
agents to combine with this class of antifolates.
Beyond the use of AICART inhibitors as anticancer drugs these compounds should
now be tested in the treatment of non-neoplastic pathologies sensitive to AMPK activation,
such as type II diabetes, and proliferative disorders caused by loss of tumor suppressors,
i.e. LKB1, TSC2, and PTEN, that are upstream regulators of mTORC1. Recent in vivo
experiments have shown that pharmacological activation of AMPK improves blood
glucose homeostasis, lipid profiles, and blood pressure in rodent models of type II
diabetes, supporting a potentially serious role for AMPK activation in the treatment of this
common metabolic disease (251). Likewise direct mTORC1 inhibitors in phase I and II
clinical trials have shown promise in the reduction of angiomyolipomas, facial
angiolypomas, and lymphangiomyomatosis, which are common consequences of
proliferative disorders due to TSC1 and TSC2 dysregulation (149, 160). Clearly, in light
of our recent data testing the use of antifolates targeting AICART as single agent therapy
or in combination with direct mTORC1 inhibitors in the treatment of metabolic and
proliferative disorders will be of great interest.
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Appendix A
Primer pairs are listed together
Chapter 2
Primers used across the length of fpgs gene: 5’ to 3’:
Primer 1 forward:
Primer 1 reverse:

5’TCCCTCCGCAGCTTCCTG3’
5’ACTGACTTGCCATCTCCCC3’

Exon A1a 1a2:
Exon A1a 2b:

5’CTTGATGTCATTTGCAGTCCAA3’
5’GTTCGCATTTCCATCCTGTG3’

Primer 3 forward:
Primer 3 reverse:

5’GACTCAGGGGTGTTGCTCT3’
5’CAGGTTCAACAAGAGATCGAGAG3’

Primer 4 forward:
Primer 4 reverse:

5’GCGTCTTGGGTTAGTGGCAG3’
5’CCATAAGTCACGTAGGCAATGC3’

Primer 5 forward:
Primer 5 reverse:

5’GGTTCAGATGCACTCGCTTG3’
5’CTGGGCAGTGGTAGCACA3’

Primer 6 forward:
Primer 6 reverse:

5’GAGAAAGCCTGTGGCAGG3’
5’AGGAATACAGTTGTAAGCCAGG3’

Exon 1 (3a):
Exon 1 (4b):

5’GCTTCTCTGCCAAGGAGTCG3’
5’GCCCTGACGCCATCCTAA3’

Primer 8 forward:
Primer 8 reverse:

5’GCACAGGTTTCTCAGAATGTAGGG3’
5’CTCTCTACCACTATACTGGACACC3’

Primer 9 forward:
Primer 9 reverse:

5’AGTAGTGGGATTAAAGGCGTGC3’
5’ ATGGGTACTGCTGGTTGTCG3’

Primer 10 forward:
Primer 10 reverse:

5’TGCCAGGGATTAGCTGTGG3’
5’CTGCCCAGCTTCCATGTCTTTA3’

Primer 11 forward:
Primer 11 reverse:

5’GACTGTGGCAAGTCATTACCAGG3’
5’CACATGAGGAACCCAAAGC3’

Primer 12 forward:
Primer 12 reverse:

5’CTACACATCCCAGTGCAGG3’
5’AGTCCCTGTTCCTCACTGAGC3’
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Primer used for Chip walking across P1 and P2:
P1 promoter
Exon A1a (1a2)
Exon A1a (1b)

5’CTTGATGTCATTTGCAGTCCAAG3’
5’ CTGGGAGATGTCCAAGTCCTG3’

Exon A1a (2a)
Exon A1a (2b)

5’GTCTCACCTGGGCAGCAAG3’
5’GTTCGCATTTCCATCCTGTG3’

Exon A1a (3a)
Exon A1a (3b)

5’CAGCTAGCTAGCCCTGTAGTGG3’
5’GGTAGGGCACAAATGACTCCAAG3’

Exon A1a (4c)
Exon A1a (4d)

5’TGCAGTCCCAGTCCAGC3’
5’AGGCAGTCTTAGCTTCGTAAGC3’

Exon A1a (5e)
Exon A1a (5f)

5’GTGGAAGGACCCATCAGGGA3’
5’AGTAGGGTTCCTAACATCACCTGC3’

Exon A1a (6a2)
Exon A1a (6b)

5’GTGTGCCAGTCTGATGCACATTAG3’
5’GGAATGAGGCGACCTTGACC3’

P2 promoter
Exon (1c)
Exon (1d )

5’CGATAGGGGTGTCATTCTTCC3’
5’GCAGCCTTTTCGGTCAAG3’

Exon 1 (2a)
Exon 1 (2b)

5’AGCCTGGAGAGACGGGGT3’
5’CCAATCCGAGCCAGCAGTTC3’

Exon 1 (3a)
Exon (3b)

5’GCTTCTCTGCCAAGGAGTCG3’
5’GCTGCTCTCGCCATGCTTC3’

Exon 1 (4a)
Exon 1 (4b)

5’CTCCCAGGAACACCCTCTTC3’
5’GCCCTGACGCCATCCTAAG3’

Exon 1 (5c)
Exon 1 (5d)

5’CGCTGCTTCTCATTGGTC3’
5’GCGGGAACGGTCAGAAA3’

Exon 1 (6a)
Exon 1 (6b2)

5’GAGCCGACTGTGCTCGACTC3’
5’ACGTGTCAGGACGGGACC3’
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Control primers for histone and RNAPII studies:
B-globin Set #2 forward (coding region)
B-globin Set#2 reverse (coding region)

5’AGGCTGCTGGTTGTCTACC3’
5’ACACTCCACACACAGTCATGG3’

GAPDH Set#1 forward (promoter)
GAPDH Set#1 reverse #2 (promoter)

5’GTCCTCGATGTCCTTGGTGC3’
5’TGGAACAGGGAGGAGCAGAG3’

GAPDH Set #2 forward (coding region)
GAPDH Set #2 reverse (coding region)

5’TCCAGTATCACTCCACTGACG3’
5’CAGGTTGCACCATATCAAGGG3’

Chapter 3
Control primers for P and PM cells lines:
Cryaa Forward (Exon 1-2)
Cryaa Reverse (Exon 2-3)

5’ATCTCTGAGGTCCGATCTAGCC3’
5’GTAGCCATGGTCATCCTGCCTC3’

Slpi Forward (Exon 1)
Slpi Reverse (Exon 2-3)

5’TCACGGTGCTCCTTGCTCTG3’
5’CTTCCTCCACACTGGTTTCG3’

Expression control primers (Rt-PCR):
mGAPDH forward (Lin)
mGAPDH reverse (Lin)

5’AACTTTGGCATTGTGGAAGGGCTC3’
5’TGGAAGAGTGGGAGTTGCTGTTGA3

P1 expression primers (Rt-PCR):
A1b forward
A1b reverse

5’TGTGGCTGAGAAGTTCTGGTGG3’
5’CGCACAGCATCCTGAAAGG3’

Exon 3b reverse

5’CTTCCCTTTGGTCCCAGTGACATGAA3’

Exon 6R reverse

5’AGACATGGCTGTCGTCCTTGAACT3’

Exon 1 forward

5’CTAGCTTGCGGTGGCATTAAGACT3’

De novo methyltransferase primers (Rt-PCR):
DNMT3a forward
DNMT3a reverse

5’GTAACCTTCCTGGCATGAACA3’
5’ACTCTTGCAGCTCCAGCTTATC3’

DNMT3b forward

5’CTGAATTACACGCAGGACATGAC3’
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DNMT3b reverse

5’TCAGAGCCATTCCCATCATCTAC3’

Bisulfite primers:
Sense: 201:
Antisense BSS3:

5’TAGGGTTTTTTTGAAGTTTATTTTGTA3’
5’CATCTAACTAACATCCTACCTAACAA3’

Sense 202C:
Antisense BSS4:

5’AGTTTTATTTGGGTAGTAAGGTTAATTTTAG3
5’TCCTAATAAATAAAACACAAATAACTCC3’

Sense 203A1A:
Antisense BSS11:

5’AGAAGTTTTGGTGGGAAGTAG3’
5’CTAATATCTCACCTACCTCCTATATAACAC3’

Sense 203C:
Antisense BSS10

5’ATTTTTGTTGATAGTTATTTGGAGTAGGTG3’
5’CCCCAACCTAACTATAATTAATCATCTA3’
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